Novel methods for early phase clinical trials by Cotterill, Amy
Novel Methods for
Early Phase Clinical Trials
Amy Louise Cotterill, B.Sc., M.Sc.
Submitted for the degree of Doctor of Philosophy
at Lancaster University.
August 21, 2015
Novel Methods for Early Phase Clinical Trials
Amy Louise Cotterill, B.Sc., M.Sc.
Submitted for the degree of Doctor of Philosophy at Lancaster University.
August 21, 2015
Abstract
Early phase clinical trials are conducted with limited time and patient resources.
Despite design restrictions, patient safety must be prioritised and trial conclusions
must be accurate; maximising a promising treatment’s chance of success in later large-
scale, long-term trials. Increasing the efficiency of early phase clinical trials, through
utilising available data more effectively, can lead to improved decision making during,
and as a result of, the trial. This thesis contains three distinct pieces of research; each
of which proposes a novel, early phase clinical trial design with this overall objective.
The initial focus of the thesis is on dose-escalation. In the single-agent setting,
subgroups of the population, between which the reaction to treatment may differ,
are accounted for in dose-escalation. This is achieved using a Bayesian model-based
approach to dose-escalation with spike and slab priors in order to identify a recom-
mended dose of the treatment (for use in later trials) in each subgroup. Accounting
for a potential subgroup effect in a dose-escalation trial can yield safety benefits for
I
II
patients within, and post- trial due to subgorup-specific dosing which should improve
the benefit-risk ratio of the treatment.
Dual-agent dose-escalation is considered next. In the dual-agent setting, single-
agent data, including toxicity and pharmacokinetic exposure information, is available.
This information is used to define escalation rules that combine the outputs of inde-
pendent dose-toxicity and dose-exposure models which are fitted to emerging trial
data. This solution is practical to implement and reduces the subjectivity that cur-
rently surrounds the use of exposure data in dose-escalation. In addition, escalation
decisions and consistency of the final recommended dose-pair are improved.
The focus of the third piece of research changes. In this work, Bayesian sample
size calculations for single-arm and randomised phase II trials with time-to-event end-
points are considered. Calculation of the sample size required for a trial is based on a
proportional hazards assumption and utilises historical data on the control (and ex-
perimental) treatments. The sample sizes obtained are consistent with those currently
used in practice while better accounting for available information and uncertainty in
parameter estimates of the time-to-event distribution. Investigating allocation ratio’s
in the randomised setting provides a basis for deciding whether a control arm is indeed
necessary. That is, in a randomised trial, whether it is necessary for any patients to
be randomised to the control treatment arm.
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Chapter 1
Introduction
1.1 Early Phase Clinical Trials
It can take up to 15 years for a novel treatment to progress through the research
and development process before finally being made available to patients. As well as
being lengthy, this process is expensive with current estimates exceeding one billion
dollars (Mestre-Ferrandiz et al., 2013; Paul et al., 2010). This figure accounts not
only for the research and development costs of the successful treatment, but also for
the costs incurred from evaluating treatments that were subsequently not pursued. In
this thesis, we propose methods which could help to reduce the cost and duration of
the clinical trials stage in the research and development process of a novel treatment
with minimal negative impact on the trial outcomes.
Clinical trials follow pre-clinical (in vitro and in vivo) studies in the drug de-
velopment process. A clinical trial is defined in ICH E6 (CDER/CBER, 1996) as
“Any investigation in human subjects intended to discover the ... effects [beneficial or
1
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harmful] of an investigational product(s) ... with the object of ascertaining its safety
and/or efficacy”; where efficacy is the treatment’s “true biological effect” (Piantadosi,
1997). Of interest are experimental/investigational treatments, which are considered
throughout this thesis to be one or more treatments administered to patients in a
novel application or combination.
Ethical guidelines based on the Declaration of Helsinki (World Medical Associa-
tion et al., 2013) govern the coduct of clinical trials. The guidelines highlight that the
welfare of patients, treated within and outside of clinical trials, is the main priority.
Relevant ethical considerations will be mentioned, but are not discussed at length,
in this thesis. An overview of the aspects of clinical trial design pertinent to the
novel methods proposed in this thesis are given in Chapters 2 and 5. Further prac-
tical information on clinical trial design can be found in Pocock (2004) and industry
guidelines are provided by the International Conference on Harmonisation of technical
requirements for registration of pharmaceuticals for human use.
In this thesis, the term ‘early phase clinical trials’ refers to non-confirmatory tri-
als, often described as phase I and II. That is, the clinical trials investigating an
experimental treatment’s relatively short-term safety and/or efficacy in a controlled
population. If suitable evidence of safety and efficacy is observed in these early phase
clinical trials, then the experimental treatment proceeds to large-scale phase III tri-
als. Phase III clinical trials are confirmatory trials of the treatment’s effectiveness, or
beneficial effect, in the general patient population under standard use. The treatment
must have a sufficiently positive benefit-risk ratio to be considered suitable for use
in the general population. If successful, the phase III trial can lead to the treatment
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being licensed. Post-licencing research is then carried out to continually monitor the
treatment and its use once it is made available for use outside of clinical trials.
Arrowsmith and Millar (2013) show that lack of efficacy is the main reason for
a treatment failing in phase III trials - the most costly stage of drug research and
development (Paul et al., 2010). Reducing the number of treatments which fail for
lack of efficacy in phase III trials could therefore have a big impact on the overall cost
of drug development. Two ways of approaching this issue are:
i. To enable phase III clinical trials to stop for futility before the calculated number
of patients have been treated in the trial. In this way, less patients are treated
with a sub-optimum treatment. This option is becoming increasingly common in
phase II trials;
ii. Improving early phase clinical trial designs. Obtaining more accurate inferences
from the early phase trials could lead to better informed decisions being made
concerning whether or not the experimental treatment should progress to phase
III trials.
The latter approach is considered in this thesis because it is the preferred option,
due to the resource savings in terms of the design, start up and conduct of part of a
phase III clinical trial which would be incurred in carrying out the first option. In each
of the novel designs proposed in this thesis, data which are often already available
at the design stage of the trial or collected during the clinical trial are utilised more
effectively than in current practice. In doing this, the operating characteristics of the
trial are improved in some way.
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There are many potential benefits of improving the design of early phase clinical
trials. As a consequence of improved trial designs, better decisions can be made,
decreasing the time and cost of the drug development process. This can be achieved
by ensuring that a promising treatment is pursued, and conversely that an ineffica-
cious treatment is dropped early on in clinical trials. A promising treatment should
therefore get to market quicker and with a reduced ecomonic burden. This is directly
beneficial for trial sponsors. In addition, decreasing the cost of drug development of
the treatment increases the chance of it being made available to potential patients,
possibly sooner and at a lower cost.
As well as benefits for the potential patient market, patients involved in clinical
trials could benefit from improved clinical trial designs. More efficient trials, through
making better use of available data, can improve the safety of trials for participants
and reduce the number treated with sub-optimal doses/treatments. This in turn may
increase participation in trials, possibly further reducing trial durations.
In this work, simulation studies (based on published data from previous clinical
trials), are used to compare the properties of standard early phase clinical trial designs
to the proposed designs. The proposed designs all use Bayesian methodology and are
intended to be practical to implement. The proposed designs are not intended as a
sequence of clinical trials, but rather they relate to different settings in which the
additional data of interest is likely to be available. Specifically, the use of biomarker,
pharmacokinetic and historical survival data are considered.
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1.2 Focus of Thesis
The initial focus of this thesis is on phase I dose-escalation trials in oncology which aim
to recommend a dose of the experimental treatment for administration to patients in
future trials of the treatment. An assumption, that both toxicity and efficacy increase
monotonically with dose of the treatment, means that the recommended dose must
provide a compromise between being highly toxic yet efficacious and being non-toxic
yet inefficacious. Failure to identify the optimum dose of treatment can therefore lead
to its failure in later trials investigating its safety and efficacy. More information on
the design and conduct of dose-escalation trials is given in Chapter 2.
Dose-escalation of a single experimental treatment is considered in Chapter 3.
The proposed dose-escalation method allows for a potential difference in reaction
(explicityly toxicity) to the treatment between two subgroups of the patient popula-
tion. These subgroups can be identified using a biomarker which has been selected
based on historical data and/or pre-clinical information which is indicative of poten-
tial differences in tolerance to the treatment between the subgroups that it defines.
The methodology developed aims to recommend different doses of the experimental
treatment for use in each of the pre-defined subgroups, when this is necessary.
In Chapter 4, we go on to consider dose-escalation of a combination of two exper-
imental treatments. In this setting, a dose of each treatment must be recommeded
for use in future trials, and hence, a recommended dose-pair is identified from the
trial. When designing the combination trial, some data from the single-agent trials
of each treatment will be available. Single-agent pharmacokinetic information, which
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provides a measure of the exposure of the body to the drug, can be used to obtain
desirable exposure intervals for each treatment. The proposed dose-escalation method
for a dual-agent treatment uses this information to improve the consistency in esti-
mation of the recommended dose-pair and to reduce the risk of patients experiencing
undesirably high exposures, especially in the presence of drug-drug interactions.
The focus of the thesis then turns to phase II clinical trials which collect prelimi-
nary evidence of a treatment’s efficacy. Restrictions on the size and duration of phase
II clinical trials lead to inferences on a treatment’s efficacy often being based on a
short-term, often binary, endpoint. Inferences based on a binary endpoint generally
require observation of fewer patients to reach a conclusion, and hence, they tend to
have lower trial costs than those based on a time-to-event endpoint. The short-term
(binary or time-to-event) endpoint often used in phase II trials in place the actual
time-to-event endpoint of interest (often time to mortality or disease progression)
which is to be considered in the phase III trial. The reason for this is that the se-
lected short-term endpoint is expected to be available much sooner than the actual
endpoint of interest, and hence, the trial duration and therefore cost is reduced.
If the short-term endpoint is not highly correlated and causally linked with the
actual time-to-event endpoint of interest, then data from the phase II trial will poorly
predict phase III efficacy. Another instance, which can arise in both oncology and
translational medicine, where little is to be gained from using a short-term endpoint
is that in which no feasible or worthwhile short-term endpoint is available. An in-
troduction to phase II clinical trials and the common design restrictions is given in
Chapter 5 along with an introduction to sample size calculation in this setting.
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A novel method of sample size calculation, for a single-arm and a randomised
phase II trial, is presented in Chapter 6. The calculation uses Bayesian methodology
and is based on a proportional hazards assumption between the (short-term or ac-
tual) time-to-event endpoint of interest on the experimental and control treatments.
The proposed method of sample size calculation is relevant for an experimental treat-
ment being investigated in an application where a relevant time-to-event endpoint
can feasibly be collected, historical data on the control treatment is available and
a confirmatory phase III trial will follow. The resulting sample sizes aree greater
than the corresponding calculation based on a binary endpoint and the trial duration
greater than that based on a shorter-term time-to-event endpoint. However, in the
applications discussed, where these are not feasible or worthwhile alternatives, the use
of Bayesian methodology to incorporate historical data enables the number of events
required in the trial to be reduced when compared to the frequentist counterpart.
The main results, applications, limitations and future work for these topics are
discussed in Chapter 7.
Chapter 2
Bayesian Model Based Methods in
Dose-escalation
2.1 Dose-escalation Trials in Oncology
Dose-escalation trials are usually first-in-man trials of an experimental treatment in
a given application. Despite the necessary focus of these trials on safety, due to the
relatively untested nature of the treatment, their main objective is to identify a dose
(or doses) of the treatment for exploration in a greater number of patients in trials
of its efficacy. In order to maximise the treatment’s chance of success in later trials,
the dose(s) recommended for use in future trials must be accurately selected. In this
thesis we consider identification of a single recommended dose of treatment but the
extension of the definition to identify mulitple recommended doses is straight-forward.
The recommended dose is an estimate of the optimal dose of the treatment, that is,
a dose which is efficacious and has an acceptable level of toxicity.
8
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The ethics of patients involved in dose-escalation trials require that they are ex-
posed to no more risk than is absolutely necessary (World Medical Association et al.,
2013). In estimating the optimal dose of a relatively untested treatment it is there-
fore not plausible to immediately administer patients with a dose of the experimental
treatment which has a high chance of being toxic. Erring on the side of caution, and
under the assumption that the toxicity of a treatment increases monotonically with
dose, a low dose of the treatment is administered to the first cohort of patients. A
cohort is a group of patients enrolled at the same stage in dose-escalation and treated
with the same dose of the experimental treatment. Only once this dose is found
to be tolerated, in terms of its toxic side-effects, can a higher dose be given to the
proceeding cohort. This process, along with possible de-escalation or treatment of
additional patients at a dose, continues until it is decided that the optimal dose has
been estimated within a desired level of accuracy (Pocock, 2004).
The sequential nature of dose-escalation trials means that, in order to control the
duration of the trial, the decision over whether to proceed to a higher dose must be
based on an endpoint which is available relatively soon after administration of the
treatment. For this reason, estimation of the optimal dose of a treatment is generally
based on a short-term safety endpoint. An implicit assumption is that as the toxicity
of a treatment increases, so does its efficacy. The optimal dose can then be defined as
the TD100θ; the dose which has probability θ of causing an unacceptable toxicity in
a patient. The TD100θ is hoped to be efficacious enough to be beneficial to patients.
The recommended dose from a dose-escalation trial can then be defined as T̂D100θ,
the estimated TD100θ.
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Standard, ‘acceptable’ values of θ, such as 0.16, (though difficult to justify) exist
and are often used. An unacceptable toxicity on the other hand is disease, patient
group and treatment target dependent and must be defined on a trial by trial basis.
This is usually done in terms of dose limiting toxicities (DLTs). DLTs are toxic side-
effects which are felt to be caused by unacceptably high levels of the treatment. This
means that even if the treatment was considered efficacious at this dose, its benefit-risk
ratio would not be suitable to warrant its administration to patients, hence, limiting
the dose of the experimental treatment administered to patients (NCI, 2014). For
example: Nausea and vomiting are not acceptable side-effects of an asthma treatment
so they would both be included in the list of DLT’s. However, in an oncology trial,
the seriousness of the condition may lead to vomiting still being classified as a DLT
but nausea, though not desirable, may not be.
The work in Chapters 3 and 4 focusses on dose-escalation trials of cytotoxic drugs
used to treat cancer patients. Since cytotoxic drugs aim to kill cells, the assumption
that toxicity increases monotonically with dose is commonly used. For other can-
cer treatments, such as protein inhibitors, this may not be the case and a different
approach is required (see the design of Zhang et al., 2006, for example).
In oncology trials, treatments are usually administered to cancer patients in cycles
(typically of length 21 or 28 days) until the patient’s disease progresses or the exper-
imental treatment is withdrawn due to safety concerns. Outside of oncology, phase
I trial participants are often healthy volunteers. The patient is therefore expected
to return to a ‘healthy’ status upon stopping the treatment. As a result, it is com-
mon for participants to take a break from the treatment before being re-dosed at a
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higher dose level. A single patient can therefore contribute data to multiple dose levels
(Whitehead et al., 2001). This is rare in oncology trials where participants are usually
cancer patients, potentially with no alternative treatment options. Intra-patient dose-
escalation can occur in cancer patients but the outcome would be conditional on the
previous outcome due to the patient’s deteriorating state. Although this dependence
is also present in healthy volunteer studies, the trial designs used in such a situation
are designed to minimise the impact of this effect. Although this dependence is also
present in healthy volunteer studies, the trial designs used in such a situation are
designed to minimise the impact of this effect. For this reason, aswell as for ease and
trial duration considerations, only binary, cycle 1 DLT information is typically used in
dose-escalation decisions in oncology trials. Dose-escalation methods do exist which
utilise toxicity data from later cycles (Sinclair and Whitehead, 2014) but this option
is not considered in this thesis.
Most of the dose-escalation trial designs discussed in this thesis are transferable
to applications outside of oncology, providing that the assumptions underlying the
designs are relevant. However, the designs may need to be adapted to suit the specific
needs of the patients involved in the trial. Regardless of the patient-group, there are
some issues and practicalities that must be addressed when designing a dose-escalation
trial which are, more or less, unique from later trials. According to Rosenberger and
Haines (2002) and Storer (1989), some of these are:
Non-hypothesis driven: The objective of dose-escalation is to identify the recom-
mended dose of the experimental treatment, not to test specific hypotheses. The
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definition of the recommended dose, although fixed for a single trial, can vary
between trials.
No control group: Only a small number of patients are treated at each dose of
treatment and so comparison between the experimental treatment and a control
treatment would be difficult to do reliably. Due to the lack of a concurrent
control group, no reliable estimate of treatment effect can be made at this stage.
Ethics: Trial patients must not be exposed to unnecessary risk and so the trial must
be efficient, obtaining the maximum possible evidence to accurately estimate
the TD100θ using as few patients as possible. If the recommended dose is too
high, then patients in later trials will be exposed to unnecessary levels of risk, it
is therefore better to be conservative in the estimate of the TD100θ. However, if
the estimate is too low then future patients will receive a sub-optimal treatment,
possibly resulting in incorrectly abandoning the experimental treatment. A
balance between the ethics of trial and future patients must be found.
Small samples: The number of patients exposed to a possibly non-beneficial treat-
ment with unknown toxicity must be minimised. In addition, treating more
patients than is required to identify the T̂D100θ with suitable accuracy would
lead to an increase in trial duration, delaying progression to efficacy trials of
the treatment. As a consequence of the limited number of patients treated in
dose-escalation trials, the resulting estimate of the T̂D100θ is highly dependent
on the patients selected for the trial.
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Sequential, often long observation times are required: Dose-escalation is se-
quential so that all trial data, including the most recently observed, is used
to select the dose for administration to the next cohort of patients. This is done
to make the trial as safe as possible for each participating patient. The long
trial duration can lead to possible non-treatment related drop-out.
Toxicity grading can be subjective: Clear definitions of what constitutes a DLT
must be pre-specied to reduce classification errors.
Patients treated at sub-optimal doses: By the nature of dose-escalation, some
patients will be treated below the TD100θ and others above it, though this
number must be minimised.
2.2 Bayesian Model Based Methods
During dose-escalation, decisions must be made over when to escalate the dose of the
experimental treatment, and by how much. Further, a decision as to when to stop the
trial, having identified the T̂D100θ with suitable accuracy, is required. As mentioned
in Section 2.1, these decisions will be made based on binary cycle 1 DLT information.
In oncology, a treatment administered at the optimum dosage has the potential to
make a drastic difference to the lives of the late-stage cancer patients involved in the
trial. As a result, rapid escalation is plausible so that fewer patients are treated with
inefficacious doses. In trials using cancer patients, there is also an increased tolerance
for overdosing than there is in healthy volunteer trials. However, overdosing is still
classed as being more dangerous than underdosing and so a balance must be struck;
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the rate of escalation must be controlled while not treating unnecessary numbers of
patients at overly low doses.
An intuitive dose-escalation trial design invoves specifying simple rules which de-
fine when escalation, de-escalation or expansion of a dose should occur, and under
what conditions to stop the trial. Such designs are algorithmic, the most widely
known and used being the 3 + 3 design (Carter, 1973). An example of potential de-
sision rules for such a design are given in Section 4.1. Such designs are simple to
implement but have many short-comings (e.g. Chen and Beckman, 2009; Goodman
et al., 1995; Reiner et al., 1999; Rogatko et al., 2007; Thall and Lee, 2003), not least
their non-quantitive definition of the recommended dose as a “dose which, if exceeded,
would put patients at unacceptable risk for toxicity” (Rosenberger and Haines, 2002).
The recommended dose from these trials is not really an estimate of the TD100θ; it
is usually referred to as the maximum tolerated dose.
An alternative class of designs are model-based. Such designs do not require se-
quential administration of each dose of treatment pre-specified for use in the trial and,
hence, allow faster escalation (when required) than algorithmic designs. Model-based
designs also have the ability to include safety constraints on escalation. In addition,
these designs allow much more flexibility in the design and running of the trial, as well
as enabling qualitative definition of the recommended dose as the T̂D100θ. This is
achieved through assuming some model for the dose-toxicity relationship and updat-
ing the model estimates as data arises. At the end of the trial, the dose with expected
posterior probability of DLT closest to θ is selected as the T̂D100θ.
In the Continual reassessment method (CRM) (O’Quigley et al., 1990), the dose-
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toxicity model is described by some function. O’Quigley et al. state that a one-
parameter model is suitable to accurately estimate the T̂D100θ. Other authors (e.g.
Neuenschwander et al., 2008; Whitehead and Williamson, 1998) instead use a two-
parameter dose-toxicity model which is better suited than a one-parameter model to
model the entire dose-toxicity curve (O’Quigley et al., 1990). This can be advanta-
geous as it allows straight-forward inference (compared to that from the CRM) about
doses aside from the T̂D100θ to be drawn. This may be required in practice if updated
clinical opinion leads to the target toxicity level θ being changed. Another example
where knowledge of the entire dose-toxicity curve can be useful is when multiple doses
of the treatment are to be taken to phase II efficacy trials to determine which of the
selected doses has the best benefit to risk ratio. Taking forward a dose with a tox-
icity rate too far below θ would not be beneficial, given the assumption that this
corresponds to low efficacy. Knowledge of the entire dose-toxicity curve is required to
sensibly deduce this.
When it is not felt that a reasonable assumption can be made concerning the
form of the dose-toxicity curve, then a curve-free design may be preferable. Curve-
free methods, such as those proposed by Gasparini and Eisele (2000) and Whitehead
et al. (2010), have been suggested as non-parametric alternatives to algorithmic and
model-based designs. Curve-free designs require specification of the prior expected
probability of DLT at each dose of the treatment which is to be made available for
administration to patients in the trial. These probabilities are updated during the trial
as data arises. As with model-based methods, curve-free designs enable quantitative
definition of the recommended dose as the T̂D100θ. The operating characteristics of
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model-based and curve-free designs are comparable, with clear differences only really
arising in the correct/mis- specification of the underlying model for the dose-toxicity
relationship in model-based designs (Jaki et al., 2013). A comparison of the properties
of algorithmic, model-based and curve-free dose-escalation trial designs is presented
by Jaki et al. (2013).
For the work in this thesis, we assume that it is reasonable to assume a model
for the dose-toxicity relationship and, therefore, model-based designs are the focus
of further discussions on dose-escalation methods. Frequentist model-based designs
have been proposed (e.g. O’Quigley and Shen, 1996) but in early phase trials (includ-
ing dose-escalation) where there is belief in the treatment but little observed data,
Bayesian designs can be beneficial. The use of a Bayesian design enables intuitive in-
corporation of relevant historical data along with available trial data. Increasing the
amount of information upon which trial decisions are based can improve the safety of
the trial for patients. For this reason, the dose-escalation designs proposed in this the-
sis use Bayesian methods. Two existing Bayesian model-based designs are described
in detail in Section 2.2.2. These are the Bayesian (two-parameter) logistic regression
approaches of Whitehead and Williamson (1998) and Neuenschwander et al. (2008).
Alternative Bayesian model-based approaches exist (e.g. Babb et al., 1998; Thall and
Lee, 2003), all of which are based on the same basic principles.
A literature review of model-based dose-escalation trial designs for a single-agent
treatment is given in Section 3.1.1. In Section 3.2, the design of Whitehead and
Williamson (1998) is extended to allow different recommended doses to be selected
in each of two pre-defined subgroups, if this is deemed necessary. In Section 4.3,
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a dual-agent dose-escalation trial design which incorporates pharmacokinetic data
is considered. The design underlying this method is based on the dose-escalation
method described by Neuenschwander et al. (2008). Through the comparison of the
Whitehead & Williamson design and that of Neuenschwander et al., in Section 2.2.2,
and demonstration of extensions to these designs in Chapters 3 and 4, it should be
clear that most alternative, model-based dose-escalation methods could be extended
to similar end.
2.2.1 Bayesian Methods
Bayesian methods are endorsed for use in small clinical trials within the pharmaceuti-
cal industry (CHMP et al., 2006). Adamina et al. (2009) discuss the potential benefits
of using Bayesian statistics in oncology. Bayesian methods can be especially useful in
early phase clinical trials where belief in the experimental treatment heavily outweighs
knowledge of it in practice (given that the treatment has progressed to clinical trials).
Bayesian trial designs enable prior belief about the treatment to be incorporated into
the trial along with trial data. This means that trials are subjective, and consequently
the use of Bayesian statistics can be controversial. However, when prior information is
wisely incorporated, such designs should be more efficient than their frequentist coun-
terparts because they make better use of available information. Bayesian designs can
be seen as a means of formalising learning and, in many cases, the resulting inferences
are more natural than those obtained from a frequentist analysis.
In the trial designs presented in this thesis, an understanding of the Bayesian
paradigm is assumed (otherwise see Hoff, 2009, for an overview). Take, for example,
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Yjx to be a binary indicator of whether patient j, treated with dose x from the set of
available doses d, experienced a DLT in the first cycle of treatment. The probability




1 if patient j experienced a DLT at dose x,
0 otherwise.
Say that from nx patients treated at dose x, tx =
∑nx
j=1 yjx is the number who
experienced a DLT in the first cycle of treatment. Set ux = nx − tx as the number
of patients who did not experience a DLT at dose x in this time. Now, the random
variable of which tx is a realisation is Tx with Tx ∼ Binomial(nx, pi(x)).The likelihood







∝ {pi(x)}tx{1− pi(x)}ux .
In the Bayesian setting, a prior distribution f0(pi(x)) is specified for the probability
that a patient treated with dose x experiences a DLT. The Beta distribution is a
natural choice of prior distribution for binomial data because it is the conjugate prior
to the binomial likelihood. This means that the prior and posterior distributions have
the same form and upon observing more data, only the parameters of the posterior
distribution are updated and not the distributional shape (Hoff, 2009). In addition,
the parameters of the beta distribution have an interpretation which is relevant to
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this setting. For the prior pi(x) ∼ Beta(ax, bx), ax can be interpreted as the number of
patients who experienced a DLT and bx as the number who did not experience a DLT,
at dose x. The mean of the distribution is then a/(a+ b), the proportion of patients
who experienced a DLT at dose x. The posterior distribution of the probability of
DLT at dose x, given tx DLTs observed in nx patients treated at dose x, is then
obtained from the prior and likelihood of the observed data using Bayes Theorem
(Bayes and Price, 1763):
f(pi(x)|tx) ∝ f(tx|pi(x))f0(pi(x)),
⇒ pi(x)|tx ∼ Beta(ax + tx, bx + ux).
Take a simple example: Prior to dosing any patients, the prior belief is that if
six patients were treated at dose x, then two of them would experience a DLT in the
first cycle of treatment. This can be represented by the prior distribution, f0(x) ∼
Beta(2, 4), shown by the dashed black curve in Figure 2.2.1. Now, say that in a cohort
of three patients treated at dose x, two DLTs were observed. The prior distribution
can be updated to give the posterior distribution, f(pi(x)|tx) ∼ Beta(2 + tx, 4 +ux) ≡
Beta(4, 5) which is shown by the solid grey curve in Figure 2.2.1.
From the resulting posterior distribution, posterior probabilities can be calculated.
For example, the posterior probability that pi(x) is greater than 0.35 is 0.71 (repre-
sented by the shaded area in Figure 2.2.1). So, with observation of two out of three
patients in a cohort experiencing a DLT at dose x, the probability that pi(x) is greater
than 0.35 has increased from 0.43, based only upon prior belief, to 0.71. This process
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can be repeated after responses are observed from each cohort of patients to obtain
the updated distribution of pi(x). Similarly for other values of x, where x is an element
of the available dose set d. This is done under an assumption of independence of the
doses making up dose set d.
















Figure 2.2.1: Prior Beta(2, 4) distribution (shown by the dashed black curve) and
posterior Beta(4, 5) distribution (shown by the solid grey curve) of pi(x) with the
shaded area being equal to the posterior probability of pi(x) being greater than 0.35.
In the example presented, the posterior distribution is tractible due to model
conjugacy and the posterior probabilities can be calculated analytically. This will
not always be the case. For example, using a logistic regression model to describe the
relationship between dose and the probability that a patient experiences a DLT results
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in a complex posterior distribution for any given prior. Markov Chain Monte Carlo
(MCMC) can be used to obtain inferences from complex distributions of this kind.
A short overview of MCMC methods is given here but more details can be found in
Robert and Casella (2005). As an alternative to MCMC, for situations involving only
a few unknown parameters, numerical methods may be better suited. These methods
are less computationally intensive than MCMC and hence, in low dimensions are
quicker to obtain inferences from than MCMC.
A Markov chain of length H is a sequence of random variables Zh, for h =
1, 2, ..., H, for which the distribution of Zh is conditional only on the value of Z(h−1).
So, for a given starting value, z0, the value of z1 is dependent only upon the value of
z0. Similarly, the value of z2 is dependent only upon the value of z1, and so on. The
values z0, z1, ..., zH form the Markov Chain.
Markov Chain Monte Carlo methods define a distribution p(.) which has the same
limiting distribution as the posterior distribution of interest. A sample from p(.), with
the initial section of the chain removed as ‘burn-in’ (the part of the chain before it
converged to a sample of the limiting distribution), is then in effect a sample from
the posterior distribution of interest, f(.).
Inferences on the posterior distribution can be calculated from the sample us-
ing Monte Carlo methods. Monte Carlo methods take generated samples from the
posterior distribution and uses the strong law of large numbers to replace complex in-
tegrations with sums. Take z1, z2, ..., zH , to be a sample from the limiting distribution
p(z) and the posterior distribution of interest to be f(.). The mean of the distribution
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Computer programs are available which perform MCMC for a range of problems,
removing the need to personally program an algorithm to perform the required calcu-
lations. Different programs and packages use different algorithms but for the relatively
simple problems tackled in this work, the specific choice of algorithm is fairly irrel-
evant. Simulations were carried out using R (R Core Team, 2014) and the MCMC
package selected for the work in Chapter 3 was BoomSpikeSlab (Scott, 2014) and
that in Chapter 4 was Rstan (Stan Development Team, 2013). BoomSpikeSlab uses
variable selection based on the work of George and McCulloch (1997) and Tu¨chler
(2008). Rstan is based on a no U-turn sampler which is described in detail in the
manual (Stan Development Team, 2012). The packages are discussed in further detail
in the relevant chapter.
2.2.2 Conduct of a Bayesian Logistic Regression Approach
in Dose-escalation
A range of Bayesian model-based dose-escalation designs have been proposed by dif-
ferent authors. Although the method of escalation and/or selection of the T̂D100θ
differs between these methods, the underlying methodology is very similar in most
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cases. In these approaches, risk is defined as the probability of experiencing a DLT
and the TD100θ is treated as an unknown parameter requiring estimation. Under
this definition, the T̂D100θ can be identified from a continuous range of doses, even
if it is not one of the discrete doses administered to patients during the trial.
In finding the recommended dose by dose-escalation, it is assumed (as stated in
Whitehead and Williamson, 1998) that: i) The probability that a patient experiences
a DLT increases monotonically with dose of the treatment, ii) The probability that
the treatment is efficacious increases monotonically with dose of the treatment, iii)
Information on whether a patient experienced a DLT is available relatively soon after
administration of the treatment. Under these standard assumptions, most Bayesian
model-based approaches to dose-escalation follow the same basic method:
1. Specify the general trial set-up;
2. Specify the decision rules: For escalation and stopping;
3. Specify the model(s) for the dose-response relationship(s) utilised in the decision
rules (defined in Step 2);
4. Specify priors on the parameters of the selected dose-response model(s) (defined
in Step 3);
5. Identify a start dose for the trial;
6. Administer a cohort of patients with the dose considered “optimal” for them at
their time of entry to the trial, based on the decision rules defined in Step 2;
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7. Update the dose-response model(s) (defined in Step 3) with the observed patient
responses;
8. Dose-escalation continues by repeating Steps 6 and 7 until one of the stopping
criteria (defined in Step 2) is met;
9. Identify the recommended dose for use in future trials of the treatment.
Each of the steps in dose-escalation are described in turn in the remainder of this
section. The discussion follows two Bayesian logistic regression approaches and high-
lights the differences between the methods. The two designs are those of Whitehead
and Williamson (1998) and Neuenschwander et al. (2008) which are the underlying
designs for the methods of dose-escalation proposed in Chapters 3 and 4, respectively.
Step 1: Specify the general trial set-up
Pre-clinical and historical trial data are extrapolated in order to identify an expected
therapeutic dose range of the experimental treatment. Together with practical con-
siderations, which may constrain the dose levels of a treatment available for admin-
istration from a continuous range to a set of doses (for a drug in tablet form, say),
this information can be used to identify a set of doses to be made avaiable for ad-
ministration to patients in the trial. Although in practice dose-escalation (using a
model-based design) is not constrained to these pre-specified doses, pre-specification
is necessary for simulation purposes. Simulation is encouraged by regulatory agencies
in clinical trial design (Manolis et al., 2013) to confirm that operating characteristics
of the proposed trial are reasonable under a range of potential scenarios.
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Operating characteristics (or tradition in some cases) of the design are also likely
to influence the choice of cohort size used in the trial. Cohorts consisting of a single
patient provide optimal escalation decisions by selecting the next dose for administra-
tion using all available data under a Bayesian approach which explores the available
dose range (Gerke and Siedentop, 2008). However, larger cohorts of size 3-6 are com-
mon. Using larger cohorts means that, in general, more information is obtained at
each dose, removing the risk of escalating after a single/couple of observations at a
dose. This can slow escalation but comes from algorithmic methods in which de-
escalation and re-escalation is not generally considered. Practical reasons such as
timings of dose-escalation meetings (in which clinical and statistical experts meet to
discuss the next escalation step) can also be motivators for inflated cohort sizes. Un-
der Bayesian methodology, the cohort size can differ between cohorts. Small cohorts
could be used at the start of the trial when the probability of a patient experiencing
a DLT is expected to be low. At higher doses, where there is greater uncertainty over
the expected toxicity, larger cohorts can be used.
Knowledge of the treatment area is used to draw up a list of toxicities which are
considered to be dose-limiting for the treatment of interest. The time-frame in which
these toxicities will be considered to impact dose-escalation decisions (commonly the
first cycle of treatment in oncology) is decided. Another practical consideration is
the maximum number of patients available for the trial. This might be based on the
availability of resources, prevelance of the condition and expected recruitment rates.
Another design consideration is the definition of the recommended dose. White-
head and Williamson (1998) select a single value of θ, as a toxicity level which, under
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the assumption that toxicity increases monotonically with efficacy, implies a suitable
level of efficiacy of the treatment without unnecessary toxicity. Based upon this, the
TD100θ is clearly defined as the dose with probability θ of causing a DLT in a patient.
Ideally, the recommended dose would then be defined as the estimate of the TD100θ
resulting from the trial. Practical additions to this definition are often necessary. For
example, these could restrict selection of the recommended dose to those administered
in the trial, or to doses with probability of a patient experiencing a DLT less than
some value, δ (for δ > θ). If this were the case, then the TD100θ corresponds to the
dose with the targeted toxicity level θ which satisfies an additional safety criterion
based on toxicity rate δ. As well as its used in the definition of the recommended dose,
δ can be useful in escalation to control the rate of escalation and reduce the chance
of undesirably large escalation steps being taken in the presence of uncertainty. The
use of δ in escalation is discussed further in the explanation of Step 2.
Instead of defining a point probabilities of toxicity, Neuenschwander et al. (2008)
classify the probability of DLT in relation to its expected efficacy. For example, a
dose x with probability pi(x) of causing a DLT in a patient is classified:
• for pi(x) ∈ [0.00, 0.16] as an underdose;
• for pi(x) ∈ (0.16, 0.35] as being in the target toxicity interval; and
• for pi(x) ∈ (0.35, 1.00] as an overdose.
This is simply an alternative method of defining the target toxicity. Although
it is a more general criteria, the toxicity classifications clearly define the boundaries
between acceptable and unacceptable levels of toxicity of the treatment. The use of
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the toxicity interval instead of using a point estimate accounts for the lack of power to
detect a single value of θ in relatively small dose-escalation trials. The recommended
dose in this case is defined as the dose which maximises the posterior probability of
being in the target toxicity interval. Using the TD100θ notation, the recommended
dose by this method has θ ∈ (0.16, 0.35]. As before, the recommended dose could be
restricted to administered doses and a safety criterion involving δ can be incorporated.
So, in this case (as with the method of Whitehead & Williamson) the recommended
dose is not truly T̂D100θ due to the safety criterion and potentially the restricted
dose set available for administration to patients. In this thesis, T̂D100θ refers to
the recommended dose definition, including safety and/or other constraints on the
selection of the recommended dose.
Step 2: Specify the decision rules
In estimating the TD100θ, two kinds of decision rules need to be specified: The
escalation rule determines when to escalate and by how much, and the stopping rule
which determines when to stop the trial either for safety concerns or having estimated
the TD100θ with a suitable level of accuracy.
A fully Bayesian procedure administers patients with the dose of treatment which
maximises a specified gain function. Difficulties of such an approach can arise in
defining the gain function. Several gain functions are defined in Whitehead and
Williamson (1998). The gain function of interest to us is the patient gain;
1
{pˆi(x)− θ}2 ,
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where pˆi(x) is the posterior estimate of the probability that a patient administered
dose x of the experimental treatment experiences a DLT. The model used to estimate
pˆi(x) is discussed in Step 3. Based upon this gain function, patients are administered
the dose which, based on the posterior modal estimates of the model parameters, has
posterior probability of toxicity closest to the (single) target toxicity level θ. So, use of
this gain function leads to patients being administered the dose (from those available
in the trial) which is optimal for them based on all currently available data. Basing
the estimate of pˆi(x) on the posterior modal estimates of the model parameters, as
opposed to the full posterior distribution, can be considered a waste of information.
However, for the small amounts of data available in dose-escalation, it can be argued
that the choice of estimate has little effect. The posterior modal estimates are used
here instead of alternative point estimates such as the mean and median. This is
because, for the model and priors defined by Whitehead & Williamson, the modal
estimate is derived through conjugate analysis where the other inferences are not.
This make the modal estimate less computationally intensive to derive.
The patient gain function can be employed as the only escalation rule in a dose-
escalation trial (as in Whitehead and Williamson, 1998). However, doing so can lead
to undesirably rapid escalation in some situations. For example, trial data overcom-
ing prior data early on in the trial leading to the skipping of multiple pre-specified
doses. One method of controlling escalation is to specify maximum increases for esca-
lation steps. Alternatively, or as well as incorporating this restriction, safety criteria
based on the model estimates can be introduced (in a similar way to the Escalation
With Overdose Control criteria used by Babb et al., 1998). This can be achieved by
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extending the definition of the escalation rule to:
• Administer patients the dose which, based on the posterior modal estimates of
the model parameters, maximises the patient gain 1/{pˆi(x) − θ} for estimate
pˆi(x) based on the assumed model, within doses which satisfy pi(x) < δ.
Whitehead and Williamson (1998) suggest alternative formulations of the patient
gain which are more conservative and also propose gain functions based around infor-
mation gain. Use of the information gain can lead to quicker and potentially improved
identification of the TD100θ over the patient gain. However, it is not the preferred
gain function because it is not as beneficial for patients involved in the trial as the
patient gain. This is because the dose administered to patients is that which max-
imises the information which can be obtained; this is beneficial to investigators but
may lead to patients being dosed sub-optimally based on current information.
Neuenschwander et al. (2008) define a target toxicity range, as opposed to a single
point value, and utilise the entire posterior distribution in making inferences from
the model. This is done to allow for uncertainty in pˆi(x) and that which surround
the choice of a single target toxicity, θ. The counter-part escalation rule to that of
Whitehead and Williamson (1998) which accounts for these design differences is;
• Administer patients the dose which, based on the full posterior distribution of
pˆi(x), has maximum posterior probability based on the assumed model
of being in the target toxicity interval within doses with posterior proba-
bility of being classified as an overdose < δ.
The other decision rules that we consider are stopping rules. Ideally these will
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come into force when the TD100θ has been estimated with suitable accuracy. This
decision could be based upon the width of credible intervals around the estimate of
the TD100θ (Whitehead and Williamson, 1998). Equivalently, for the Neuenschwan-
der et al. (2008) set-up, having a posterior probability of being in the target toxicity
interval greater than some boundary could warrant stopping the trial for accuracy.
Under both methods, it is difficult to specify the boundary defining accurate esti-
mation of the TD100θ. To reduce the chance of prematurely stopping the trial for
accuracy, checks based on the definition of the TD100θ identified from the trial can
also be incorporated. For example, ensuring that at least 9 patients have been treated
at the estimated TD100θ or that doses above the estimated TD100θ do not satisfy
the safety criteria.
Practical and ethical reasons warrant the use of two additional stopping rules. A
rule of practicality may be: once a given number of patients have been treated in the
trial, escalation ceases (if it has not already done so for accuracy). A rule that ensures
that the trial is ethical enables escalation to stop if no dose from those available for
the trial satisfies the safety constraint on escalation. Implicitly, this stopping rule
implies that doses below the pre-specified dose range are expected to be too low to be
efficacious regardless of their toxicity. If this is not the case then de-escalation could
occur within an extended dose range.
Step 3: Specify the model(s) for the dose-response relationship(s)
The designs of Whitehead and Williamson (1998) and Neuenschwander et al. (2008)
both utilise only one dose-response model in dose-escalation. That is, they both model
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the dose-toxicity relationship. They consider the probability of a patient experiencing
a DLT at dose x, pi(x), to be suitably modelled by a two-parameter logistic regression
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Instead of using the dose of treatment directly in this model, the transformation
log(x/d∗ + 1) was used. One is added to the standardised dose to enable the model
to handle a zero dose of treatment. Although this transformation seems unnecessary
for the single-agent trials discussed so far, it becomes more relevant later on when
combination trials are discussed.
The reference dose d∗ is used to standardise the actual dose in the model. This
transformation, as well as taking the log of the standardised dose, changes the scale
that doses are considered on. In this thesis, this is the transformation used to demon-
strate the methods.Alternatively, the untransformed dose or another one-to-one trans-
formation of dose could be used with no negative impact on inferences or interpreta-
tion. The transformation selected for use in the model should be one which produces
an suitable increase in the probability of toxicity for a one unit increase in trans-
formed dose. This is therefore more of a clinical than statistical consideration with
experience showing that relationships based on untransformed dose usually lead to
escalation decisionswhich are considered to be too cautious.
The proposed dose-escalation design in Section 3.2 extends this dose-toxicity model
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to a four-parameter model with the additional terms relating to subgroup membership.
In Section 4.2, the two-parameter dose-toxicity model is extended to a five-parameter
model for a dual-agent treatment and in addition, a dose-exposure model is specified.
For ease of notation in Chapter 4, the two-parameter dose-toxicity model in Equation
2.2.1 is re-parameterised with log(α) and β in place of β0 and β1 to make the notation
clearer in the dual-agent setting. These extended/additional dose-response models
and their corresponding use in dose-escalation are discussed in the Chapters 3 and 4,
respectively, alongside examples of prior specification for each. Prior specification on
the model parameters is also discussed in Step 4.
Step 4: Specify priors on the model parameters
It is possible to incorporate available, relevant historical information on the exper-
imental treatment into the prior(s) on the dose-response model(s). Whitehead and
Williamson (1998) use the intuitive interpretation of the Beta distribution with prior
data (as described in Section 2.2.1) to specify Beta distributions on the probability
of toxicity at two independent doses. In order to avoid the prior over-riding trial
data, which may contradict the prior, the prior data are down-weighted compared to
the trial data. The result is that down-weighted prior data are incorporated into the
model as if it were trial data under this design. See Tsutakawa (1975) for full details
of this prior derivation and Whitehead and Williamson (1998) for details on eliciting
such a prior from expert opinion.
As an alternative method of prior elicitation, Neuenschwander et al. (2008) propose
utilising relevant historical data to specify a bi-variate normal distribution on the
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model parameters β0 and log(β1). This can be achieved using a meta-analytic type
approach similar in derivation to a power prior (Ibrahim and Chen, 2000). The
parameters of the bi-variate normal distribution can be found as follows:
1. Obtain a relatively non-informative prior on β0 and log(β1):
i. Assume a median probability of DLT at the reference dose d∗;
ii. Assume that doubling the dose of treatment would double the odds of a
patient experiencing a DLT;
iii. Assume large standard deviations for each parameter and that the correla-
tion between the parameters is equal to zero;
iv. The resulting confidence intervals for the probability of toxicity will cover
most of the probability space.
2. Update the non-informative prior derived in Step 1 with the historical toxicity
data;
3. Assume some level of between trial heterogeneity for the historical trial and that
to be performed;
4. Use the assumed between trial heterogeneity to increase the variance of β0 and
log(β1) using a meta-analytic type approach to obtain a weakly-informative
prior distribution for use in the trial.
In the prior elicitation methods used by Whitehead and Williamson (1998) and
Neuenschwander et al. (2008), the prior data is effectively down-weighted compared
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to the trial data. This is done to account for heterogeneity between data which will
be collected in the current trial and the historical data used in prior elicitation. We
therefore expect that, the more similar the current and historical trials, the less the
historical data is down-weighted. Whitehead and Williamson (1998) select the weight
of the historical data in terms of the total number of patients the data will represent
in the posterior distribution. Neuenschwander et al. (2008) instead take all available
historical data and increase the variance of the resulting distribution to account for
heterogeneity. Both of these methods have the same general effect of decreasing the
information provided by the prior.
A lack of relevant prior information does not render Bayesian designs useless. If
no suitable prior information is available, then a weakly informative prior can be
used. This could be derived from Step 1 of the prior derivation for the design of
Neuenschwander et al. (2008). Alternatively, and arguably more useful, is to specify
a weakly informative prior which helps to control the operating characteristics of the
trial. For example, setting the prior such that the desired start dose for the trial
is that which optimises the specified gain function. Also, specifying the prior such
that escalation resulting from its use is suitably cautious, under a range of likely
scenario’s. Specifying the prior in this way leads it, in some sense, to take the role of
escalation rules which restrict the rate of escalation. Such a prior can be obtained for
the Whitehead and Williamson (1998) method with hypothetical data, as opposed to
elicited data, being used and a range of likely trial scenarios being investigated.
When the prior is selected to control the operating characteristics of the trial, the
prior data is heavily down-weighted, to say 1/10th of the planned sample size of the
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trial (as in Whitehead and Williamson, 1998). This means that the prior help to will
control escalation at the beginning of the trial but will quite easily be over-powered
by trial data. Later escalation decisions are therefore expected to be more heavily
data driven. An example of such a prior is demonstrated in the work in Chapter 3.
On the other hand, the work in Chapter 4 demonstrates the setting where relevant
data is available from historical trials and so this is not as heavily down-weighted.
Step 5: Identify a start dose for the trial
Ideally, the start dose for the trial would be selected as the dose which is optimal based
on the specified prior and gain function. This may be the case when the prior is chosen
to control the operating characteristics of the trial, with consideration of the toxicity
of the desired start dose, this may be the case. Alternatively, the start dose can be
forced to be a desired dose (from those classified as safe by the safety criterion). When
this is the case, escalation rules which constrain the rate of escalation will probably
over-ride model decisions in the initial few cohorts treated in dose-escalation. This is
because the data acquired in these initial cohorts are gaining evidence on low doses
which, based on prior data and the model specified, are already believed to be safe.
Step 6: Administer patients with the “optimal” dose
The first cohort of patients treated in the trial will be administered with the start
dose for the trial. This could be a forced dose or optimal based on prior knowledge,
as discussed in Step 5. Later cohorts of patients are administered the dose which is
optimal based on the escalation criteria defined for the trial (as discussed in Step 2).
The dose advised for escalation by the model is the optimal dose based on the
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model specified, escalation criteria defined and information inputted to the model. In
practice, the dose advised by the model is not always administered to patients since
experts review additional historical or current trial data (including safety data not
used in the model, efficacy and pharmacokinetic data), along with the model recom-
mendation, in selecting the actual dose for administration. Data used in escalation
decisions which is not formally incorporated in the escalation criteria is being used
subjectively.
Step 7: Update the dose-response model(s)
The specified dose-response model(s) are updated with the observed patient responses
and inferences required for the trial decision rules are obtained from them.
Step 8: Dose-escalation continues until a stopping criterion is met
The trial continues through escalation, including possible stationary or even de-
escalation steps by repeating Steps 6 and 7 until one of the stopping rules specified
for the trial in Step 2 is met. At this point, dose-escalation stops and the model is
updated with all information obtained in the trial.
Step 9: Identify the recommended dose
When one of the stopping rules is met, dose-escalation stops. By this point, the
estimate of the TD100θ should have converged to the true value if a suitable number
of patients have been treated in the trial. In practice it is common to confirm safety of
the recommended dose by carrying out a dose-expansion trial but this stage in trials
is not covered in this thesis.
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If the trial was stopped for safety concerns, then there is no dose recommended
for use in future trials. The binary nature of the toxicity endpoint used mean that
chance toxicities at low doses can lead to this, even when it is not necessarily the case.
If, instead, the trial stopped for non-safety related reasons, then a recommended
dose for use in future trials can be identified. The most intuitive definition of the
recommended dose is the T̂D100θ, the dose which optimises the escalation criteria
based on all available information. As discussed in Step 1 with regard to the definition
of the recommended dose, in practice other criteria may also need to be considered in
defining the recommended dose.
2.3 Dual-agent Dose-escalation
A single drug can make an effective treatment but sometimes cells develop resistance
or need to be targeted through multiple pathways in order for the treatment to be
efficacious (Greco et al., 1996). In an attempt to overcome these problems, or sim-
ply to increase the efficacy of a treatment, multiple drugs can be administered as a
combination treatment.
In this thesis, any novel treatment which is under investigation is called an ‘ex-
perimental treatment’. In a clinical trial of a mono-therapy/single-agent treatment,
there is only one experimental treatment. When more than one experimental treat-
ment is administered to a patient, the combination is referred to as the ‘combination
treatment’. For ease, when the context is clear, the combination treatment will sim-
ply be referred to as the treatment. Standard treatments which cannot ethically be
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withheld from patients are not classified as experimental treatments. So, an experi-
mental treatment administered alongside standard treatment is still referred to as a
single-agent. Similarly, when two experimental treatments are administered on top
of standard treatment, the dual-agent combination treatment refers only to the two
experimental treatments. The dual-agent setting is the one discussed in the remainder
of this thesis when referring to a combination, unless specifically stated otherwise.
The objective of a dose-escalation trial of a combination treatment is to identify the
toxic dose combination with probability θ of causing a DLT in a patient (TDC100θ).
An obvious complication over the single-agent setting is that there are now multiple
drugs to escalate. The number of available dose levels of each drug can make it
implausible to test each possible combination in sequence. When this is the case,
only a range of the possible dose combinations can be tested.
Another complication in the dual-agent setting is that drug-drug interactions
(DDIs) can occur. In this work, DDIs are assumed only to occur between the ex-
perimental treatments and not with standard treatment (alternatively for the effect
to be consistent across the trial population under an assumption of homogeneity).
When a DDI occurs, there will either be a synergistic or an antagonistic reaction
compared to the event of no interaction. Synergy is when the experimental treat-
ments work together to produce a beneficial effect greater than that expected from
either single-agent in the case of no interaction. Antagonism on the other hand is
when the experimental treatments work against each other, resulting in an overall
beneficial effect which is less than that expected in the case of no interaction. Dif-
ficulties arise in defining ‘no interaction’ since multiple models have been defined to
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describe it and with none being distinctly better than the other in many situations
(Su¨hnel, 1998). This issue is addressed in Section 4.2 in relation to the dose-response
models used for toxicity and exposure data, where exposure is a measure of the con-
centration of a drug in the body (more details on exposure data are given in Section
2.4.2).
DDIs can affect toxicity and/or exposure (Rodrigues, 2008). Dose-toxicity and
dose-exposure interactions are not always aligned (proportionally, say) and can not
be reliably predicted from pre-clinical data. Greco et al. (1996) give the example of an
in vitro test of a combination treatment which results in an antagonistic DDI being
expected in the clinical setting. This may be the observed interaction. On the other
hand, if the combination is more specific to tumour cells than normal cells, then the
effect may be decreased toxicity, despite increased exposure being observed due to the
antagonistic reaction occurring. Greco et al. (1996) suggest that until there is better
knowledge of drug pathways and modes of action, pre-clinical DDI information should
be used to obtain a better idea of the mechanism of the drugs’ actions rather than as
a predictor of clinical outcome.
We maintain the assumption that toxicity increases monotonically with dose for a
single-agent treatment. In the combination setting, this leads to marginal monotonic-
ity. However, the monotonicity assumption is not used in the two-dimensional space.
Since we wish to identify the TDC100θ, the dose-toxicity surface (which combines the
dose-toxicity curves of each of the two drugs when administered in combination) is
of interest. The plot in Figure 2.3.1 shows an example dose-toxicity surface. It can
be seen that in the combination, multiple dose-pairs have probability θ of causing a
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DLT in a patient. Information other than DLT data (such as exposure data) is useful
in selecting which of the dose-pairs, with probability θ of causing a DLT in a patient,
should be recommended for use in future trials of the treatment. More information
about dose-response surfaces in relation to the choice of drug-drug interaction models
can be found in Greco et al. (1995).
Dose-escalation of a combination treatment follows the same general steps as de-
scribed in Section 2.2.2. At the time of design of a combination dose-escalation trial,
single-agent trials of both of the relevant treatments will have been completed and
pre-clinical trials on the combination will have been carried out. This means that
some safety, pharmacokinetic and possibly efficacy data available will be available on
the single-agent treatments. This information can be used in defining the decision
rules and prior distribution used in the combination trial. Although pre-clinical in-
formation on DDIs is highly speculative, this data can used in specifying priors on
the model parameters relating to the possible DDI. The high level of uncertainty over
the interaction is encompassed through a high prior variance.
A review of Bayesian, dual-agent dose-escalation methods is given in Section 4.1.
In the remainder of Chapter 4, a design for utilising pharmacokinetic exposure data
in dual-agent dose-escalation is considered.
2.4 Utilising Additional Data in Dose-escalation
Some of the benefits of using Bayesian dose-escalation trial designs, such as those
described in Section 2.1, are being recognised and model-based designs are becoming























Figure 2.3.1: Example dose-toxicity surface for a combination treatment of drugs A
and B.
more common in practice (Biswas et al., 2009). A recent review by Dahlberg et al.
(2014) concluded that sample sizes of phase I trials are increasing. This reflects
recognition from trial sponsors of the importance of obtaining accurate results from
phase I trials. Despite these advances, there is still work to be done in this area.
Paul et al. (2010) recognise that spending more on phase I trials could decrease drug
development costs in the long-term. Considering data other than DLT information
during dose-escalation can be beneficial to long-term drug development by improving
decisions made in, and resulting from, dose-escalation trials.
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In order for the incorporation of additional data in trial designs to be feasible
in practice, the extra information needed to set up and run the trial must be easily
obtained within the constraints of the trial. The fact that of the 98 drugs approved
in 2000, only 27 were chemically new (Schmid and Smith, 2004), shows that often,
instead of chemically new treatments being developed, new applications (e.g. pop-
ulations, diseases) or useful combinations of already accepted treatments are being
found. In these situations, the treatment still needs to be shown to be efficacious
but initial research costs involved in drug discovery are minimal (Schmid and Smith,
2004) and speed of development compared to a chemically new treatment is increased.
It also means that data are likely to be available which can be used to aid the design
of future trials of a treatment in the new application or combination.
In this thesis, we consider using biomarker and pharmacokinetic data to improve
escalation decisions. These data are discussed in detail in Sections 2.4.1 and 2.4.2 be-
fore being incorporated into dose-escalation designs in Chapters 3 and 4, respectively.
The proposed dose-escalation designs are practical to implement since the additional
data they require during the trial are available within reasonable time constraints.
2.4.1 Biomarker Data to Identify Patient Subgroups
The reaction to a certain treatment may differ between subgroups of a patient pop-
ulation. This reaction could cause a change in the way the body processes the drug,
affecting the safety and/or efficacy of the treatment. For example, the presence of
KRAS mutations in colorectal cancer is a reliable predictor of poor response to spe-
cific common treatments for this disease (Lie`vre et al., 2006). Indicators of differences
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in reaction to treatment, such as presence of KRAS mutation, can be referred to as
biomarkers of susceptibility (WHO, 1993). These biomarkers include physical char-
acteristics such as age, gender or ethnicity, as well as genetic differences. From here
on, the term ‘biomarker’ is used to refer to a biomarker of susceptibility.
Currently, the over-riding use of biomarkers in early phase clinical trials is to
exclude certain patient subgroups from treatment (in order to justify an assumption
of a homogeneous trial population). If, before the trial, it is known that no dose of the
treatment has a suitable benefit-risk ratio in the subgroup, then it may be just as well
to exclude members of that subgroup from the trial. It is possible though that in the
potentially excluded subgroup, a lower dose (that identified for the remaining patient
population) could have suitable efficacy gains for use as a secondary line of treatment
in this subgroup, say. Conversely, ignoring potential subgroup effects is also not ideal
because it can lead to a diluted treatment effect. When this is suspected to be the case,
it can be investigated through phase II/III enrichment designs (see Temple, 2005, for
a short overview of such designs). Often these designs drop subgroups with the lowest
efficacy, resulting in the use of a sub-optimal dose in the remaining population. A
literature review of clinical trial designs which account for potential subgroup effects
is given in Section 3.1.2.
Due to a limited number of patients being involved in early phase clinical trials,
reliable identification of relevant biomarkers within the trial is unrealistic. Potential
subgroups of interest can, however, be identified before the trial begins in some cases.
For example, differences between patient reactions in historical trials of the same
treatment in another application, or of a treatment with similar action in the same
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application, can be used to identify a biomarker of interest. Texts (e.g. Jain, 2010)
which report the findings of exploratory trials to produce lists of biomarkers for specific
diseases which are likely to be influential are also available.
There is therefore scope for using subgroup data, based on a pre-defined biomarker,
to advise dose-escalation (see ICH E6 CDER/CBER, 2011). The trial population
could then be wider, increasing the population that the treatment could be found to
be efficacious in. Allowing different optimal doses to be estimated in each subgroup
can improve the benefit-risk ratios for patients. The potential loss of accounting for
a subgroup effect when in fact there is not one, is considerably less detrimental than
not accounting for a subgroup effect when in fact there is one.
2.4.2 Pharmacokinetic Data in the Combination Setting
Pharmacokinetic (PK) data measures the exposure, or level, of the drug in the body.
It is concerned with the absorption, distribution, metabolism and excretion of a drug
(Ka¨lle´n, 2008). The PK properties of a drug are thoroughly investigated as part of
pharmacology trials which monitor patients dosed at a specific range of concentrations
of the experimental treatment. Although an in-depth analysis of the PK properties of
a drug is possible in dose-escalation trials, some PK data are routinely obtained from
some, or all, trial patients to form part of the treatment’s safety profile. Despite this,
its use in dose-escalation is at present often only informal, if at all. It is therefore
plausible that benefit could be gained by formally incorporating this already available
PK information into dose-escalation trial designs.
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Jambhekar et al. (2009) give an introduction to PK data, the basics of which are
described here. The PK exposure parameters of interest to us can be calculated from
a patient’s concentration-time curve. This is obtained by taking blood samples from
the patient at regular intervals (for example, at times t = 0.5, 1, 2, 4, 8, 16, 24 and 48
hours) after administration of the treatment at time t = 0. Each of the samples is
analysed to find the plasma concentration of the drug in the patient’s blood at the
sampled time. This information is then plotted to obtain a patient’s concentration-
time curve, such as that shown in Figure 2.4.1.
Figure 2.4.1: Example concentration-time plot showing the pharmacokinetic exposure
parameters, Cmax and AUC.
The PK parameters most likely to be relevant in dose-escalation are two measures
of exposure, Cmax and AUCJ , which are marked on Figure 2.4.1. These exposure pa-
rameters are continuous variables which, by definition, are restricted to being greater
than zero. The first is the maximum exposure (after administration) to the treatment,
Cmax, which occurs at time tmax. The second is the area under the concentration-time
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curve, AUCJ . This is a measure of the total exposure to the trial drug over time
interval J . Some common values of J are:
• 0− 24: The AUC between t = 0 and t = 24 hours, which can be calculated by
fitting a curve to the observed exposures,
• τ : The AUC between t = 0 and t = time at the end of the cycle, which (assuming
that the plasma concentration of the drug at the end of the cycle was obtained)
can also be calculated by fitting a curve to the observed exposures,
• ∞: The AUC between t = 0 and t =∞, which is obtained by extrapolating the
curve fitted to the observed exposures.
In a dose-escalation trial of a treatment administered once weekly with a cycle
of length 28 days, full PK profiles of patients may be taken on days 1, 8 and 22 of
treatment, for example. The PK profile taken at day 1 is used to obtain an idea of
the characteristics of the treatment after a single dose. Profiles taken at days 8 and
22 are used to monitor the multiple-dosing characteristics of the treatment. This is
to check that multiple-dosing is not leading to excessive build up of the treatment in
patients, resulting in excessively high exposure. The final PK profile, at day 22, is
hoped to be late enough in the treatment cycle that the system has reached a steady
state. This means that upon continued dosing at the same regimen, the exposure
pattern is expected to remain constant.
Calculation of exposure parameters by fitting a curve to each patient’s data in-
dividually (as described above) is common in dose-escalation trials when only a few
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patients data are treated at each dose. However, in specific pharmacology trials, pop-
ulation PK models are fitted which use a single model for the data from all patients.
Population PK models require less intensive sampling and give an idea of the variabil-
ity in the parameters between patients. They can also be used to obtain additional
inferences about the exposure to the drug. More information about the population
PK methods can be found in Ka¨lle´n (2008).
We have chosen to utilise PK data in dose-escalation because it can be an early
indicator of efficacy or long-term toxicity (Clark et al., 1994). Although it is unlikely
for a dose-escalation trial to be of sufficient duration to observe efficacy or long-term
toxicity outcomes directly, PK data obtained during the dose-escalation trial can be
used to obtain an idea of the likelihood/risk of these outcomes. This means that the
number of patients dosed at unnecessarily high levels can be reduced; based on an
assumption that a suitable benefit-risk ratio has already been met at a dose with lower
toxicity. The chance of long-term toxicity can also potentially be reduced. Application
of the PK data in this way is more pertinent in the combination setting because of
the availability of historical single-agent data to advise on the use of exposure data
in escalation and the possibility of DDIs.
The intensive sampling routine planned for each patient, to estimate the exposure
parameters, mean that it is common to have missing values within a patient’s PK
profile or for an entire profile to be missing. There can also be delays in the PK data
being processed so that the exposure parameters of a cohort are not ready for the
dose-escalation meeting to decide the dose for the next cohort of patients. Currently,
this does not delay escalation because PK data are not essential for making such
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a decision. This situation is not ideal. Hopefully, in proposing a practical dose-
escalation design with improved operating characteristics over standard designs, the





Dose-escalation trials commonly assume a homogeneous trial population to iden-
tify a single recommended dose of the experimental treatment for use in future trials.
Incorrectly assuming a homogeneous population can lead to a diluted treatment ef-
fect in a heterogeneous population. Equally, exclusion of a subgroup that could in
fact benefit from the treatment can cause a beneficial treatment effect to be missed.
Accounting for a potential subgroup effect (i.e. difference in reaction to the treat-
ment between subgroups) in dose-escalation can increase the chance of finding the
treatment to be efficacious in a larger patient population.
The case of two pre-defined subgroups is considered. Biomarker information from
historical trials investigating the same treatment in an alternative application, for
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example, can be used to identify subgroups of interest.
A standard Bayesian model-based method of dose-escalation is extended to ac-
count for a subgroup effect by including covariates for subgroup membership in the
dose-toxicity model. A stratified design performs well but uses available data ineffi-
ciently and makes no inferences concerning presence of a subgroup effect. A hypothesis
test could potentially rectify this problem but the small sample sizes result in a low
powered test. As an alternative, we propose the use of spike and slab priors for identi-
fying presence of a subgroup effect. This method assesses the presence of a subgroup
effect at each escalation step and at the end of the trial. This enables efficient use
of the available trial data throughout escalation and in identifying the recommended
dose(s). A simulation study, based on real trial data, was carried out and this design
was found to be both promising and feasible.
Keywords: Dose-escalation, subgroup effect, biomarker, Bayesian model-based method,
spike and slab.
3.1 Introduction
The aim of a dose-escalation trial is to identify the recommended dose of an ex-
perimental treatment to be used in later phase trials investigating the treatment’s
efficacy. To maximise the treatment’s chance of success in efficacy trials, it is impor-
tant that the recommended dose is optimal for the patient population. Despite this,
time restrictions mean that selection of the recommended dose is often based purely
on toxicity data which are available relatively soon after treatment. The toxicity data
upon which decisions are based is usually a binary indicator of whether a patient
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experienced a dose-limiting toxicity (DLT) in their first cycle of treatment.
A common assumption in dose-escalation trials is that toxicity increases monotoni-
cally with the dose of the treatment. Since the recommended dose is chosen based only
on toxicity data, an implicit assumption is that increasing toxicity leads to increased
efficacy of the treatment. Using a Bayesian model-based design for dose escalation,
the optimal dose can be referred to as the TD100θ (Whitehead and Williamson, 1998).
That is, the dose of treatment with probability θ of causing a dose-limiting toxicity
in a patient within their first cycle of treatment. Bayesian model-based designs re-
quire a model to be assumed for the dose-toxicity relationship. These designs can
utilise available trial data and prior knowledge to advise escalation and estimate the
TD100θ.
In standard dose-escalation trial, the trial population is assumed to be homoge-
neous (Rosenberger and Haines, 2002) and a single TD100θ is identified for the entire
population. However, in a general patient population this is unlikely to be the case.
Variability between subgroups of patients in a population can lead to differences in
tolerance or efficacy of the treatment. Consequently, the benefit-risk ratio of the treat-
ment is impacted for subgroup members. When there is notable variability between
subgroups of a population, we refer to the presence of a subgroup effect. Often, the
underlying cause of variability is unknown but there can be visible or measurable
indicators, referred to as biomarkers, which can be used as intermediate markers of
subgroup membership. Examples include ethnicity, pre-treatment or a genetic muta-
tion. For example, presence of a KRAS mutation in patients with non-small cell lung
cancer indicates lower survival when treated with Erlotinib and chemotherapy, than
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is usual for patients without the mutation (Lie`vre et al., 2006).
The limited number of patients available for treatment in dose-escalation trials
makes in-trial identification of relevant biomarkers unrealistic. Instead, we consider
cases where historical information is used to pre-define potential biomarkers of inter-
est. For example, historical trials of the same treatment in another application, or of
a treatment with similar action being tested in the same application, can be used to
identify a biomarker of interest.
Currently, historical data on potential subgroup effects is largely utilised in the
specification of trial inclusion criteria. These can be used to reduce the variability in
the trial population in order to justify an assumption of a homogeneous trial popula-
tion. In doing this, the population to whom the treatment could be made available
is restricted. There is also a risk of excluding patients who could in fact benefit from
the treatment. This was the case for Cetuximab, a treatment for colorectal cancer,
which was initially tested in a restricted population. It was later noticed that pa-
tients excluded from the original trial could in fact benefit from the treatment (Chen
and Beckman, 2009). As a consequence, further trials had to be carried out in the
additional patient group.
On the other hand, inclusion of a subgroup (in the trial population) in which the
treatment is inefficacious could mask a treatment effect in the remaining population.
Gefitinib for the treatment of non-small cell lung cancer is an example where this was
the case. On further investigation, the subgroup effect was identified and a reduced
population who could benefit from Gefitinib found (Chen and Beckman, 2009). In
both the Cetuximab and Gefitinib examples, the error was highlighted and adjusted
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for. Unfortunately there are potentialy many similar cases for which the error has
not been realised. In addition, had a potential subgroup effect been accounted for at
the design stage of these trials, then more efficient trials which utilised less resources
could have been implemented.
It is becoming more common for potential subgroup effects (aside from in ex-
ploratory analyses) to be considered in phase II and III trials. In these so called
enrichment trials, subgroup effects are investigated in order to identify a subgroup
of the population who appear most likely to benefit from the treatment (see Temple,
2005, for a short overview of such designs). This can lead to exclusion of a subgroup
of the patient population from the trial. In such a case, the dose being used in the
trial was selected based on patients from the initial population. The recommended
dose may therefore be sub-optimal for the final population. In addition, administering
different doses of the treatment between subgroups might suffice, removing the need
to completely exclude subgroups from the trial. Ideally, through accounting for a po-
tential subgroup effect in dose-escalation, we will estimate a TD100θ in each subgroup
when this is necessary. This can increase the chance of finding the treatment to be
efficacious in a larger patient population and is a step towards patient-specific dosing.
In Section 3.1.1, a Bayesian model-based method of dose-escalation which is cur-
rently used and assumes a homogeneous population is described and the general no-
tation used in the remainder of the chapter is introduced. This continues into a brief
review of alternative model-based dose-escalation designs, and in Section 3.1.2 cur-
rent methods of accounting for a subgroup effect in clinical trials are discussed. The
standard dose-escalation trial design described in Section 3.1.1 is used as the under-
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lying design for the proposed methods of accounting for a potential subgroup effect
in dose-escalation. The proposed methods are presented in Section 3.2 and compared
through a simulation study in Section 3.3. The chapter concludes with a discussion
of the methods, their limitations and possible extensions in Section 3.4.
3.1.1 A Standard Bayesian Model-based Method of Dose-
escalation
Bayesian model-based designs enable available prior and trial information to be utilised
in dose-escalation decisions. Using all of this available information in dose-escalation
makes escalation decisions more efficient and also safer for patients involved in the
trial. The approach of Whitehead and Williamson (1998) is a standard Bayesian
model-based method of dose-escalation which assumes a homogeneous trial popula-
tion; their method is described here. It is used as the baseline for comparison of
the proposed methods and also as the design underlying the proposed methods for
accounting for a potential subgroup effect in dose-escalation which are described in
Sections 3.2.1, 3.2.2 and 3.2.3. Alternative approaches such as the continual reassess-
ment method (O’Quigley et al., 1990) could, however, also be used as the basis for
the extensions discussed below.
Dose set d of the experimental treatment is to be made available for administra-
tion to patients in the dose-escalation trial. In reality, escalation using a model-based
design is not constrained to this dose set but it is required for the purpose of sim-
ulation. Define the dose of treatment administered to a patient as x ∈ d and d∗ as
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some fixed reference dose used to standardise dose in the dose-toxicity model. We are
interested in pi(x), the probability that a patient experiences a DLT given dose x of
the experimental treatment. Specifically, the value of x for which pi(x) = θ. Escala-
tion under the standard design, assuming a homogeneous trial population, proceeds
as follows:











where pi(x) = P(DLT|x). (3.1.1)
We consider the transformed, standardised dose, log(x/d∗ + 1) in the assumed
dose-toxicity model but an alternative one-to-one transformation could be used.
Choice of the reference dose and transformation is given in Section 2.2.2 under
Step 3;
2. Set a prior on the model parameters: This is achieved by specifying pseudo data
relating to a prior proportion of DLTs occuring at two ‘prior’ doses. This prior
data is weighted to total a fraction of the planned sample size of the trial. A
value of 1/10th, as used by Whitehead and Williamson (1998), is used in this
chapter; further discussion about the choice of weight is given in Section 2.2.2
under Step 4. By incorporating the pseudo data into the dose-toxicity model in
the same way as trial data, beta priors are effectively induced on the probability
of toxicity at the two doses (Tsutakawa, 1975). The prior proportion of DLTs
at the two doses can be elicited from clinical experts (as described in Whitehead
and Williamson, 1998, for example). Alternatively, the prior can be selected to
CHAPTER 3. Dose-escalation Strategies which Utilise Subgroup Information 56
control the operating characteristics of dose-escalation. For example, specifying:
• The desired start dose for the trial as the lower of the two doses selected
for prior specification with a prior proportion of DLTs equal to θ;
• A dose at the top of the planned dose range for the other prior dose with
a prior proportion of DLTs selected to control the rate of escalation under
some likely trial scenarios.
3. Allocate patients the dose x ∈ d which, based on the prior and available trial
data at their time of arrival into the trial:
• Maximises the patient gain, 1{pˆi(x)−θ}2 ;
• Within doses which satisfy the safety criterion, pˆi(x) < δ,
for an unacceptable level of toxicity δ and pˆi(x) = 1/[1 + e−{βˆ0+βˆ1 log(x/d
∗+1)}]
where βˆ0 and βˆ1 are the modal a posteri (MAP) estimates of the model pa-
rameters. When prior knowledge is incorporated into the dose-toxicity model
as pseudo data, the MAP estimates are equivalent to the maximum likelihood
estimates of the parameters so that standard software can be used without the
need for Markov Chain Monte Carlo.
4. Stop escalation:
• For safety if at any point in the trial no available doses satisfy the safety
criterion: No recommended dose is declared;
• Once a maximum number of patients have been treated in the trial: The
recommended dose is declared as the estimated TD100θ for the entire
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population based on data collected in the trial (i.e. not including prior
data). That is, the dose which maximises the patient gain and satisfies the
safety criterion (based on the two-parameter dose-toxicity model of Equa-
tion 3.1.1), from the range of available doses which are less than or equal
to the maximum dose administered during the trial.
Other authors, such as Neuenschwander et al. (2008), have assumed the same two-
parameter dose-toxicity model for dose-escalation. Their approach differs in specifi-
cation of escalation rules for the trial (Step 3). Whitehead and Williamson (1998)
themselves suggest alternatives to those described here but we have chosen to use the
patient gain as the most ethical option. Addition of the safety constraints in a similar
manner to Babb et al. (1998) control the rate of esclation, improving the safety of the
trial for the patients involved.
Alternative dose-toxicity models have been suggested; the continual reassessment
method (CRM) of O’Quigley et al. (1990) uses a one-parameter power model which ac-
curately estimates the TD100θ but does not effectively model the entire dose-toxicity
relationship. Goodman et al. (1995), among others, have proposed modifications on
the CRM to reduce the aggressiveness of escalation. A two-parameter model is more
suitable than a one-parameter model for comparison of the dose-toxicity relationship
between subgroups, as we are interested in. This is because, although the subgroup
effect may not lead to different recommended doses in each subgroups, the shape of
the dose-toxicity curves between subgroups may differ. This could indicate different
reactions to the treatment across the dose range which may be pronounced in the
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efficacy or longer-term toxicity outcomes which will be investigated in later trials.
Other Bayesian model-based designs have been proposed which aim to optimise
escalation, although these are often considered unethical as they do not account for
the needs of patients (Dette et al., 2008; Haines et al., 2003). Reviews of dose-toxicity
models and available methods of dose-escalation are provided in Rosenberger and
Haines (2002) and Jaki et al. (2013). Most Bayesian model-based dose-escalation
trial designs have the same foundations and so the methods presented in this chapter
could be altered for the use of an alternative dose-toxicity model or escalation rules.
3.1.2 Current Methods of Accounting for Subgroup Informa-
tion in Clinical Trials
The most straight-forward way to account for a subgroup effect in dose-escalation is to
stratify by subgroup membership and carry out independent dose-escalation in each
subgroup. This has been done in practice (e.g. Nicholson et al., 1998) but is ineffi-
cient (in its use of information for identifying a dose for escalation and estimating the
TD100θ), especially if there is in fact no underlying subgroup effect. Wijesinha and
Piantadosi (1995) and O’Quigley et al. (1999) propose using additional terms in the
dose-esclation model to account for subgroup membership. In this way, some infor-
mation is shared between subgroups during escalation. Babb and Rogatko (2001) use
a similar method but consider a continuous biomarker; their design is demonstrated
in Cheng et al. (2004).
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In current practice, it is more common for a subgroup effect to be investigated
in later phase trials. Such designs use hypothesis testing at an interim point in the
trial to identify subgroup(s) of the population that react favourably to treatment and
hence it is felt worth pursuing the experimental treatment in (Brannath et al., 2009;
Chen and Beckman, 2009; Jenkins et al., 2011).
3.2 Proposed Methods of Accounting for Subgroup
Information in Dose-escalation
When the trial population is truly homogeneous, then a standard method of dose-
escalation (such as that of Whitehead and Williamson, 1998, which was described
in Section 3.1.2), which does not account for a potential subgroup effect, will be
suitable. However, when there is uncertainty around the assumption of a homogeneous
population, then this design is not appropriate. We compare the standard design to
three alternative methods of dose-escalation which account for subgroup membership
throughout escalation.
Say that patients entering the trial can be reliably classified as being in one of
two distinct, clearly identifiable subgroups based on the presence or absence of a
pre-defined biomarker. The treatment is expected to be more toxic in the biomarker
positive patients than in the remaining biomarker negative patients. Let I+ be an
indicator of subgroup membership which is equal to 1 for a biomarker positive patient
and 0 for a biomarker negative patient.
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Some of the benefits of Bayesian dose-escalation designs have discussed in Sections
2.2 and 3.1.1. The main reason being that using all available information in dose-
escalation leads to more informed escalation decisions which should reduce the risk
and increase the benefit of treatment for trial patients. As we have mentioned, the
use of prior data in Bayesian trial designs can be intuitive and beneficial. However, it
also makes the escalation decisions subjective. To remove the subjectivity in conclu-
sions drawn from the trial, we have chosen not to use the prior data in selecting the
recommended dose(s) for use in future trials. This is therefore found in a frequentist
manner, by fitting the trial data to the logistic regression model. In addition, since the
prior data used in demonstration of the methods given in this chapter is been specified
to control the operating characteristics of the trial, it does not seem appropriate for
the prior data to be accounted for when drawing conclusions from the trial.
3.2.1 Method 1: Include Terms for Subgroup Membership
In this method, the standard two-parameter dose-toxicity model from Equation 3.1.1
is extended to include terms for subgroup membership. This enables escalation deci-
sions to be made which account for subgroup membership. Hence, making the dose
administered to patients better suited to them. A consequence of allowing esclation
to differ between subgroups is that the safety stopping criterion can come into play
for one or both subgroups. Escalation under this method proceeds as follows:
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where pi(x, I+) = P(DLT|x, I+).
If historical evidence of a subgroup effect led to strong belief of its impact on
either the intercept or slope parameter of the dose-toxicity model, then one of
the additional terms could be removed and the resulting three-parameter model
used in place of the four-parameter model. However, with a lack of information
on the expected impact of the subgroup effect on the dose-toxicity relationship,
the four-parameter dose-toxicity model is able to capture potential variability
in both parameters;
2. Set a prior on the model parameters: This can be achieved in a similar manner
to that for the standard design by specifying pseudo data on two doses for the
biomarker positive subgroup and two doses for the biomarker negative subgroup.
The pseudo data for each subgroup is weighted to, say 1/10th, of the planned
sample size in that subgroup.
3. Allocate patients the dose x ∈ d which, based on their subgroup membership,
the prior and available trial data at their time of arrival into the trial:
• Maximises the patient gain, 1{pˆi(x,I+)−θ}2 ;
• Within doses which satisfy the safety criterion, pˆi(x, I+) < δ,
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for unacceptable level of toxicity δ and for MAP estimates of the model param-
eters βˆ0, βˆ1, βˆ2 and βˆ3, pˆi(x, I+) = 1/(1 + e−[βˆ0+βˆ1 log(x/d
∗+1)+I+{βˆ2+βˆ3 log(x/d∗+1)}]).
4. Stop escalation:
• For safety in a subgroup if at any point in the trial no available doses satisfy
the safety criterion for that subgroup: No recommended dose is declared
in that subgroup. Escalation continues in the other subgroup using the
two-parameter model of Equation 3.1.1 fitted to data from patients in the
remaining subgroup only;
• Once a maximum number of patients have been treated in the trial:
– If one subgroup stopped for safety: The recommended dose is declared
in the remaining subgroup as the estimated TD100θ based on data
collected in the trial (i.e. not including prior data). That is, the
dose which maximises the patient gain and satisfies the safety criterion
(based on the two-parameter dose-toxicity model of Equation 3.1.1
fitted to the data from patients in that subgroup only), from the range
of available doses which are less than or equal to the maximum dose
administered to patients in the respective subgroup during the trial;
– If neither subgroup stopped for safety: A recommended dose is de-
clared in each subgroup as the estimated TD100θs for s = +,−, rep-
resenting that in the biomarker positive and negative subgroups re-
spectively, based on data collected in the trial (i.e. not including prior
data). That is, the dose which maximises the patient gain and satisfies
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the safety criterion (based on the four-parameter dose-toxicity model
of Equation 3.2.1), from the range of available doses which are less
than or equal to the maximum dose administered to patients in the
respective subgroup during the trial.
By including covariates for subgroup membership in the dose-toxicity model, this
method of dose-escalation enables recommended doses to be subgroup specific. A
TD100θ is estimated in each subgroup (unless one or both subgroups stop for safety).
When these recommendations are different between subgroups, then we expect that
a significant subgroup effect has been observed. When the recommendations are
the same between subgroups, this could be down to there truly being no significant
subgroup effect. On the other hand, it could be a result of the discrete dose set or
insufficient size of the trial to detect a difference. Under this method we have no way
of telling this, and indeed deciding whether it would be beneficial to pool the data or
if it would be beneficial to continue investigation of the subgorup effect which become
clear when longer-term toxicity or efficacy outcomes are investigated.
The next method incorporates a formal test of whether a significant subgroup
effect was observed in an attempt to clarify and formalise the conclusion drawn from
the dose-escalation trials over the presence of a subgroup effect. In this case, the
result of the hypothesis test is interpreted as a decision over whether a subgroup
effect was observed. If it is concluded that a subgroup effect is present and the dose
recommendations from the two subgroups are still the same, then this is likely to be
caused by the use of discrete dose set in the trial.
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3.2.2 Method 2: Hypothesis Test Concerning Presence of a
Subgroup Effect
This method forms an extension of Method 1. The escalation and stopping procedure
is unchanged, the only difference comes in selecting the recommended dose(s) when
neither subgroup stopped for safety during the trial. Under this eventuality, instead of
automatically recommending a dose in each subgroup, a hypothesis test is performed
in an attempt to determine whether a subgroup effect was observed in the trial. As
mentioned in Section 3.2, to reduce the subjectivity in the selection of the recom-
mended dose(s), a frequentist calculation of the recommended dose is used. Following
from this logic, a likelihood based hypothesis test is considered in this method. If the
test concludes that:
• No significant subgroup effect was observed: The data are pooled and a single
recommended dose is declared for the entire population as the estimated TD100θ
based on data collected in the trial (i.e. not including prior data). That is, the
dose which maximises the patient gain and satisfies the safety criterion (based
on the two-parameter dose-toxicity model of Equation 3.1.1), from the range of
available doses which are less than or equal to the maximum dose administered
during the trial;
• A significant subgroup effect was observed: As before, a recommended dose is
declared in each subgroup as the estimated TD100θs for s = +,− based on
data collected in the trial (i.e. not including prior data). That is, the dose
which maximises the patient gain and satisfies the safety criterion (based on
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the four-parameter dose-toxicity model of Equation 3.2.1), from the range of
available doses which are less than or equal to the maximum dose administered
to patients in the respective subgroup during the trial.
In this method, it is still possible to obtain the same dose recommendation from
both subgroups despite a decision that a subgroup effect is present. However, this does
provide a formal test of whether a subgroup effect was observed. This information
can be useful in planning future trials. When no subgroup effect is detected, then the
recommended dose is found with more accuracy under this method than in Method
1, since the data are pooled and fitted to the two-parameter dose-toxicity model.
A range of hypothesis tests are possible. We consider a z-test on the difference
between recommended doses from the two subgroups. The test is based on the asymp-
totic approximation, T̂D100θ ∼ N(E[TD100θ],Var[TD100θ]) and for estimate of the
recommended dose T̂D100θs in subgroup s, the null (H0) and alternative (H1) hy-
potheses are;
H0 : T̂D100θ− − T̂D100θ+ = 0 versus H1 : T̂D100θ− − T̂D100θ+ 6= 0.
We fix the significance level of the (two-sided) test, P(reject H0|H0 true) = α. The
power of the test, P(reject H0|H0 not true) = 1− β, then depends on the specified α
and the number of patients in the trial.
Although this test uses asymptotic results, it was selected because it avoids the
need for corrections for multiple testing and the use of equivalence hypotheses, both
of which further lower the power of an already low-powered test. Further details of
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this hypothesis test, along with details concerning its choice over some alternative
hypotheses, are given in Appendix 3.5.1. As an alternative method which does not
encounter this problem, we propose a fully Bayesian approach using spike and slab
priors for variable selection.
3.2.3 Method 3: Fully Bayesian Method Using Spike and
Slab Priors for Variable Selection
This method is based on the four-parameter dose-toxicity model given in Equation
3.2.1. In Method 2, the four-parameter dose-toxicity model was used throughout
escalation and a decision as to whether the two-parameter model (which does not
account for subgroup membership) is sufficient only made at the end of the trial.
So during escalation, Method 2 assumed a subgroup effect was present; it did not
allow for the fact that a subgorup effect may not be present until the trial analysis.
In addition, the hypothesis test described for Method 2 was based on the difference
in dose recommendations in the two subgroups. Hence, only providing information
concerning whether the subgroup effect affected the point estimate of the TD100θ
and not on the entire dose-toxicity curve. Alternative frequentist hypothesis tests
which can achieve this were investigated but were found to be too low-powered to be
practical; details can be found in Appendix 3.5.1.
The Bayesian alternative that we propose overcomes these problems to some extent
by using spike and slab priors on the model terms for subgroup membership (β2 and
β3 in Equation 3.2.1). This allows more efficient use of emerging trial data during
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escalation by allowing for presence or absence of a subgroup effect throughout the
trial. This is achieved by deciding at each escalation step, based on data available at
that time, whether the two-parameter or four-parameter model is more suitable.
A spike and slab prior is effectively a two-component mixture prior. One compo-
nent is usually a normal prior with high variance which makes up the ‘slab’ part of
the prior. The other part is the ‘spike’ component which is selected as a distribution
which has a large mass at zero. We choose to use a Dirac delta function, δ0 (a point
mass at zero), which results in a sparsity inducing spike and slab mixture prior. Fig-
ure 3.2.1 gives an example of a potential mixture prior on β composed of a normal
slab and Dirac delta function spike. The result of using these priors is that a positive
probability is placed on the probability of the term being equal to zero. Based upon
this, spike and slab priors can be used in variable selection.
Now, take γ2 to be a latent indicator function which indicates inclusion (when
equal to 1, and is zero otherwise) of the variable β2 in the dose-toxicity model. Then
the resulting spike and slab prior on β2 can be written as:
β2|γ2 ∼ γ2N(0, σ22) + (1− γ2)δ0.
The decision over whether β2 is required in the model, based on available data,
can be based on its probability of inclusion in the model, w2. This can be estimated
by placing a Bernoulli prior on γ2 such that;
γ2 ∼ wγ22 (1− w2)(1−γ2).
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Figure 3.2.1: Example of a mixture prior on β composed of a normal slab and Dirac
delta function spike.
Similarly we can consider a latent indicator function γ3 and probability of inclusion
w3 on β3. We assume that w2 is independent of w3 and as such, a prior setting of
w2 = w3 = 0.5 implies a prior belief that one of the two predictors for subgroup
effect are significant in the model (see Chapter 10 of Do et al., 2013). If instead, w2
or w3 is set equal to 1, then the corresponding term will be forced into the model
with a normal prior (the slab component of the prior corresponding to that term)
placed on it. This is effectively what is done for β0 and β1 which we require in the
dose-toxicity model. We assume independence of w2 and w3 to increase the chance,
over an alternative which assumes some dependence, that either β2 or β3 is selected
in the model. This makes the model more flexible by allowing the model to capture
heterogeneity in the form of a shift, slope difference or a combination of these which
is useful since we have no information on the expected cause of the subgorup effect.
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With prior information regarding this, dependence between these parameters could
be defined.
A range of algorithms exist for implementing Bayesian variable selection using
spike and slab priors in the linear regression setting (e.g. George and McCulloch,
1997; Ishwaran and Rao, 2005; Scheipl, 2011). Authors such as Wagner and Duller
(2012) and Tu¨chler (2008) have extended these methods to the logistic regression
setting. The applications of Bayesian variable selection for logistic regression models
is wide-ranging; Wagner and Duller (2012) aim to identify relevant risk factors for
bleeding while Genkin et al. (2005) is concerned with text categorisation. Methods
which deal with multivariate regression and ANOVA are also available (e.g. Carvalho
et al., 2008) which have application in selection of variables relating to gene expression.
We specified a dirac delta function for the ‘spike’ component of the prior on the
terms for subgroup membership. Alternative choices include use of a normal distri-
bution with large mass at zero and a double exponential model (or Lasso model, see
Tibshirani, 1996, for details). Although a mixture of normal distributions results in
a continuous prior, it is one which is not sparsity inducing. As a result, a straight-
forward decision concerning whether a term should be included in the model cannot
be made. Bernardo et al. (2011) compare a range of prior settings, including those
mentioned, and obtain no clear conclusion over the ‘better’ sparsity inducing prior.
A method related to Bayesian variable selection is Bayesian model averaging Hoet-
ing et al. (1999). Although such methods would be feasible with the small number of
parameters in our model, we wish to obtain a clear decision over whether the terms
for subgroup membership should be included in the model. For this reason, we choose
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to use variable selection.
When spike and slab priors are used, we have a form of in-built decision making
process over whether these additional terms are required in the model. Once the
relevant variables have been identified, the selected model is fitted to the data and
escalation decisions can be made based upon this. Escalation decisions now occurs in
two stages; variable selection and model fitting.
Escalation under this method follows the standard method described in Section
3.1.1 until a difference in outcomes between the pre-defined subgroups has been ob-
served. Note that, if the specified pseudo data relates to a prior subgroup effect, then
spike and slab will be implemented from the start of the trial. Once a difference in
outcomes between subgroups is observed, escalation under this method proceeds as
follows;


















where pi(x, I+) = P(DLT|x, I+).
The terms β0 and β1 will always be included in the model used for escalation.
However, spike and slab priors are specified on β2 and β3 and so one or both of
these terms could be set equal to zero in the model for escalation.
2. Set a prior on the model parameters: Pseudo-data of the same form used in
Method 1 (and 2) is used to define priors; for the variable selection and model
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fitting stages in escalation.
Variable selection: Fit the pseudo data to the four-parameter logistic regres-
sion model of Equation 3.2.1. The resulting coefficient estimates are used
to derive the slab component of the priors on the four parameters of the
dose-toxicity model. A method of deriving the prior for variable selection
is given in Appendix 3.5.2 with regard to the prior used in the simulation
study (presented in Section 3.3).
Model fitting: This can be achieved in the same way as for Method 1 (and 2).
3. Escalation follows the two-step process:
Variable selection: Fit the spike and slab model using Markov Chain Monte
Carlo (MCMC). After removing burn-in iterations, find w2 and w3 (the
probability that each term was included in the dose-toxicity model which is
always 1 for β0 and β1 but varies for β2 and β3). If the inclusion probability
of the parameter is greater than some pre-specified boundary, then that
term will be non-zero in the fitted model. Otherwise it is equal to zero for
this model fit.
Model fitting: Allocate patients the dose x ∈ d which, based on their sub-
group membership (if relevant), the prior and available trial data at their
time of arrival into the trial:
• Maximises the patient gain, 1{pˆi(x,I+)−θ}2 ,
• Within doses which satisfy the safety criterion, pˆi(x, I+) < δ,
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for unacceptable level of toxicity δ and pˆi(x, I+) = 1/[1+e−{βˆ0+βˆ1 log(x/d
∗+1)+y}]
where y is the terms for subgroup membership identified during variable se-
lection for inclusion in the model. The estimates βˆ0, βˆ1, and potentially βˆ2
and/or βˆ3, are the MAP estimates of the dose-toxicity model parameters.
4. Stop escalation:
• For safety in a subgroup if at any point in the trial no available doses satisfy
the safety criterion for that subgroup: No recommended dose is declared
in that subgroup. Escalation continues in the other subgroup using the
two-parameter dose-toxicity model of Equation 3.1.1 fitted to data from
patients in that subgroup only.
• Once a maximum number of patients have been treated in the trial:
– If one subgroup stopped for safety: The recommended dose is declared
in the remaining subgroup as the estimated TD100θ based on data
collected in the trial (i.e. not including prior data). That is, the
dose which maximises the patient gain and satisfies the safety criterion
(based on the two-parameter dose-toxicity model of Equation 3.1.1
fitted to the data from patients in that subgroup only), from the range
of available doses which are less than or equal to the maximum dose
administered to patients in the respective subgroup during the trial.
– If neither subgroups stopped for safety: Carry out variable selection,
∗ If β2 and β3 are equal to zero: The data are pooled and a sin-
gle recommended dose is declared for the entire population as the
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estimated TD100θ based on data collected in the trial (i.e. not in-
cluding prior data). That is, the dose which maximises the patient
gain and satisfies the safety criterion (based on the two-parameter
dose-toxicity model of Equation 3.1.1), from the range of available
doses which are less than or equal to the maximum dose adminis-
tered during the trial.
∗ If β2 and/or β3 is non-zero: As in Method 1, a recommended dose is
declared in each subgroup as the estimated TD100θs for s = +,−
based on data collected in the trial (i.e. not including prior data).
That is, the dose which maximises the patient gain and satisfies the
safety criterion (based on the four-parameter dose-toxicity model
of Equation 3.2.1), from the range of available doses which are less
than or equal to the maximum dose administered to patients in
the respective subgroup during the trial.
The overall set-up of this method is relatively similar to the previous methods.
However, before model fitting can occur in Step 3, variable selection must be carried
out (and a relevant prior specified). The use of spike and slab priors mean that the
model used in variable selection is not conjugate and so MCMC is required, making
Method 3 more computationally complex than the previous methods.
The use of spike and slab priors on the terms for subgroup membership enable
escalation decisions to be founded on the most relevant model, based on data available
at that stage of the trial. This will make escalation more efficient and be beneficial
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for patients. In addition, by considering whether each variable should be included in
the model, the entire dose-toxicity curve is compared between groups as opposed to
merely a point estimate of dose recommendation.
There is no formal test of whether a subgroup effect was observed in this method
and so the decision over the presence or absence of a subgroup effect is exploratory.
These exploratory conclusions, together with historical information and clinical ex-
pertise on the expected subgroup effect, may be suitable to decide whether a subgroup
effect should be accounted for in later phase trials. Alternatively, a hypothesis test
could be carried out on the final trial data with no adverse effect on escalation, al-
though this has the aforementioned issues.
3.3 Simulation Study
Data from the single-agent paediatric dose-escalation trial reported by Nicholson et al.
(1998) were used as the basis for the simulation study presented in this section. In
the reported trial, Nicholson et al. (1998) used stratification to account for a potential
subgroup effect and escalation proceeded in each subgroup under an ‘up and down’
design (see Storer, 1989, for an example of such a design). In this trial, biomarker
positive patients had experienced a specific line of prior treatment which the biomarker
negative patients had not. The decision to stratify by this prior treatment came from
evidence obtained in adult trials of the treatment.
The data obtained in the trial is given in Table 3.3.1, both by subgroup mem-
bership and as the pooled data. Based upon the algorithmic design and definition of
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the recommended dose specified in Nicholson et al. (1998), the maximum tolerated
doses were identified as 215 and 180mg/m2 in the biomarker negative and biomarker
positive subgroups, respectively. Now, had the two-parameter dose-toxicity model in
Equation 3.1.1 been fitted to these data, the results are likely to have been different.
For example, under a model-based approach. the TD16 in the biomarker positive
subgroup is very similar to the maximum tolerated dose identified under the algorith-
mic design at 181mg/m2. However, in the biomarker negative subgroup, the TD16 is
244mg/m2 under the model-based approach. It is the TD16 that we aim to identify
in the simulation study in the remainder of this section.
Number of DLTs observed by dose (mg/m2) Recommended dose (mg/m2) based on
100 150 180 215 245 260 Total algorithmic design model-fit to data
I+ = 0 subgroup 0/5 0/4 0/4 0/6 2/7 1/1 3/27 215 244
I+ = 1 subgroup 1/6 0/4 0/8 2/4 - - 3/22 180 181
Pooled data 1/11 0/8 0/12 2/10 2/7 1/1 6/49 - 206
Table 3.3.1: Toxicity data observed in the dose-escalation trial reported in Nicholson
et al. (1998), given by subgroup membership and as the pooled data. Also given is
the recommended dose declared from the trial; as a maximum tolerated dose based
on escalation by an algorithmic design in each subgroup, and the TD16 (given a
continuous range of doses) based on fitting the dose-toxicity model in Equation 3.1.1
to the data.
3.3.1 Simulation Study Design
The simulation study here is presented to illustrate the proposed dose-escalation meth-
ods described in Section 3.2. We compare them to the baseline method; the standard
Bayesian model-based method of dose-escalation which was presented in Section 3.1.1.
We specify the dose set available for the trial as those used by Nicholson et al.
(1998), d = {100, 150, 180, 215, 245, 260}mg/m2. The recommended dose from adult
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trials was 200mg/m2, this dose is selected as the reference dose which is used to
standardise doses in the dose-toxicity model. The starting dose for the trial was
taken to be the lowest available dose of 100mg/m2 and we specify θ = 0.16 and set
the unacceptable probability of toxicity, for use in the safety criterion, as δ = 0.35.
So, we aim to identify the dose, from those available which are less than the maximum
administered in the trial, which has posterior probability of causing a DLT in a patient
closest to 0.16 with estimated probability of toxicity less that 0.35.
We consider that upon entry to the trial, patients were reliably identified as being
either biomarker positive or biomarker negative. Patients were recruited in cohorts of
size 2 throughout the trial. Each cohort consists of one biomarker positive and one
biomarker negative patient unless one subgroup has stopped escalation early, in which
case both patients in the cohort will be from the remaining subgroup. The maximum
number of patients to be treated in the trial is 60. If neither subgroup stops escalation
early, then this will be made up of 30 patients from each subgroup. In the case of the
baseline method, escalation will continue until 60 patients have been treated in the
trial unless the trial stops early for safety. Although this might not be realistic, it is
used here to enable us to compare the methods with a fixed amount of information.
The prior was specified such that it is worth 1/10th of the planned sample size.
That is, a total of 6 prior patients consisting of 3 on each subgroup. We specified
the same prior data in both subgroups, this is done here to aid comparability of the
methods but could of course be altered for use in a real trial. After running a range of
potential pseudo-data specifications (details of these are given in Appendix 3.5.3) the
prior data we used in the simulation study was selected as that in Table 3.3.2. Under
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this prior specification, the dose-toxicity model advises a start dose of 100mg/m2 (i.e.
fitting only the pseudo data to the dose-toxicity model, the escalation rule advises
a dose of 100mg/m2 for escalation). In addition, under the scenario of no observed
DLTs, the chosen prior leads to reasonable paced escalation with no skipped doses.
Upon observation of a DLT at a low dose, it was felt likely for the model to re-escalate
within the specified maximum trial size. Clearly these properties differ between the
baseline approach and an approach which considers potential subgroup effect. For
comparability between methods, our chosen prior is acceptable under both settings.
Number of DLTs observed by dose (mg/m2)
100 260
I+ = 0 subgroup (1/3)/2 (1/2)/1
I+ = 1 subgroup (1/3)/2 (1/2)/1
Pooled data (2/3)/4 1/2
Table 3.3.2: Prior pseudo-data used for the simulation study, given by subgroup
membership and the pooled data.
In the simulation study, toxicity data were generated from the four-parameter
dose-toxicity model given in Equation 3.2.1. The parameter values of β0 and β1 used
for data generation were the mean estimates obtained from a frequentist model fit
to Equation 3.1.1 using the pooled trial data (given in Table 3.3.1). The parameter
values for β2 and β3 were varied depending upon the simulated scenario. A ‘true’
probability of DLT refers to the probability of DLT based upon the dose-toxicity
model and parameter values from which data were simulated. Similarly, a ‘true’
recommended dose refers to the dose, from the discrete set available for the trial,
which has estimated probability of causing a DLT in a patient closest to the TD16
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(from those estimates less than 0.35) based upon the model and parameter values
from which data were simulated.
The type I error level for the hypothesis test in dose-escalation Method 2 was set
at 0.30. This is likely to be too high to be accepted in practice but lower error levels
were investigated but traditional type I error specifications of 0.05 and 0.10 turned
out to be extremely low powered and, hence, not worth presenting here. Details of
the power calculation which support this statement are given in Appendix 3.5.1.
Simulations for all methods were carried out using R (R Core Team, 2014). Method
3 required the addition of a variable selection step in the escalation procedure com-
pared to the other methods. This step was carried out using the BoomSpikeSlab
package (Scott, 2014) which is based on variable selection for logistic regression mod-
els as described by Tu¨chler (2008). Given that we have no outside information to
suggest otherwise, the default settings were used for most parameters required by the
functions called from BoomSpikeSlab. Details of these parameters are given in Ap-
pendix 3.5.2 along with details of prior specification for the variable selection steps.
Running the Markov Chain for 20, 000 iterations and removing 5, 000 as burn-in was
found to be suitable for convergence. We set the prior inclusion probability for β2
and β3 equal to 0.5; this is a relatively non-informative setting. We specify that a
parameter is non-zero in the fitted model if it has posterior probability of inclusion
in the model greater than 0.25. This relatively low value was chosen through sim-
ulation studies as a value which led to a reasonable chance of the parameters being
included in the model, despite the small amount of data available. Investigations into
the choice of the probability for inclusion of the terms in the model, along with ones
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investigating the prior inclusion probability, are given in Appendix 3.5.4.
Results are presented for the following six scenarios based on estimates from 1, 000
simulated trials under the given scenario and method. The true probabilities of toxi-
city at each available dose for each of the scenarios are given in Table 3.3.3 and plots
of the dose-toxicity curves they are generated from are given in Appendix 3.5.5:
1. No subgroup effect: This scenario is included for comparison of the methods
when the ‘true’ recommended dose is the same for both subgroups. This could
arise when the population is truly homogeneous, or when the biomarker consid-
ered in the trial is not the cause of the subgroup effect observed in the trial.
2. A small subgroup effect: Causing only one dose level difference in true recom-
mended doses between subgroups. This scenario is included to investigate the
sensitivity of the methods to small differences in tolerance to the treatment
between the subgroups.
3. A medium subgroup effect: Causing two dose level difference in true recom-
mended doses between subgroups. This scenario, and the next, is included to
investigate the sensitivity of the methods to varying degrees of subgroup effect.
4. A medium subgroup effect: Causing three dose level difference in true recom-
mended doses between subgroups.
5. A large subgroup effect: No safe dose in the biomarker positive subgroup and
a true recommended dose in the biomarker positive subgroup in the middle of
the available dose range.
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6. No safe dose in either subgroup: This scenario is included to demonstrate the
effectiveness of the safety criterion when there are no safe doses in either sub-
group.
Scenario 100 150 180 215 245 260 100 150 180 215 245 260
1 0.02 0.06 0.10 0.18X 0.28 0.33 0.02 0.06 0.10 0.18X 0.28 0.33
2 0.02 0.06 0.10 0.18
X
0.28 0.33 0.02 0.08 0.14
X
0.26 0.38 0.45
3 0.02 0.06 0.10 0.18X 0.28 0.33 0.03 0.13X 0.24 0.42 0.58 0.65
4 0.02 0.06 0.10 0.18X 0.28 0.33 0.09X 0.36 0.60 0.81 0.90 0.93
5 0.02 0.06 0.10 0.18
X
0.28 0.33 0.42 0.90 0.97 0.99 1.00 1.00
6 0.38 0.67 0.79 0.88 0.93 0.94 0.38 0.67 0.79 0.88 0.93 0.94
Scenario β0 β1 β2 β3 100 150 180 215 245 260
1 -7.10 7.68 0.00 0.00 0.02 0.06 0.10 0.18
X
0.28 0.33
7 -7.10 7.68 0.75 0.75 0.05 0.16X 0.28 0.45 0.60 0.66
8 -7.10 7.68 0.30 1.30 0.04 0.15X 0.26 0.44 0.59 0.66
9 -7.10 7.68 1.30 0.30 0.07 0.21X 0.34 0.51 0.64 0.70
10 -7.10 7.68 3.00 -3.00 0.10 0.19
X
0.25 0.34 0.41 0.45
11 -7.10 7.68 -2.00 5.00 0.02 0.12
X
0.28 0.54 0.74 0.81
P(DLT|d, I+ = 0) P(DLT|d, I+ = 1)
P(DLT|d, I+ = 1)Parameter value
Table 3.3.3: Simulated probability of DLT at each dose (in mg/m2) to be tested in
simulations, given for each subgroup. Grey cells highlight dose-pairs with probabil-
ity of causing a DLT in a patient greater than 0.35. The ‘X’ marks the dose with
probability of toxicity closest to 0.16, in cases where there is a tolerated dose.
3.3.2 Simulation Study Results
The standard Bayesian model-based dose-escalation trial design described in Section
3.1.1 (based on the assumption of a homogeneous trial population) is used as the base-
line method for comparison of the three proposed dose-escalation methods described
in Section 3.2, which account for a potential subgroup effect. When recommended
dose(s) are referred to, these are the frequentist estimates; they are obtained by fit-
ting the relevant logistic regression model to the trial data only i.e. not including
prior data. The prior that we used for the simulation study was selected to control
the operating characteristics of the trial; it was not based on real trial data. For
this reason, it is not appropriate for the prior data to affect the final outcome of the
trial. If, however, the prior was selected based on historical data, then it may be
desirable to consider this data in identifying the recommended dose(s) from the trial.
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Even in this setting, a frequentist estimate might be used to reduce the subjectivity
of decisions made from the dose-escalation trial that could impact on future trials of
the treatment.
From Table 3.3.4 we can see that in Scenarios 1-4, where there was a tolerated dose
available for each subgroup, most trials ran to the maximum number of patients with
less than 10% of trials stopping early for safety in one subgroup. In these scenarios, the
average proportion of toxicities observed overall was between 12 and 16%. Although
the average proportion of toxicities observed was fairly consistent across scenarios in
the biomarker negative subgroup (under Methods 1-3), that in the biomarker positive
subgroup increased as the true subgroup effect increased. This is in part due to the
higher toxicity levels of all available doses.
Escalation Average number patients Average proportion toxicities
Scenario method Overall I+ = 0 I+ = 1 Overall I+ = 0 I+ = 1
Baseline 59.94 29.97 29.97 0.12 0.12 0.12
1 1 and 2 58.59 29.45 29.14 0.12 0.14 0.15
3 58.97 29.49 29.48 0.12 0.14 0.13
Baseline 60.00 30.00 30.00 0.12 0.10 0.15
2 1 and 2 58.79 29.42 29.37 0.13 0.14 0.15
3 58.96 29.48 29.48 0.13 0.13 0.15
Baseline 60.00 30.00 30.00 0.13 0.08 0.19
3 1 and 2 58.36 29.57 28.80 0.14 0.13 0.18
3 58.04 29.34 28.71 0.14 0.14 0.19
Baseline 59.67 29.84 29.84 0.16 0.05 0.27
4 1 and 2 56.40 29.36 27.04 0.14 0.14 0.23
3 56.38 29.45 26.93 0.15 0.14 0.24
Baseline 52.55 26.28 26.28 0.26 0.03 0.49
5 1 and 2 35.87 29.30 6.57 0.19 0.14 0.70
3 36.39 29.57 6.82 0.19 0.14 0.69
Baseline 18.88 9.44 9.44 0.55 0.55 0.56
6 1 and 2 17.31 8.92 8.39 0.55 0.67 0.68
3 18.57 9.32 9.26 0.54 0.66 0.66
Table 3.3.4: Average number of patients treated per trial in total and in each sub-
group, average proportion of toxicities observed per trial in total and in each subgroup.
The average proportion of toxicities observed in the biomarker negative subgroup
under the baseline method decreases for Scenario 1 through 5 while that in the
biomarker negative group increases. This is for no substantial difference in the number
CHAPTER 3. Dose-escalation Strategies which Utilise Subgroup Information 82
of patients treated between subgroups. This contrasting proportion of DLTs observed
in the two subgroups demonstrates that throughout trials, most biomarker negative
patients were being underdosed, with an average of only 3% experiencing DLTs in
Scenario 5, while on average 49% of biomarker positive patients treated experienced
DLTs in this scenario and hence many were likely overdosed.
We also see that, despite there being no tolerated dose in the biomarker positive
subgroup in Scenario 5, under the baseline method, an average of 26.28 patients
were treated in this subgroup per trial. This is compared to around 7 under the
methods which accounted for a subgroup effect. It is the ability of the methods which
account for a potential subgroup effect to stop for safety in one subgroup but continue
escalation in the other that leads to this advantage.
The reduced number of patients treated in the biomarker positive subgroup un-
der Methods 1-3 in Scenario 5 and the sample sizes observed for both subgroups in
Scenario 6 show that the stopping criterion for safety is effective. It had the effect
of reducing the overall average sample size from 60 to below 19 when there was no
tolerated dose in either subgroup. In that scenario (Scenario 6), all methods were
comparable, with around 90% of trials correctly identifying that there was no tol-
erated dose in either subgroup (Table 3.3.5). The baseline method was comparable
to the alternative in this case because its underlying assumption, that there was no
subgroup effect, was correct.
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Escalation
Scenario Method 0 1 2 None 100 150 180 215 245 260 None 100 150 180 215 245 260
Baseline 1000 0 0 0.01 0.01 0.05 0.49 0.36
X
0.07 0.02 0.01 0.01 0.05 0.49 0.36
X
0.07 0.02
1 1 0 951 49 0.02 0.02 0.11 0.39 0.33
X
0.08 0.04 0.03 0.02 0.10 0.38 0.33
X
0.09 0.04
2 755 196 49 0.02 0.01 0.07 0.39 0.40
X
0.09 0.03 0.03 0.01 0.06 0.39 0.39
X
0.09 0.03
3 666 298 36 0.03 0.01 0.09 0.40 0.36
X
0.09 0.03 0.02 0.01 0.10 0.40 0.36
X
0.08 0.03
Baseline 1000 0 0 0.01 0.01 0.11 0.58 0.28
X
0.02 0.00 0.01 0.01 0.11 0.58
X
0.28 0.02 0.00
2 1 0 962 38 0.03 0.01 0.11 0.42 0.32
X
0.07 0.04 0.02 0.03 0.25 0.49
X
0.19 0.02 0.00
2 745 217 38 0.02 0.01 0.09 0.47 0.32
X
0.06 0.03 0.02 0.01 0.15 0.52
X
0.25 0.04 0.02
3 662 304 34 0.02 0.02 0.11 0.45 0.32
X
0.06 0.03 0.02 0.03 0.20 0.50
X
0.22 0.02 0.01
Baseline 1000 0 0 0.00 0.01 0.34 0.59 0.06
X
0.00 0.00 0.00 0.01 0.34
X
0.59 0.06 0.00 0.00
3 1 0 945 55 0.02 0.02 0.13 0.36 0.32
X
0.10 0.04 0.04 0.13 0.55
X
0.26 0.01 0.00 0.00
2 662 283 55 0.02 0.01 0.19 0.43 0.24
X
0.08 0.02 0.05 0.06 0.36
X
0.41 0.10 0.01 0.02
3 423 511 66 0.03 0.01 0.17 0.41 0.26
X
0.08 0.04 0.05 0.10 0.47
X
0.35 0.03 0.00 0.00
Baseline 1000 0 0 0.01 0.30 0.68 0.01 0.00
X
0.00 0.00 0.01 0.30
X
0.68 0.01 0.00 0.00 0.00
4 1 0 871 129 0.03 0.02 0.12 0.40 0.32
X
0.08 0.03 0.11 0.76
X
0.13 0.00 0.00 0.00 0.00
2 519 352 129 0.04 0.05 0.25 0.35 0.23
X
0.06 0.03 0.12 0.37
X
0.25 0.16 0.06 0.01 0.02
3 73 804 123 0.02 0.04 0.13 0.36 0.34
X
0.09 0.03 0.11 0.74
X
0.15 0.00 0.00 0.00 0.00




0.83 0.00 0.00 0.00 0.00 0.00




0.05 0.00 0.00 0.00 0.00 0.00




0.00 0.01 0.01 0.01 0.00 0.01




0.05 0.00 0.00 0.00 0.00 0.00
Baseline 1000 0 0 0.89
X
0.10 0.00 0.00 0.00 0.00 0.00 0.89
X
0.10 0.00 0.00 0.00 0.00 0.00
6 1 0 183 817 0.89
X
0.10 0.00 0.00 0.00 0.00 0.00 0.91
X
0.09 0.00 0.00 0.00 0.00 0.00
2 183 0 817 0.89
X
0.10 0.00 0.00 0.00 0.00 0.00 0.91
X
0.09 0.00 0.00 0.00 0.00 0.00
3 323 0 677 0.90
X
0.10 0.00 0.00 0.00 0.00 0.00 0.90
X
0.10 0.00 0.00 0.00 0.00 0.00
Significant subgroup effect I+ = 0 I+ = 1
Recommended dose
Table 3.3.5: Number of trials which identify a subgroup effect (0 = no subgroup
effect, 1 = significant subgroup effect, 2 = defaulted to subgroup effect after stopping
for safety in one subgroup) and proportion of times each dose was recommended by
subgroup out of trials giving a recommended dose (based on a frequentist calculation).
Grey cells highlight dose-pairs with probability of causing a DLT in a patient greater
than 0.35. The ‘X’ marks the dose with probability of toxicity closest to 0.16.
In Scenario 1, the bulk of recommended doses by all methods are split between
180mg/m2 and 215mg/m2. This is not completely unexpected as the true TD16 for
this scenario is 206mg/m2 which falls between the two but being slightly closer to
215mg/m2. The true recommended doses, along with the probability of toxicity for
all scenarios are given in Table 3.3.3. The locations of the recommended doses in
Scenario 1 were also similar across all methods. This suggests that when a suitable
number of patients are treated in each subgroup (with 30 appearing to be suitable),
the recommended dose is identified with a reasonable level of accuracy. So, even when
there is no subgroup effect, there is no clear loss in using a method which accounts for
a potential subgroup effect compared to the baseline method when a sufficient number
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of patients are treated. Note that, if the baseline method was run with a total of 30
patients (based on number treated per assumed homogeneous population), then the
recommended dose locations would be the same (aside from simulation error) as those
from one or other subgroup under Method 1.
Now consider the locations of recommended doses from Scenarios 2-5 (Table 3.3.5).
As the subgroup effect increases, the baseline method gets progressively worse. This
is because under the baseline method, the assumption is that all observations arise
from the same population; the resulting recommended dose is effectively a compromise
between the true recommended doses from the two subgroups. The most undesirable
outcome from the baseline method arises from Scenario 5 where the true recommended
dose in the biomarker negative subgroup is 215mg/m2 and there is no tolerated dose
in the biomarker positive subgorup. In 17% of trials the baseline method stops for
safety in both subgroups, and in the remaining trials it identified the recommended
dose for the entire population as 100mg/m2. This means that 83% of the time a dose
which has ‘true’ probability of DLT of 0.02 (expected to be inefficacious) and 0.42
(undesirably toxic) in the two subgroups is recommended for further testing.
Method 1, which considers a potential subgroup effect throughout escalation and
in dose recommendation, performs much better than the baseline. This suggests
that 30 patients, with the levels of variability observed here, are suitable to identify
a recommended dose in a homogeneous population with reasonable accuracy. As
previously discussed, ideally we would like some idea of whether a subgroup effect was
in fact observed. This could be achieved using a hypothesis test (as in Method 2).
In Scenario 1, the proportion of correctly identified recommended doses by Method 2
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was greater than that from Method 1. This is because 79% of trials failed to reject the
null hypothesis, hence correctly concluding the absence of a subgroup effect. Based on
this conclusion, data were pooled and a more accurate dose recommendation obtained
than would be based on half the data (as in Method 1).
Unfortunately, the low power of the hypothesis test means that although the rec-
ommended doses from Method 2 improve upon the baseline in Scenarios 2-4, they
are notably worse than those from Method 1. Method 3 was designed to avoid this
problem and does so fairly successfully. Only small differences in recommended dose
locations are seen between the baseline method and Method 3 in Scenario 1, with a
conclusion of no subgroup effect under Method 3 66.6% of the time. Under Scenarios
2-5, the recommended doses by Method 3 are improved upon those from Method 2,
suggesting that it has more power to detect a subgroup effect than the hypothesis
test. In the presence of a medium subgroup effect (as in Scenarios 3 and 4), the
spike and slab priors are effective in identifying a subgroup effect. The proportion of
times a subgroup effect is correctly identified is 57.7% and 92.7% in Scenarios 3 and
4, respectively. This is compared to only 33.8% and 48.1% under Method 2.
Additional scenarios
In addition to the simulations described above, Method 3 was run with a maximum
of 120 patients per subgroup. From these results we were able to conclude that
given a suitable number of patients, this method provides good estimation of the
recommended dose in each subgroup. The results tables are given in Appendix 3.5.6.
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Some additional scenarios were also run; the purpose was to investigate the sen-
sitivity of the methods to different parameter values in the data generating dose-
toxicity model. The same parameter values used to generate data for both subgroups
in Scenario 1 were used for the biomarker negative subgroup, resulting in a true rec-
ommended dose of 215mg/m2 in this subgroup in all cases. For the biomarker positive
subgroup, the values of β2 and β3 were altered to create different scenarios but in a
way that resulted in a true recommended dose of 150mg/m2 in each case. The result-
ing dose-toxicity curves are shown in Figure 3.3.1. The corresponding true probability
of DLT at each available dose is given in Appendix 3.5.5 along with a table giving
some additional operating characteristics of the design.


















Figure 3.3.1: The dose-toxicity curves used to generate data in additional Scenarios
7-11. Horizontal lines are references at P(DLT|d) = 0.16 and 0.35. The solid black
curve on each plot represents that of the biomarker negative subgroup in all scenarios.
The dose-toxicity curves for the biomarker positive group in these scenarios are shown
for Scenarios 7-11 by the dashed red, green, dark blue, light blue and purple curves,
respectively.
CHAPTER 3. Dose-escalation Strategies which Utilise Subgroup Information 87
From the locations of the recommended doses for these additional scenarios, which
are presented in Table 3.3.6, we can confirm that we have run a suitable number of
simulations to be relatively certain in our conclusions drawn, for the given setting.
This is seen from the consistency in the outcomes of the biomarker negative subgroup.
The rest of this discussion is focussed on operating characteristics in the biomarker
positive subgroup.
Escalation
Scenario Method 0 1 2 None 100 150 180 215 245 260 None 100 150 180 215 245 260
Baseline 1000 0 0 0.01 0.02 0.48 0.45 0.04
X
0.00 0.00 0.01 0.02 0.48
X
0.45 0.04 0.00 0.00
7 1 0 936 64 0.02 0.02 0.13 0.37 0.33
X
0.09 0.04 0.05 0.21 0.58
X
0.15 0.01 0.00 0.00
2 602 334 64 0.02 0.01 0.20 0.42 0.24
X
0.08 0.03 0.05 0.11 0.41
X
0.33 0.07 0.01 0.02
3 364 567 69 0.02 0.02 0.21 0.37 0.29
X
0.06 0.03 0.06 0.20 0.53
X
0.20 0.02 0.00 0.00
Baseline 1000 0 0 0.01 0.02 0.42 0.52 0.04
X
0.00 0.00 0.01 0.02 0.42
X
0.52 0.04 0.00 0.00
8 1 0 928 72 0.03 0.01 0.11 0.41 0.33
X
0.07 0.04 0.05 0.16 0.57
X
0.21 0.01 0.00 0.00
2 649 279 72 0.03 0.01 0.20 0.44 0.24
X
0.06 0.02 0.06 0.07 0.39
X
0.39 0.08 0.01 0.01
3 399 540 61 0.02 0.02 0.19 0.39 0.28
X
0.07 0.03 0.04 0.15 0.51
X
0.27 0.03 0.00 0.00
Baseline 1000 0 0 0.00 0.07 0.65 0.27 0.01
X
0.00 0.00 0.00 0.07 0.65
X
0.27 0.01 0.00 0.00
9 1 0 896 104 0.02 0.01 0.13 0.41 0.32
X
0.07 0.04 0.10 0.40 0.45
X
0.06 0.00 0.00 0.00
2 562 334 104 0.03 0.03 0.24 0.38 0.22
X
0.07 0.02 0.11 0.20 0.37
X
0.24 0.05 0.01 0.01
3 268 636 96 0.02 0.03 0.21 0.36 0.28
X
0.07 0.04 0.09 0.33 0.46
X
0.11 0.01 0.00 0.00
Baseline 1000 0 0 0.01 0.08 0.42 0.41 0.07
X
0.01 0.00 0.01 0.08 0.42
X
0.41 0.07 0.01 0.00
10 1 0 860 140 0.02 0.01 0.14 0.40 0.31
X
0.08 0.04 0.14 0.33 0.36
X
0.14 0.03 0.00 0.00
2 553 307 140 0.03 0.03 0.22 0.38 0.26
X
0.07 0.03 0.14 0.17 0.31
X
0.26 0.08 0.01 0.02
3 336 535 129 0.03 0.03 0.18 0.37 0.29
X
0.07 0.04 0.12 0.31 0.33
X
0.19 0.04 0.00 0.00
Baseline 1000 0 0 0.00 0.00 0.38 0.60 0.01
X
0.00 0.00 0.00 0.00 0.38
X
0.60 0.01 0.00 0.00
11 1 0 972 28 0.02 0.02 0.13 0.40 0.32
X
0.08 0.04 0.01 0.08 0.65
X
0.26 0.00 0.00 0.00
2 684 288 28 0.02 0.01 0.19 0.46 0.24
X
0.06 0.02 0.01 0.03 0.41
X
0.42 0.09 0.01 0.02
3 406 559 35 0.03 0.01 0.19 0.37 0.27
X
0.09 0.04 0.02 0.08 0.57
X
0.31 0.02 0.00 0.00
Significant subgroup effect I+ = 0 I+ = 1
Recommended dose
Table 3.3.6: Number of trials which identify a subgroup effect (0 = no subgroup
effect, 1 = significant subgroup effect, 2 = defaulted to subgroup effect after stopping
for safety in one subgroup) and proportion of times each dose was recommended by
subgroup out of trials giving a recommended dose (based on a frequentist calculation),
for Scenarios 7-11. Grey cells highlight dose-pairs with probability of causing a DLT
in a patient greater than 0.35. The ‘X’ marks the dose with probability of toxicity
closest to 0.16.
It is difficult to make any firm conclusions concerning the effect of each of the
parameters on the methods but it is clear that the overall comparisons between the
methods which we have already made stand in all cases. Despite the different pa-
rameter values used to generate data in Scenarios 7 and 8, the resulting dose-toxicity
CHAPTER 3. Dose-escalation Strategies which Utilise Subgroup Information 88
curves are fairly similar over the dose range of interest. This is likely to be the reason
that the operating characteristics of these scenarios are similar. Although the dose-
toxicity curve for Scenario 9 is not greatly dissimilar to those of Scenarios 7 and 8,
there appears to an increased chance of stopping early. This could be down to the
value of β2 being greater than β3 because this observation is more evident in Scenario
10 which has an even larger difference in parameter values. Scenario 11 results in
a dose-toxicity curve with low toxicity at low doses but then increases steeply. The
average proportion of toxicities observed in the trial are therefore decreased and fewer
trials stop for safety.
Allowing early stopping for accuracy
Although a total of 30 patients (or more) in each subgroup is desirable, it is not always
feasible. Along with the stopping rules which were used in the previous simulations
(for safety in a subgroup or having treated the maximum number of patients in each
subgroup), we now include one for accuracy. That is, the trial can stop for accuracy
in a subgroup if a minimum of 5 patients have been treated at the dose advised for
administration to the next cohort of patients and the ratio of the upper and lower
bounds of the 95% credible interval around the estimate of that dose is less than 5 (as
used by Whitehead et al., 2006a). We compare the impact of this stopping rule on
Methods 1 and 3. The baseline design is not considered here because we have already
confirmed that it is not suitable when a subgroup effect is present. In a homogeneous
population, the effect of stopping rules is similar to that seen in one subgroup for
Method 1. Method 2 is not considered because it would require use of an interim
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analysis. The reduced number of patients available at the interim analysis, as well as
control for multiplicity, would result in the test being even lower powered.
Introducing the stopping rule for accuracy was effective in reducing the sample
size of the trial; this can be seen from the operating characteristics of the methods
presented in Table 3.3.7. In Scenarios 1-4, where there was a tolerated dose in each
subgroup, the average number of patients in the trial is between 45 and 51 in both
methods. Even based on these reduced sample sizes, the locations of the recommended
doses are still compacted around the true recommended dose; this can be seen in Table
3.3.8. Table 3.3.9 shows the reason that trials stopped. We see that in Scenario 1,
under both methods, 45-49% of trials stopped early for accuracy in both subgroups. In
Method 1 for Scenarios 2-5, the proportion of trials which stopped early for accuracy
was consistently around these values when there was a tolerated dose in the subgroup.
Escalation Average number patients Average proportion toxicities
Scenario method Overall I+ = 0 I+ = 1 Overall I+ = 0 I+ = 1
1 1 48.80 24.12 24.68 0.12 0.14 0.14
3 47.36 23.70 23.66 0.11 0.13 0.12
2 1 48.22 24.39 23.83 0.13 0.14 0.16
3 47.90 23.31 24.59 0.12 0.13 0.15
3 1 49.29 24.99 24.29 0.14 0.13 0.18
3 47.77 22.01 25.77 0.13 0.11 0.18
4 1 50.84 24.51 26.33 0.15 0.14 0.23
3 45.40 18.94 26.46 0.15 0.12 0.26
5 1 32.55 25.58 6.97 0.19 0.14 0.68
3 26.87 20.03 6.84 0.20 0.12 0.71
6 1 19.19 9.45 9.74 0.53 0.65 0.66
3 18.80 9.13 9.66 0.53 0.67 0.65
Table 3.3.7: Average number of patients treated per trial in total and in each sub-
group, average proportion of toxicities observed per trial in total and in each subgroup,
in simulations which allow early stopping for accuracy.
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In Method 3, the proportion of trials which stop for accuracy in the biomarker
negative subgroup increases as the true subgroup effect increases, while decreasing
in the biomarker positive subgroup. The reason for this large discrepancy is the
model selection identifying the presence of a subgroup effect. It is therefore better
able to estimate the dose-toxicity curve in the biomarker negative subgroup. This is
because of the spread of data. On the other hand the high uncertainty surrounding
the estimation of the dose-toxicity curve in the biomarker positive subgroup, caused
by a lack of data at higher doses, leads to the reduced number of trials which stop for
accuracy as the subgroup effect increases.
Escalation
Scenario Method None 100 150 180 215 245 260 None 100 150 180 215 245 260
1 1 0.04 0.02 0.13 0.33 0.32
X
0.08 0.09 0.03 0.01 0.14 0.35 0.34
X
0.06 0.08
3 0.03 0.01 0.11 0.43 0.26
X
0.10 0.06 0.02 0.02 0.10 0.42 0.24
X
0.12 0.07
2 1 0.03 0.02 0.14 0.34 0.32
X
0.06 0.09 0.03 0.03 0.24 0.43
X
0.23 0.02 0.02
3 0.03 0.02 0.12 0.44 0.22
X
0.10 0.07 0.03 0.03 0.23 0.48
X
0.17 0.05 0.02
3 1 0.02 0.03 0.12 0.35 0.32
X
0.08 0.09 0.04 0.12 0.46
X
0.32 0.05 0.00 0.00
3 0.02 0.02 0.16 0.41 0.20
X
0.11 0.07 0.05 0.10 0.45
X
0.36 0.04 0.01 0.00
4 1 0.03 0.01 0.13 0.35 0.31
X
0.07 0.09 0.11 0.74
X
0.14 0.00 0.00 0.00 0.00
3 0.03 0.02 0.11 0.41 0.20
X
0.13 0.10 0.12 0.74
X
0.14 0.00 0.00 0.00 0.00




0.06 0.00 0.00 0.00 0.00 0.00




0.07 0.00 0.00 0.00 0.00 0.00
6 1 0.89
X
0.11 0.00 0.00 0.00 0.00 0.00 0.88
X
0.12 0.00 0.00 0.00 0.00 0.00
3 0.90
X
0.10 0.00 0.00 0.00 0.00 0.00 0.89
X
0.11 0.00 0.00 0.00 0.00 0.00
I+ = 0 I+ = 1
Recommended dose
Table 3.3.8: Number of trials which identify a subgroup effect (0 = no subgroup
effect, 1 = significant subgroup effect, 2 = defaulted to subgroup effect after stopping
for safety in one subgroup) and proportion of times each dose was recommended by
subgroup out of trials giving a recommended dose (based on a frequentist calculation),
for Scenarios 7-11, in simulations which allow early stopping for accuracy. Grey cells
highlight dose-pairs with probability of causing a DLT in a patient greater than 0.35.
The ‘X’ marks the dose with probability of toxicity closest to 0.16.
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Reason trial stopped
Escalation I+ = 0 I+ = 1
Scenario method Safety Max Accuracy Safety Max Accuracy
1 1 0.03 0.50 0.49 0.02 0.55 0.45
3 0.02 0.54 0.46 0.01 0.54 0.45
2 1 0.02 0.53 0.47 0.03 0.50 0.49
3 0.02 0.52 0.47 0.03 0.62 0.36
3 1 0.01 0.56 0.45 0.04 0.57 0.40
3 0.01 0.41 0.59 0.04 0.73 0.23
4 1 0.02 0.52 0.47 0.11 0.84 0.05
3 0.02 0.23 0.77 0.12 0.87 0.01
5 1 0.01 0.56 0.46 0.92 0.08 0.00
3 0.01 0.24 0.77 0.92 0.09 0.00
6 1 0.85 0.15 0.00 0.83 0.16 0.00
3 0.87 0.13 0.00 0.85 0.15 0.00
Table 3.3.9: Proportion of trials which stopped for safety, having treated the maximum
number of patients and for accuracy in each subgroup.
As expected, the stopping rule for accuracy does not come in to play in a subgroup
in which there is no tolerated dose (as in the biomarker positive subgroup in Scenario
5 and both subgroups in Scenario 6). This is down to the stopping rule for safety
being met.
3.4 Discussion
We extended a traditional dose-toxicity model, by including terms for subgroup mem-
bership, used in dose-escalation to account for a potential subgroup effect. In doing
so, the assumption of a homogeneous trial population is removed, reducing the risk
of a missed or masked treatment effect due to variability between subgroups of the
population. The proposed dose-escalation methods, which account for a potential
subgroup effect, follow a similar procedure to the standard Bayesian model-based de-
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sign to which they were compared. In this way, after the initial set-up of the trial,
they should be no more difficult to employ.
Simulation results showed that accounting for subgroup membership in dose-
escalation can increase the safety of escalation. Importantly, Methods 1-3 had the
ability to stop early for safety in a subgroup if there was no tolerated dose, reducing
the number of overdoses recommended for use in future trials. Although a hypothesis
test was low powered to detect a subgroup effect (shown by Method 2), simulation
results showed that a proposed method, which used spike and slab priors on the terms
for subgroup membership (presented as Method 3), was reasonably good at identify-
ing the presence of an underlying subgroup. The recommended dose locations from
Method 3 were similar to those from Method 1 but with the advantage of providing ex-
ploratory information concerning the presence of a subgroup effect. Also, when there
was no identifiable subgroup effect, escalation and identification of the recommended
dose makes better use of available data than Method 1.
The methods were initially compared with a total of 30 patients available for
treatment in each subgroup. Although such a sample size would be desirable, it is not
always feasible. The use of a stopping rule for accuracy demonstrated that an overall
sample size of 45-50 is suitable for Methods 1 and 3 to identify a recommended dose
with a relatively small loss in accuracy.
As with standard Bayesian model-based designs, the proposed methods are flexible
and practical since available doses and cohort sizes, among other design factors, can
be altered throughout the trial. We considered the optimal setting with cohorts of size
two, consisting of one biomarker positive and one biomarker negative patient (unless
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one subgroup had stopped for saftey). This could be altered but the more unevenly
distributed the patients are between subgroups, the lower powered the hypothesis test
(in Method 2) and worse the variable selection algorithm (in Method 3) will perform.
The proposed methods can allow for different values of θ to be used in each subgroup,
if required. In practice it is also still possible for the clinical team to over-ride the
model decision based on any available data.
The methods proposed here only have the potential to highlight subgroup effects
between the two pre-defined subgroups of the population. It could be beneficial to
extend this to the ordinal setting (similar to that of Tighioutart et al., 2012). However,
the sample size in dose-escalation trials is simply too small to consider identification
of a subgroup effect, with suitable power, within the trial. Rogatko et al. (2005)
propose extending the search for the optimal dose, and consideration of a subgroup
effect, beyond dose-escalation. This can also help account for population changes and
longer-term endpoints in the identification of an optimal dose.
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3.5 Appendix
3.5.1 Power Calculations
When considering Method 2, we looked into the choice of hypothesis test on the
presence of a subgroup effect in dose-escalation trials. Initially, we considered using
a difference hypothesis test on the parameters for subgroup membership such that:
H0 : β2 = 0 and β3 = 0 versus H1 : β2 6= 0 and/or β3 6= 0.
An alternative was equivalence testing which, for a dose-escalation trial conducted
using a method which accounts for a potential subgroup effect, may feel more natural.
Specifying equivalence hypotheses on the parameters for subgroup membership is
difficult. This is because, without knowing how β2 and β3 are related the equivalence
bounds are hard to specify. An alternative is to base the test on the difference in
recommended dose between the subgroups. In this case, the equivalence bounds could
be more intuitively based on a dose difference expected to have a relevant difference in
efficacy. For equivalence bound c and dose recommendations T̂D100θ− and T̂D100θ+
from the biomarker negative and positive subgroups, respectively:
H0 : T̂D100θ− − T̂D100θ+ /∈ [−c, c] versus H1 : T̂D100θ− − T̂D100θ+ ∈ [−c, c].
A difference hypothesis can also be defined which is based on the difference in rec-
ommended dose between the subgroups such that,
H0 : T̂D100θ− − T̂D100θ+ = 0 versus H1 : T̂D100θ− − T̂D100θ+ 6= 0.
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This final hypothesis test is the one that was chosen for use in simulations. The
reason is that it is the best powered hypothesis test. This is because it does not account
for mulitplicity (as in the first difference hypothesis test) and the tail probabilities
used an equivalence hypothesis. Despite this being the preferred test of the three,
it is still low-powered. Also, when testing for a subgroup effect, we would ideally
consider the entire dose-toxicity curve as opposed to the point estimate. Alternative
tests, using closed testing procedures for example, could avoid the issue of multiplicity.
However, decisions over which parameter to investigate first and the distribution of
the type I error rates could be difficult.
We can confirm mathematically that the test will be low powered: We have as-
sumed that the β parameters are normally distributed with means at the correspond-
ing maximum likelihood estimates (equivalent to MAP estimates when prior data is
incorporated in the regression in the same manner as trial data) and known variances.
Since maximum likelihood estimates are invariant to transformation, it can be said
that asymptotically, d is normally distributed with mean E[d] and variance Var(d).
Solving Equation 3.1.1 for d we find that
E[d] = d∗(ey − 1) for y = log{θ/(1− θ)} − βˆ0
βˆ1
. (3.5.1)






e2y{y2σ21 + 2ycov(β0, β1) + σ20}.
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Fitting a logistic regression model to the pooled data from the paediatric trial of
Temzolomide reported by Nicholson et al. (1998), we can obtain mean estimates of
the β’s and the covariance matrix of the terms. From these estimates we use the
formulae for E[d] and Var(d) to find the dose recommendation to be approximately
206mg/m2 and its standard deviation to be about 168.
In the simulation study, we specified the type I error rate α = 0.3 and a maximum
of 30 patients per subgroup. The power of such a trial to detect a difference of











To achieve a type I error rate of 0.3 and power 1− β = 0.2 to detect a difference
of 35mg/m2 in recommended dose between the two subgroups then the sample size
required is {




These calculations can be checked through simulation. They show that, as ex-
pected, our hypothesis test is low powered. In practice, due to the nature of dose-
escalation, the spread of observed dose levels is unlikely to be equal and is likely to
differ between subgroups and scenarios. This will lead to larger variances and differ-
ences in variance between the groups than those here, and hence even lower powered
test for a fixed sample size.
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3.5.2 Specifics of Variable Selection in Method 3
The four-parameter dose-toxicity model defined in Equation 3.2.1 to be able to account


















where pi(x, I+) = P(DLT|x, I+).
In the absence of alternative information to base the prior on, the same pseudo
data is used to define the prior for variable selection as was used for the purpose of
model fitting in all methods. That is, in each subgroup, a prior probaility of toxicity
at 100mg/m2 of 16% and a prior probability of toxicity at 260mg/m2 of 50% with 3
patients treated at each of the two prior doses. This data can be fitted to the four-
parameter dose-toxicity model to obtain MAP estimates of the parameter vector;
β = [β0, β1, β2, β3]
T
= [−3.136, 3.765, 5.993× 10−16,−7.195× 10−16]T .
The design matrix has columns: 1) the intercept term, 2) the transformed dose
(x/d+ 1), 3) the indicator of membership of the biomarker positive subgroup, 4) the
interaction between transformed dose and the indicator of subgroup membership, for
all possible combinations of the four-parameter dose-toxicity model terms. In our case
it is given by,






































































































1 0.405 0 0
1 0.405 1 0.405
1 0.560 0 0
1 0.560 1 0.560
1 0.642 0 0
1 0.642 1 0.642
1 0.730 0 0
1 0.730 1 0.730
1 0.800 0 0
1 0.800 1 0.800
1 0.833 0 0
1 0.833 1 0.833

,
From this information, the prior response vector y = Xβ can be calculated as
y = [− 1.609,−1.609,−1.029,−1.029,−0.719,−0.719,
− 0.388,−0.388,−0.125,−0.125,−0.728× 10−15,−0.728× 10−15]T .




= [0.167, 0.167, 0.263, 0.263, 0.328, 0.328,
0.404, 0.404, 0.469, 0.469, 0.500, 0.500]T .
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Based upon this we can see that the prior implies that doses of 100, 150 and
180mg/m2 are tolerated (i.e. have prior probability of toxicity less than 0.35). From
these doses, 100mg/m2 is the optimal dose (based on the escalation criteria defined
in Step 3 of the proposed methods) as it has prior probability of toxicity closest to
the target rate of 0.16.
Using BoomSpikeSlab to specify a spike and slab prior for variable selection
In the BoomSpikeSlab package, specification of the spike and slab prior was achieved
using the function SpikeSlabPrior. The arguments passed to this function are used
to define the spike and slab components of the prior. The design matrix x = X
and response vector y = y (defined above) are the arguments involved in specifying
the slab component of the prior that we defined. For specifying the slab component
of the prior, we defined the argument prior.inclusion.probabilities = c(1, 1,
0.5, 0.5) (for prior setting c and d of Table 3.5.9). The initial two components of
this vector translate to β0 and β1 being forced into the dose-toxicity model. The last
two components define the prior probability of inclusion of the terms for subgroup
membership. In our simulation study, different settings (given in Table 3.5.9) of these
parameters were investigated.
Defining these three arguments for SpikeSlabPrior meant that the alternative argu-
ments (mean.y, sd.y and expected.model.size) do not need to be defined. Default
values were used for the other arguments, details of which are given in Table 3.5.1
and reasons for this use are given in the remainder of this paragraph. The precision
matrix of the βs should always be full rank in our setting and so diagonal.shrinkage
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is not relevant. A lack of prior information to base estimates on makes defining values
of expected.r2, prior.df and optional.coefficient.estimate, which are more
suitable to our setting than the default values, difficult. We investigated the value
of prior.information.weight argument and values significantly greater than the
default caused the prior to be more influential on variable selection than we felt de-
sirable under a range of scenarios. For this reason, the default value seemed to be as
good a choice as any. Given that we are sampling only two inclusion indicators (γ2
and γ3) it does not appear to be detrimental to sample both at each iteration.
Using BoomSpikeSlab for variable selection with a spike and slab prior
In the BoomSpikeSlab package, variable selection on the logistic regression model
using a spike and slab prior was achieved using the function logit.spike. The available
prior and trial data was supplied to this function in the form of a data frame via
the argument data. The data frame has one row of information for each (prior and
available) dose of treatment with columns;
• responses: a two column matrix with the columns giving the number of suc-
cesses (experienced a DLT in their first cycle of treatment) and failures,
• log TrD: the log-transformed dose administered to the patient,
• subgroup: a 0/1 indicator of whether the patient is in the biomarker bositive
subgroup.
The logistic regression model to be fitted to the available data is passed to the func-
tion via the argument; formula = responses ∼ log TrD + subgroup*log TrD. The
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output of SpikeSlabPrior is used for the argument prior which defines the spike and
slab prior on this logistic regression model. After checking for convergence from a
range of scenarios, we specified that the chain should be run for niter = 20,000
iterations with 5, 000 iterations for burn-in (although this is not used in logit.spike).
The additional arguments ping and nthreads do not affect the output of the
function. Default values were used for the other arguments, details of which are given
in Table 3.5.2 and reasons for this use are given in the remainder of this section.
Since we wish to fit the model based on available data, which contains no missing
values, the arguments subset and na.action are not relevant. In defining the seed
for a larger function, the seed argument is also not required. The generated initial
values are suitable to fit our relatively simple model efficiently and so the default was
used for initial.value. The standard setting for contrasts was used, this is used
in a varienty of R functions and appears to be suitable here too. Since we are only
sampling for two parameters, it is suitable to sample them both at each step in the
sampling algorithm so we can leave mh.chunk.size at its default value. The default
value of proposal.df appears to work reasonably well and we have no information
to support the use of an alternative proposal distribution any more than this one.
We consider a set of available dose pairs instead of a continuous range. For this
reason, drop.unused.levels has no effect on inferences for our model; it is similar
to having the reduced available dose range. The argument clt.threshold specifies
when asymptotic results should be used and after testing a range of values of this
argument we found that its effect on escalation decisions was minimal and so we
chose to use the default value for this parameter.
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3.5.3 Prior specification
We chose to specify the prior to control the operating characteristics of the trial. This
required investigation of the likely escalation patterns of a range of prior settings. We
specify no prior subgroup effect (to aid comparison of the methods) and weight the
prior data to 1/10th of the planned trial size. So, in selecting a prior we investigated
priors consisting of 3 patients worth of data under dose-escalation Method 1 in one
subgroup.
In order to get a start dose of 100, this is selected as the lower of the prior doses
with a prior probability of DLT at this level equal to 0.16, the target toxicity level.
The higher prior dose, prior proportion of toxicities at that dose and the weighting of
patients at each of the two doses was then altered in the investigated prior settings.
These are given in Table 3.5.3.
Prior Dose
setting 100 150 180 215 245 260
1 1/6 (1.5) - - 1/3 (1.5) - -
2 1/6 (1.5) - - - - 1/3 (1.5)
3 1/6 (1.5) - - - - 1/2 (1.5)
4 1/6 (1.5) - - - - 2/3 (1.5)
5 1/6 (2) - - - - 1/3 (1)
6∗ 1/6 (2) - - - - 1/2 (1)
7 1/6 (2) - - - - 2/3 (1)
8 1/6 (1) - - - - 1/3 (2)
9 1/6 (1) - - - - 1/2 (2)
Table 3.5.3: Prior settings tested given in terms of the prior proportion of DLTs
observed at each dose and in brackets, the number of prior patients observed at that
dose out of the total of 3 patients. The ‘*’ indicates the prior setting used in the
simulation study.
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The initial scenario that we looked at was that when no DLTs were observed.
In this Scenario, prior setting 1 was found to escalate undesirably quickly, especially
upon reaching 215mg/m2 (the higher prior dose in this setting). This led to the high
prior dose used being at the top of the available dose range (as in prior settings 2-
9). In scenario 2 we can see that this has the effect of slowing escalation slightly at
higher dose levels and reducing the chance of the curve flipping. It is however still
fast escalation. This setting, as well as prior settings 5 and 8 were felt to escalate
too quickly in this likely scenario to be used in the study. Settings 4, 6 and 7 are
more cautious with escalation seemingly more controlled over the dose range. These
patterns are shown in Table 3.5.4.
Dose Prior Scenario
1 2 3 4 5 6 7 8 9
100 1 1 1 2 1 2 3 1 1
150 2 1 2 3 1 2 3 1 1
180 2 1 3 4 3 2 4 1 3
215 1 2 3 6 5 2 3 2 5
245 0 0 1 3 3 1 1 1 3
260 - - - - - - - - -
Table 3.5.4: Escalation pattern under a range of prior settings when no DLTs are
observed. Entries are the number of patients treated at each dose before the model
escalates to the next highest dose.
We went on to investigate the case where a DLT was observed. Table 3.5.5 shows
the escalation pattern for the scenario in which a DLT is observed in an early cohort of
patients at 100mg/m2. If a DLT was observed in the first patient, then the remaining
prior settings led to the escalation being stopped for safety. In settings 6 and 7
escalation could continue if a DLT was observed in the second patient treated at
100mg/m2 while the other scenarios required treatment of two patients.
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Dose Prior Scenario
3 4 6 7 9
100 2, DLT, 7 2, DLT, 10 1, DLT, 9 1, DLT, 11 2, DLT, 7
150 5 7 4 6 6
180 3 4 2 3 4
215 1 3 1 1 2
245 1 1 0 1 1
260 - - - - -
Table 3.5.5: Escalation pattern under a range of prior settings with a DLT observed
at 100mg/m2. Entries are the number of patients treated at each dose before the
model escalates, given a DLT observed at 100.
Dose Prior Scenario
3 4 6 7 9
100 1 ; 6 2 ; 8 2 ; 7 3 ; 12 1 ; 5
150 DLT ; 7 DLT ; 9 DLT ; 7 DLT ; 9 DLT ; 7
180 7 10 5 8 7
215 3 5 2 3 3
245 1 2 1 2 1
260 - - - - -
100 1 ; 1 2 2 3 1 ; 2
150 2 ; 6 3 ; 6 2 ; 7 3 ; 7 1 ; 5
180 DLT ; 8 DLT ; 13 DLT ; 7 DLT ; 10 DLT ; 10
215 5 8 3 5 6
245 2 2 1 1 2
260 - - - - -
Table 3.5.6: Escalation pattern under a range of prior settings with a DLT observed
at 150mg/m2 and 180mg/m2 for the respective table sections. Entries are the number
of patients treated at each dose before the model escalates. A semi-colon represents
a break in dosing at that level (i.e. escalation and de-escalation).
In further scenarios, observation of a DLT at 150mg/m2 and 180mg/m2 was consid-
ered. These results are given in Table 3.5.6. With observation of a DLT at 150mg/m2,
all prior settings led to administration of 100 for several patients before re-escalating.
Similarly, for observation of a DLT at 180mg/m2. In this case, scenarios 6 and 7
de-escalate by only one dose while the others de-escalate by two dose levels. Prior
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setting 6 was selected as being the most suitable prior because of its consistent escala-
tion in the case of no DLTs and the reduced number of patients (compared to setting
7) required to re-escalate if a DLT is observed early on in the trial.
In Section 3.3.2, the recommended dose locations given are based on a frequentist
model fit to the data. Table 3.5.7 presents the recommended dose locations which
would be identified using Bayesian and Table 3.5.8 the frequentist estimates from our
prior set up for Method 2. The small difference in recommendations between the two
suggest that weighting the prior to 1/10th of the final expected data appears to be
suitable to have limited effect on the final dose recommendation if a Bayesian estimate
is to be used with the sample sizes considered here.
Bayesian estimate of the recommended dose
I+ = 0 I+ = 1
Scenario None 100 150 180 215 245 260 None 100 150 180 215 245 260
1 0.02 0.02 0.11 0.42 0.35 0.05 0.03 0.03 0.02 0.10 0.43 0.32 0.05 0.04
2 0.02 0.01 0.12 0.44 0.32 0.04 0.04 0.02 0.03 0.24 0.54 0.15 0.01 0.00
3 0.02 0.01 0.13 0.41 0.33 0.06 0.04 0.04 0.13 0.58 0.24 0.01 0.00 0.00
4 0.03 0.02 0.12 0.44 0.32 0.05 0.04 0.11 0.78 0.12 0.00 0.00 0.00 0.00
5 0.03 0.01 0.10 0.42 0.34 0.05 0.04 0.98 0.02 0.00 0.00 0.00 0.00 0.00
6 0.95 0.05 0.00 0.00 0.00 0.00 0.00 0.97 0.03 0.00 0.00 0.00 0.00 0.00
Table 3.5.7: Bayesian calculations of the proportion of times each dose was recom-
mended by subgroup out of trials giving a recommended dose, based on dose-escalation
Method 2.
Frequentist estimate of the recommended dose
I+ = 0 I+ = 1
Scenario None 100 150 180 215 245 260 None 100 150 180 215 245 260
1 0.02 0.02 0.11 0.39 0.33 0.08 0.04 0.03 0.02 0.10 0.38 0.33 0.09 0.04
2 0.03 0.01 0.11 0.42 0.32 0.07 0.04 0.02 0.03 0.25 0.49 0.19 0.02 0.00
3 0.02 0.02 0.13 0.36 0.32 0.10 0.04 0.04 0.13 0.55 0.26 0.01 0.00 0.00
4 0.03 0.02 0.12 0.40 0.32 0.08 0.03 0.11 0.76 0.13 0.00 0.00 0.00 0.00
5 0.03 0.02 0.11 0.39 0.32 0.09 0.04 0.95 0.05 0.00 0.00 0.00 0.00 0.00
6 0.89 0.10 0.00 0.00 0.00 0.00 0.00 0.91 0.09 0.00 0.00 0.00 0.00 0.00
Table 3.5.8: Frequentist calculations of the proportion of times each dose was recom-
mended by subgroup out of trials giving a recommended dose, based on dose-escalation
Method 2.
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3.5.4 Investigating Inclusion Probabilities
We investigated the effect of the prior inclusion probability of β2 and β3 and also the
boundary on the inclusion probability for inclusion of terms in the fitted model. The
combinations investigated are given in Table 3.5.9.
Method Prior Prior inclusion probability on Boundary for inclusion
setting β2 β3 of term in model
a 0.3 0.3 0.25
b 0.3 0.3 0.35
3 c 0.5 0.5 0.25
d 0.5 0.5 0.35
e 0.7 0.7 0.25
f 0.7 0.7 0.25
Table 3.5.9: Combinations of prior inclusion probability and boundary for inclusion
of terms included in the model investigated in Method 3.
As expected, the average number of patients and proportion of DLTs were very
similar in each of the inclusion probability settings. This confirms the safety criterion
on escalation is effective and that, in general, escalation is targeting suitable doses.
The effect of the inclusion probability parameters on the model choice also agreed
with expectations. This can be seen from the number of trials which declared a
significant subgroup effect in escalation, as shown in Table 3.5.10 for prior settings 1
and 3. Increasing the prior inclusion probability of the parameters lead to the terms
for subgroup membership being included in the model more often. Increasing the
bound for inclusion of a term in the model led to a decrease in how often the terms
for subgorup membership were considered in the model, and hence how many trials
concluded that a significant subgroup effect was present.
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3.5.5 Dose-toxicity Scenarios Investigated and Additional Re-
sults Table
The dose-toxicity curves corresponding to Scenarios 1-6 of the simulation study are
presented in Figure 3.5.1. The parameter values and resulting probability of toxicity
for data generated for the biomarker positive subgroup for additional Scenarios 7-
11 are given in Table 3.5.11. A table showing some operating characteristics of this
design are given in Table 3.5.12.


















Figure 3.5.1: The dose-toxicity curves used to generate data in Scenarios 1-6 of the
simulation study. Horizontal lines are references at P(DLT|d) = 0.16 and 0.35. The
solid black curve represents both subgroups in Scenario 1 and the biomarker negative
subgroup in Scenarios 2-5. The dose-toxicity curve for the biomarker positive group
in these scenarios are shown by the dashed red, green, dark blue and light blue curves,
respectively. The dose-toxicity curves for both subgroups in Scenario 6 is shown by
the dashed purple curve.
CHAPTER 3. Dose-escalation Strategies which Utilise Subgroup Information 111
Scenario 100 150 180 215 245 260 100 150 180 215 245 260
1 0.02 0.06 0.10 0.18X 0.28 0.33 0.02 0.06 0.10 0.18X 0.28 0.33
2 0.02 0.06 0.10 0.18
X
0.28 0.33 0.02 0.08 0.14
X
0.26 0.38 0.45
3 0.02 0.06 0.10 0.18X 0.28 0.33 0.03 0.13X 0.24 0.42 0.58 0.65
4 0.02 0.06 0.10 0.18X 0.28 0.33 0.09X 0.36 0.60 0.81 0.90 0.93
5 0.02 0.06 0.10 0.18X 0.28 0.33 0.42 0.90 0.97 0.99 1.00 1.00
6 0.38 0.67 0.79 0.88 0.93 0.94 0.38 0.67 0.79 0.88 0.93 0.94
Scenario β0 β1 β2 β3 100 150 180 215 245 260
1 -7.10 7.68 0.00 0.00 0.02 0.06 0.10 0.18
X
0.28 0.33
7 -7.10 7.68 0.75 0.75 0.05 0.16X 0.28 0.45 0.60 0.66
8 -7.10 7.68 0.30 1.30 0.04 0.15
X
0.26 0.44 0.59 0.66
9 -7.10 7.68 1.30 0.30 0.07 0.21X 0.34 0.51 0.64 0.70
10 -7.10 7.68 3.00 -3.00 0.10 0.19X 0.25 0.34 0.41 0.45
11 -7.10 7.68 -2.00 5.00 0.02 0.12
X
0.28 0.54 0.74 0.81
P(DLT|d, I+ = 0) P(DLT|d, I+ = 1)
P(DLT|d, I+ = 1)Parameter value
Table 3.5.11: Parameter value and simulated probability of DLT at each dose (in
mg/m2) to be tested in the additional simulations, given for biomarker positive sub-
group. Dark grey cells highlight dose-pairs with probability of causing a DLT in a
patient greater than 0.35. The ‘X’ marks the dose with probability of toxicity closest
to 0.16, in cases where there is a tolerated dose.
Escalation Average number patients Average proportion toxicities
Scenario method Overall I+ = 0 I+ = 1 Overall I+ = 0 I+ = 1
Baseline 59.83 29.91 29.91 0.14 0.07 0.20
7 1 and 2 58.11 29.51 28.61 0.14 0.13 0.19
3 57.96 29.57 28.39 0.14 0.13 0.21
Baseline 59.94 29.97 29.97 0.13 0.08 0.19
8 1 and 2 57.93 29.40 28.53 0.14 0.14 0.20
3 58.19 29.48 28.71 0.14 0.13 0.20
Baseline 59.95 29.97 29.97 0.14 0.06 0.22
9 1 and 2 56.99 29.71 27.28 0.14 0.13 0.23
3 57.23 29.54 27.69 0.15 0.13 0.23
Baseline 59.71 29.86 29.86 0.14 0.08 0.20
10 1 and 2 55.78 29.54 26.25 0.15 0.13 0.27
3 56.20 29.51 26.70 0.15 0.13 0.25
Baseline 59.94 29.97 29.97 0.13 0.08 0.19
11 1 and 2 59.20 29.54 29.66 0.13 0.13 0.16
3 59.00 29.45 29.55 0.14 0.13 0.17
Table 3.5.12: The number of patients treated per trial in total and in each subgroup,
average proportion of toxicities observed per trial in total and in each subgroup, for
Scenarios 7-11.
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3.5.6 Long-run Simulations
Method 3 was run with 120 patients in each subgroup (with prior scaled up respec-
tively) to confirm that the method works in theory, given suitable amounts of data.
The results in Tables 3.5.13 and 3.5.14 confirm this.
Average number patients Average proportion toxicities
Scenario Overall I+ = 0 I+ = 1 Overall I+ = 0 I+ = 1
1 240.00 120.00 120.00 0.12 0.12 0.12
2 240.00 120.00 120.00 0.12 0.11 0.13
3 240.00 120.00 120.00 0.13 0.11 0.15
4 239.32 120.00 119.32 0.12 0.11 0.13
5 143.45 120.00 23.45 0.16 0.12 0.55
6 84.48 42.92 41.56 0.44 0.49 0.49
Table 3.5.13: Average number of patients treated per trial in total and in each sub-
group, average proportion of toxicities observed per trial in total and in each subgroup
for long-run simulations under Method 3.
Recommended dose
Significant subgroup effect I+ = 0 I+ = 1
Scenario 0 1 2 None 100 150 180 215 245 260 None 100 150 180 215 245 260
1 911.00 89.00 0.00 0.00 0.00 0.01 0.44 0.52 0.02 0.00 0.00 0.00 0.01 0.43 0.53 0.03 0.00
2 818.00 182.00 0.00 0.00 0.00 0.01 0.63 0.34 0.01 0.01 0.00 0.00 0.06 0.72 0.21 0.00 0.00
3 279.00 721.00 0.00 0.00 0.00 0.07 0.49 0.40 0.04 0.01 0.00 0.01 0.71 0.27 0.01 0.00 0.00
4 2.00 992.00 6.00 0.00 0.00 0.01 0.49 0.45 0.04 0.01 0.01 0.96 0.03 0.00 0.00 0.00 0.00
5 0.00 32.00 968.00 0.00 0.00 0.01 0.47 0.47 0.04 0.01 0.99 0.01 0.00 0.00 0.00 0.00 0.00
6 557.00 0.00 443.00 0.89 0.10 0.01 0.00 0.00 0.00 0.00 0.89 0.09 0.01 0.00 0.00 0.00 0.00
Table 3.5.14: Number of trials which identify a subgroup effect (0 = no subgroup
effect, 1 = significant subgroup effect, 2 = defaulted to subgroup effect after stopping
for safety in one subgroup) and proportion of times each dose was recommended by
subgroup out of trials giving a recommended dose (based on a frequentist calculation)
for long-run simulations under Method 3.
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Traditionally, model-based dose-escalation trial designs recommend a dose for es-
calation based on an assumed dose-toxicity relationship. Pharmacokinetic data are
often available but are currently only utilised by clinical teams in a subjective manner
to aid decision making if the dose-toxicity model recommendation is felt to be too
high. Formal incorporation of pharmacokinetic data in dose-escalation could there-
fore make the decision process more efficient and lead to an increase in the precision
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of the resulting recommended dose, as well as decreasing the subjectivity of its use.
Such an approach is investigated in the dual-agent setting using a Bayesian design,
where historical single-agent data are available to advise the use of pharmacokinetic
data in the dual-agent setting. The dose-toxicity and dose-exposure relationships are
modelled independently and the outputs combined in the escalation rules. Implemen-
tation of stopping rules highlight the practicality of the design. This is demonstrated
through an example which is evaluated using simulation.
Keywords: Dose-escalation, pharmacokinetic data, dual-agent, escalation rules, combination
treatment.
4.1 Introduction
Dose-escalation trials are usually first-in-man trials of a treatment for a given appli-
cation. They proceed by administering successive cohorts of patients with increasing
doses of the treatment in order to identify a recommended dose for use in efficacy trials
(Pocock, 2004). Despite the need for an accurate dose recommendation, to maximise
the treatment’s chance of success in efficacy trials, identification of the recommended
dose is typically based only on short-term, binary toxicity data. That is, an indicator
of whether a dose-limiting toxicity (DLT) is observed in a patient during the first
cycle of treatment. Other factors to consider in the design of a dose-escalation trial
concern patient ethics and practical issues. These considerations include minimising
the number of patients treated at sub-optimal dose levels and limits on time and
patient resources.
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A desirable dose-escalation trial design identifies the recommended dose rapidly
and reliably while maintaining patient safety as a priority. Achieving these properties
requires a compromise between the rate, in terms of the speed and efficiency of escala-
tion, and safety of escalation. These properties are controlled largely by specification
of two decision rules:
i. The escalation rule controls which dose is administered to a cohort of patients;
ii. The stopping rule controls when the trial is stopped.
Traditional, algorithmic dose-escalation trial designs are simple to implement as
they rely on fixed escalation and stopping rules. For example, the 3+3 design (Storer,
1989) requires pre-specified, available doses and treats patients in cohorts of size three.
Escalation proceeds using pre-specified decision rules such as those given here which
are described and illustrated in Jaki et al. (2013):
i. Escalation rule:
• If no DLTs are observed in a cohort of three patients, then we say that 0/3
patients in a cohort experience a DLT and administer the next cohort of
patients with the next higher pre-specified dose level;
• If 1/3 patients in a cohort experience a DLT, treat another cohort of patients
at the same dose level.
ii. Stopping rule:
• If ≥ 2/6 patients treated at a dose level experience a DLT, stop the trial.
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– The recommended dose is declared as the dose below that observed to
have an unacceptable level of toxicity. The recommended dose from
such a trial is often referred to as the maximum tolerated dose (MTD).
An alternative family of designs are model-based. These designs assume some
model for the dose-toxicity relationship, enabling quantitative definition of the rec-
ommended dose as the dose with probability θ of causing a DLT in a patient. An
overview of single-agent trial designs and the advantages of model-based designs over
other available options are given by Jaki et al. (2013).
A combination of drugs may be required to increase the effectiveness of a treat-
ment. The aim of dose-escalation of a combination treatment is traditionally to iden-
tify a recommended dose combination with probability θ of causing a DLT in a patient.
For a dual-agent treatment the recommended dose combination will be a dose-pair.
That is, a dose of each of the two drugs which, when administered together, have
probability θ of causing a DLT in a patient. An additional complication of dual-agent
over single-agent escalation is that there are now two drugs, both of which may have
to be escalated to find the recommended dose-pair. In modelling the dose-response re-
lationship, possible drug-drug interactions (DDIs) must also be accounted for. DDI’s
can act at the pharmacodynamic or pharmacokinetic level. The result is an increase,
or decrease, in toxicity and response (for a DDI acting at the pharmacodynamic level)
or in exposure (for a DDI acting at the pharmacokinetic level), compared with the
case of no interaction. The case of no interaction is defined in Section 4.2 in relation
to the relevant models.
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Harrington et al. (2013) provide a good review of dual-agent dose-escalation trial
designs and emphasise the advantages of model-based over algorithmic designs in
such a setting. The advantages include improvements in operating characteristics
such as administering fewer sub-optimal dose-pairs more reliable identification of the
recommended dose-pair. These improvements come largely from the ability of model-
based designs to use all available trial information to advise escalation decisions and
attempt to estimate the entire dose-toxicity surface. This is in contrast to algorithmic
designs which search for the recommended dose-pair with escalation decisions based
largely on information from the previous cohort.
A common method of escalation in the combination setting involves fixing the
dose of one drug and escalating the other (Dejardin et al., 2014; Ellis et al., 2013).
Where both drugs require escalation, Yuan and Guosheng (2008) propose a sequential
dose-escalation procedure. Ordering of dose-pairs in the dual-agent setting is difficult;
although pair-wise ordering is possible, it is not ideal. When more than a few doses
of each drug are being considered, then approaches (such as that of Bailey et al.,
2009) which use a single-agent model with covariates also encounter difficulties. It is
therefore preferable to model the entire dose-toxicity surface. A range of models for
dual-agents have been suggested (Braun and Wang, 2010; Huo et al., 2012; Neuen-
schwander et al., 2015; Thall et al., 2003; Wang and Ivanova, 2005; Yin and Yuan,
2009) and different escalation rules considered (Sweeting and Mander, 2012; Wheeler
et al., 2014). In this chapter we base our proposed designs on the dual-agent dose-
toxicity model specified in Neuenschwander et al. (2015), details of this model are
given in Section 4.2.1.
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Model-based designs can be employed in a Bayesian manner, allowing incorpora-
tion of prior knowledge along with all available trial data. Although Bayesian meth-
ods are arguably subjective, their use in early phase clinical trials has been endorsed
(CHMP et al., 2006) and can be beneficial at this stage in trials where little data are
available. Basing priors upon relevant, available data can reduce the subjectivity of
the design but care must still be taken to ensure sensible weighting of this historical
information. Given reasonable priors, an assumed model (which suitably describes the
dose-toxicity relationship) and specified escalation rules, an advised dose for escala-
tion can be obtained from the model. When escalation is complete, a stopping rule is
satisfied and a recommended dose-pair can be identified. In practice, at each stage in
dose-escalation, a clinical team use all available data observed but not accounted for
in the model (such as safety, efficacy, pharmacodynamic and pharmacokinetic data)
to select a dose that is typically less than or equal to that advised by the model.
Use of the data in this way is subjective and inefficient because this data is rarely
modelled at this stage in trials and its use is inconsistent.
Dual-agent dose-escalation trial designs have been proposed which account for both
binary (or ordinal) efficacy data and toxicity data (Mandrekar et al., 2007; Whitehead
et al., 2006b, 2011). Dragalin et al. (2008) allow for continuous efficacy data but base
decisions on the four-option probability combination set of binary efficacy and toxicity
outcomes. The inclusion of continuous pharmacokinetic exposure data has not been
considered in dose-escalation in the combination setting. However, several methods
have been proposed in the single-agent setting (Holford, 1995; Newell, 1994; Piantadosi
and Liu, 1996; Whitehead et al., 2007).
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In this chapter, we present a simple method of formally incorporating pharma-
cokinetic data into a Bayesian, model-based, dual-agent dose-escalation trial design
in order to improve escalation decisions. In the dual-agent setting, historical single-
agent data can be incorporated into the model through the use of informative priors.
Basing the design on single-agent data in conjunction with clinical knowledge is more
favourable than relying on pre-clinical data alone, which does not transfer reliably to
the clinical setting. In Section 4.2, the dose-toxicity and dose-exposure models are
presented. In Section 4.3, the proposed method of dose-escalation, which is practical
and utilises both dose-toxicity and dose-exposure models, is built up in four stages
from an initial basic method. In this way, the impact of the desicion rules introduced
at each stage can be seen. The practicality and overall benefits of the final proposed
method become especially clear in Section 4.4 through presentation of the results of
a simulation study comparing the methods discussed in Section 4.3. The chapter
concludes with a discussion in Section 4.5.
4.2 Modelling the Data
In this section, we describe the dose-response models underlying the proposed dose-
escalation procedure. Inferences drawn from the fitted models are used in the trial
escalation and stopping rules which are discussed in Section 4.3. Suggested prior
distributions are given with each of the models. These are used to illustrate the
proposed method in Section 4.4 but could of course be altered if available information
suggested another prior distribution might be better suited to the particular situation.
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A detailed example of prior derivation for the dual-agent trial using historical single-
agent data is given in Appendix 4.6.1. To obtain the posterior distributions of the
parameters of the dose-response models, we use Markov Chain Monte Carlo methods
as closed form solutions do not exist.
The dose-response models are presented in terms of a dual-agent dose-escalation
trial of drug A and drug B for which sufficient single-agent trial data are available. As
general notation for the dose-response relationships, take i = {A, B} as an indicator
of the administered drug for which the dose set di is available for treatment. Define
d∗i as some fixed reference dose of drug i used to standardise the doses. For xA ∈ dA
and xB ∈ dB, let {xA, xB} denote the dose-pair administered to a patient. Both of
the dose-response models use the transformed, standardised dose xi/d
∗
i + 1. This is
done so that the dual-agent models reduce to the single-agent models if a dose of zero
is used for the other drug.
4.2.1 The Dose-toxicity Model
The dose of a treatment administered to a cohort of patients is usually selected only
after the previous cohort has been treated, their responses observed and the model
updated based upon these responses. This is done to reduce the risk of toxic side-
effects for patients involved in the trial by basing decisions on all available information,
including the most current and in the case of dose-escalation potentially most relevant,
on the treatment. In order to control the trial duration, this data must be available
relatively soon after treatment. The toxicity data used in dose-escalation are typically
a binary indicator of whether a patient experienced a DLT during the first cycle of
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treatment (21 days, say).
Define pi(xi) as the probability that a patient experiences a DLT given dose xi of
drug i. Although a one-parameter power model (as used in O’Quigley et al., 1990)
can have improved identification of a target dose for a single target toxicty rate, the
two-parameter logistic regression model (used for example in Neuenschwander et al.,
2008) better estimates the entire dose-toxicity relationship (O’Quigley et al., 1990).
This improved modelling of the entire dose-toxicity relationship provides flexibility
for secondary objectives that concern toxicity rates besides θ. We therefore use the
following two-parameter model as the single-agent dose-toxicity model upon which












where pii = P(DLT|xi).(4.2.1)
To extend this single-agent model to the dual-agent setting, we need to allow
for the dose of the second drug and for a potential toxicity DDI. This is achieved
by considering the odds of toxicity at a dose of each treatment and introducing the
interaction term, ζ. For interaction parameter ζ, the dual-agent dose-toxicity model
with dose-dependent interaction term is defined as (Neuenschwander et al., 2015):










where pi(xA, xB) = P(DLT|xA, xB, possible DDI),
odds(pi0(xA, xB)) =
pi0(xA, xB)
1− pi0(xA, xB) ,
and pi0(xA, xB) = pi(xA) + pi(xB)− pi(xA)pi(xB). (4.2.3)
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From this formulation, it can be seen that a value of ζ = 0 implies no toxicity
interaction under the assumption of Bliss independence (as defined in Equation 4.2.3).
The assumption of Bliss independence holds if, for example, drugs A and B were
selected for the dual-agent trial because they target different cell pathways and, hence,
are expected to yield non-overlapping toxicities. The combination would therefore be
expected to have increased efficacy over the single-agents for a given toxicity rate.
When there is a toxicity interaction, a value of ζ > 0 implies an increase in the
odds of toxicity, while ζ < 0 implies a decrease in the odds of toxicity, in the dual-
agent setting at the reference doses compared with the case of no toxicity interaction,
assuming Bliss independence.
Multivariate normal prior distributions are specified on the single-agent parame-
ters {log(αA), log(βA)} and {log(αB), log(βB)}. A normal prior distribution is spec-
ified on the interaction parameter ζ. In the presence of a lack of reliable prior in-
formation on the potential DDI, this distribution could be centered at zero with a
large variance. Alternatively, a cautious prior could be centered on the case of an
interaction which leads to an increase in the odds of toxicity. More information on
the choice of prior is given in Appendix 4.6.1.
4.2.2 The Dose-exposure Model
To ensure the feasibility of utilising pharmacokinetic data in dose-escalation, this
data should also be available within the first cycle of treatment. The pharmacokinetic
parameters of interest to us are measures of exposure to the drug and can be obtained
from a concentration-time curve. Two useful exposure parameters are the area under
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the curve (AUC), a measure of the average drug concentration over a fixed period
of time, and the maximum concentration after administration of treatment (Cmax)
(Jambhekar et al., 2009). The single-agent model used as the basis for the dual-
agent dose-exposure model is a linear regression model for the logarithm of a selected
pharmacokinetic exposure parameter (PK), given dose xi of drug i is
log(PK(xi)) ∼ N
(









Note that we consider a single exposure parameter (e.g. AUC or Cmax), which has
been chosen for each drug. The choice of exposure parameter should be motivated by
whether toxicity in the single-agent trials appeared to be driven by AUC or Cmax. This
model is equivalent to the standard regression model for dose-proportionality, which
is frequently utilised in pharmacokinetic studies, with φ2 as the power coefficient. The
only difference is that we use the transformed, standardised dose. This is done here
so that in the dual-agent extension of this model, the same transformation of dose is
used for both drugs. The transformation we have chosen allows for zero doses of the
drugs which is important for consistency in the dual-agent setting.
The case of no exposure interaction for drug A is defined such that the exposure
to drug A is equal to that expected if administered as a single-agent. Similarly for
no exposure interaction for drug B. So, for interaction parameters, φ3A and φ3B, the
dual-agent dose-exposure models are as follows:
log(PK(xA)) ∼ N
(















and log(PK(xB)) ∼ N
(
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The result is two dose-exposure models: one for the exposure to drug A and
another for exposure to drug B. From this formulation, it can be seen that for PK(xA),
a value of φ3A = 0 (or xB = 0) implies no exposure interaction. When there is an
exposure interaction, a value of φ3A > 0 implies an increase in exposure to drug
A, while φ3A < 0 implies a decrease in exposure to drug A, at the reference doses
compared to the case of no exposure interaction. Similarly for exposure to drug B.
Multivariate normal prior distributions are used on the single-agent parameters
{φ1A, φ2A} and {φ1B, φ2B} and inverse gamma prior distributions used for each of the
between-patient variability parameters, σ2A and σ
2
B. As with the interaction parameter
for the dose-toxicity model, a normal prior distribution is specified on each of the
interaction parameters φ3A and φ3A, and the same logic stands in the face of little
prior information on these parameters. More information on the choice of prior is
given in Appendix 4.6.1.
4.2.3 Applying the Models
In Zhou et al. (2008), for the case of a single-agent dose-escalation trial, dose-toxicity
and dose-exposure relationships are modelled independently by Equations 4.2.1 and
4.2.4, respectively. An optimum dose for administration to the next cohort of patients
is identified for each model independently as the largest dose which satisfies specified
safety criterion. The dose actually administered to patients is the minimum of the
doses advised by the independent models.
We extend the single-agent models from Zhou et al. (2008) to the dual-agent setting
(maintaining independent models for the dose-response relationships), resulting in the
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dual-agent models in Equations 4.2.2, 4.2.5 and 4.2.6. We then combine the outputs
of the models in the trial escalation rules. Our proposed escalation rules differ from
those in Zhou et al. (2008) but incorporate similar safety constraints and targeting of
exposure values, when this is accounted for. The method we propose is one possible
extension of Zhou et al. (2008) in which models for the dose-toxicity and dose-exposure
relationships are independent. The resulting model formulations lend themselves in
a relatively straight-forward manner to prior specifications based on dose-escalation
data from the corresponding single-agent trials.
4.3 Dual-agent Trial Designs
One of the implicit assumptions underlying dose-escalation trials is that efficacy mono-
tonically increases with toxicity. For this reason, toxicity can be classified in relation
to its expected effect on efficacy, as in Neuenschwander et al. (2008). It is often more
realistic to target a desirable toxicity range, rather than a single value, and so we
define the following toxicity intervals:
• piAB ∈ [0.00, 0.16) as an underdose;
• piAB ∈ [0.16, 0.35) as in the target toxicity interval; and
• piAB ∈ [0.35, 1.00] as an overdose.
Based on the assumption of monotonicity, and in terms of these toxicity classifica-
tions, the recommended dose-pair from the trial would be the dose-pair with greatest
posterior probability of estimated toxicity being in the target toxicity interval.
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We define a similar classification system for exposure with desirable exposures of
drug i lying within [Li, Ui]. Using single-agent data, Ui can typically be easily defined,
but identifying Li can be more difficult. This is because exposure levels corresponding
to excessive toxicity are more easily identified from historical data than relationships
with efficacy, which would be better suited to selecting the lower bound. So instead
of directly defining the boundaries, a single, target exposure Ei < Ui is defined for
each drug. Doses with desirable exposures are then chosen to have exposure values
within a certain percentage (20% for our evaluations) of this target level. As with
toxicity, categorise exposure resulting from a dose-pair of drugs A and B such that: an
undesirably low exposure has PK(xA) < LA and PK(xB) < LB and an undesirably
high exposure has PK(xA) > UA or PK(xB) > UB; this leaves a desirable exposure to
result in at least one exposure in the target interval and neither exposure being greater
than the corresponding upper limit. In relation to these exposure classifications, the
recommeneded dose-pair from the trial would be the dose-pair that leads to posterior
estimates P̂K(xA) and P̂K(xB) closest to their corresponding target exposures values.
From these classification systems for toxicity and exposure, it is clear that the
instinctive definition of the recommended dose-pair is dependent upon the trial es-
calation and stopping rules. However, this does not mean that when exposure data
is not considered during escalation that the definition of the recommended dose-pair
based upon exposure classification is irrelevant. When there is no reliable prior infor-
mation on target exposure values, or in the unlikely event that cycle 1 binary toxicity
and exposure data are highly correlated, then there will be no benefit to consider-
ing exposure data. However, when there is prior knowledge linking exposure data to
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long-term toxicity and/or effiacy, then this data should be considered for the benefit
of patients and suitable drug development decisions to be made. Instead of defining
a ‘true’ recommended dose-pair based on a combination of toxicity and efficacy, we
have chosen to highlight the recommendations by each classification separately. This
is done for clarity in comparisons of the methods and to highlight the difference in
outcomes between scenarios.
In the remainder of this section some base decision rules, which are employed in
each of four further methods, are described. The four methods each have specific
decision rules (on top of the base ones) which are built on from Method 1 to Method
4. Method 1 is a simple method of dose-escalation concerned only with identifying
the recommended dose-pair from toxicity data. Method 2 has more focus on patient
safety and is a standard method of dual-agent model-based dose-escalation. The
proposed method is presented as Method 3 and incorporates pharmacokinetic data
into escalation decisions. Method 4 is equivalent to Method 3 except that it allows the
study to stop based on sufficient precision about the recommended dose-pair. This
final method is included to show that the proposed method (Method 3) is practical
to employ in terms of the required number of patients. Results of a simulation study
comparing these four methods are presented in Section 4.4.
The following base decision rules which constrain the step size in escalation and
stop the trial for patient resources are employed in all methods:
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i. Escalation rule:
• Escalate by a maximum of one dose-level of each drug from the dose-pair
administered to the most recently treated cohort of patients.
– This constraint is included to make escalation safer for patients by con-
trolling the speed of escalation.
ii. Stopping rule:
• If 60 patients have been treated, stop the trial.
– The recommended dose-pair is declared as the dose-pair which would
be chosen for escalation out of those doses already administered in the
trial, were the trial to continue.
Method 1: Optimise the probability of being in the target toxicity interval
This method is concerned only with optimising the probability of being in the target
toxicity interval. This is achieved by using the following decision rule in addition to
the base rules:
i. Escalation rule:
• Administer the dose-pair which maximises the posterior probability,
P(pi(xA, xB) ∈ [0.16, 0.35)|{xA, xB}).
Within constraints of the base escalation rules, escalation under this method will occur
rapidly to the dose-pair with maximum probability of toxicity in the target toxicity
interval, out of available dose-pairs. No account is taken of sub-optimal dosing in
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terms of toxicity or exposure. Escalation decisions are based soley on the dual-agent
dose-toxicity model in Equation 4.2.2 with the corresponding normal priors described
in Section 4.2.1.
Method 2: Optimise the probability of being in the target toxicity interval,
within safety constraints
Patient safety is of priority in a dose-escalation trial and so it is intuitive for esca-
lation to be restricted by some safety criteria. This method utilises a safety con-
straint. We define the safety criterion as only allowing escalation to dose-pairs
with posterior probability of overdose less than 25%, mathematically P(pi(xA, xB) ∈
[0.35, 1.00]|{xA, xB}) < 0.25. Using the safety criterion in escalation implies an ad-
ditional stopping rule when no dose-pairs satisfy the safety constraint. The decision
rules for this method, in addition to the base rules, are therefore the following:
i. Escalation rule:
• Administer the dose-pair which maximises the posterior probability,
P(pi(xA, xB) ∈ [0.16, 0.35)|{xA, xB});
• within dose-pairs which satisfy the safety criterion.
ii. Stopping rule:
• If no dose-pairs satisfy the safety criterion, stop the trial.
– No recommended dose-pair declared.
As with Method 1, this method bases escalation decisions soley on the dual-agent
dose-toxicity model in Equation 4.2.2 with the corresponding normal priors described
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in Section 4.2.1. However, escalation under this method is more cautious, given the
additional safety constraint on escalation. This design also enables the trial to stop
for safety concerns if none of the available dose-pairs satisfy the safety criterion based
on the available data. These additional benefits of the design over that of Method 1
are the reason that it is often used in practice.
Method 3: Use pharmacokinetic information to select doses, within safety
constraints
On paper, Method 2 is used in current practice. However, in reality additional, non-
formal decision rules are often used by the clinical team, enabling them to incorporate
additional data without formalising its use. The subjectivity in decisions based on
this additional data will lead to inefficiencies and inconsistencies in its use. In this
chapter we are interested in formalising the use of pharmacokinetic data.
Pharmacokinetic information can often be an indicator of efficacy and/or long-
term safety (Clark et al., 1994). It is reasonable to argue that if a suitable level of
efficacy is reached, then it is unnecessary to escalate beyond this dose, risking greater
toxicity. Also, unreasonably high exposure values should be avoided as they may
indicate increased risk of toxicity being observed within, or after, the first cycle of
treatment. Considering the benefit-risk ratio of the treatment in this way in dose-
escalation trials can be beneficial to patient safety and increase the chance of the
treatment being found to be efficacious and not overly toxic in later phase trials.
Safety of patients is a priority and for this reason, we maintain the toxicity safety
constraint in our proposed design. The difference between this method and that of
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Method 2 is that rather than escalation being based on optimising a toxicity criterion,
we instead escalate based on an exposure criterion, within dose-pairs which satisfy the
toxicity safety criterion. This is achieved using the following decision rules in addition
to the base rules:
i. Escalation rule:
• Administer the dose-pair which minimises the generalised squared in-
ter point distance (Deza and Deza, 2009) of expected posterior expo-
sure parameters from the target values;
• within dose-pairs which satisfy the safety criterion.
ii. Stopping rule:
• If no dose-pairs satisfy the safety criterion, stop the trial.
– No recommended dose-pair declared.















for i = {A, B} with Ei, the target exposure values defined when classifying exposure
data and P̂K(xiA) and σ̂ih, the estimated exposure value and standard deviation in
exposure at iteration h of the Markov chain.
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In contrast to Methods 1 and 2, the escalation decisions in this method are based
on toxicity and exposure criteria. The models for each of these relationships are fit-
ted independently using Equations 4.2.2, 4.2.5 and 4.2.6 and corresponding priors
described in Sections 4.2.1 and 4.2.2 for the dose-toxicity and dose-exposure mod-
els, respectively. The output of the independent models are then combined via the
escalation rules.
Method 4: Allow for early stopping
This method uses exactly the same escalation rules as Method 3. The method of fitting
the dose-toxicity and dose-exposure models independently using Equations 4.2.2, 4.2.5
and 4.2.6, with corresponding priors described in Sections 4.2.1 and 4.2.2, is therefore
the same with the output of the independent models again combined via the escalation
rules. The difference is that additional stopping rules are specified. This introduces
the option for the trial to stop early, having identified the recommended dose-pair.
A sample size of 60 (as used in the previous methods) or greater would be desirable
for a trial. However, this is not always feasible or necessary. Stopping rules can there-
fore be implemented which allow early stopping if the estimate of the recommended
dose-pair is reasonably accurate. To achieve this, the following decision rules are used
in addition to the base rules:
i. Escalation rule:
• Administer the dose-pair which minimises the generalised squared inter point
distance of expected posterior exposure parameters from the target values;
• within dose-pairs which satisfy the safety criterion.
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ii. Stopping rule:
• If no dose-pairs satisfy the safety criterion, stop the trial.
– No recommended dose-pair declared.
• If at the recommended dose for escalation, criteria (a)-(c) are satisfied:
(a) 9 patients have already been treated;
(b) No higher adjoining dose-pair satisfies the safety criterion;
(c) One or both of the following criteria are satisfied and is the highest
among dose-pairs which satisfy the safety criterion:
· Toxicity stopping criterion: The posterior probability of being
in the target toxicity interval is greater than 0.70, that is
P(pi(xA, xB) ∈ [0.16, 0.35)|{xA, xB}) > 0.70
· Exposure stopping criterion: The posterior probability of at
least one drug having exposure within the desirable exposure interval
and neither drug having undesirably high exposure, that is
P({PK(xA) ∈ [LA, UA] ∪ PK(xB) ∈ [LB, UB]}
∩ {PK(xA) < UA} ∩ {PK(xB) < UB}|{xA, xB}) > 0.25.
– The recommended dose-pair is declared as the dose-pair which would
be chosen for escalation, out of those doses already administered in the
trial, were the trial to continue.
Design features, including the maximum sample size and tolerances for the safety
criterion and stopping rules, used in the decision rules specified in this section, as well
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as in the simulation example in the next section, are flexible. The maximum sample
size of 60 patients was chosen as a desirable but not often feasible sample size to
obtain an idea of long-term operating characteristics of the methods. The tolerances
for stopping rules were then selected as values which produce desirable early stopping
characteristics under the example scenario given in Section 4.4. Choices of doses,
target values and distance measure used in the example were chosen as values felt to
be reasonable based on available data. These values are flexible and can be adjusted
based on available information and desired operating characteristics of a trial.
4.4 Simulation Study Results
Data from two single-agent trials was used as the basis for the simulation study
presented in this section. Single-agent data for drug A was taken from Bristol-Myers
Squibb (2007-2011) and that for drug B from Merck Sharp & Dohme Corp. (2009-
2012). Single-agent dose-toxicity and dose-exposure models, as given in Equations
4.2.1 and 4.2.4 respectively, were fitted independently to the single-agent data in a
frequentist manner. The resulting single-agent parameter estimates were used as the
basis for priors on the parameters, after accounting for between-trial heterogeneity
(which was discussed in Section 2.2.2 and is described in relation to the example used
in simulations in Appendix 4.6.1). In this case, no information was available on the
interaction between the two drugs and so weakly informative priors, centered on the
case of no interaction, were taken for these parameters. The data and method of prior
elicitation used to obtain the following prior distributions, as used in the simulation
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study, are explained in detail in Appendix 4.6.1.























ζ ∼ N(0, 0.23)



































1/σ2A ∼ Gamma(15, 1/7.63),
1/σ2B ∼ Gamma(15, 1/2.47).
Reference doses and target exposure values of the two drugs were selected at
the single-agent maximum tolerated doses according to the single-agent models in
Equations 4.2.1 and 4.2.4. Although the model does not require pre-specification of
available doses, this was done for the purpose of simulation. Available doses were
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selected for drug A as dA = {10, 15, 20, 25, 30} with reference dose d∗A = 25 and target
exposure value 300 and for drug B as dB = {20, 40, 60, 80, 100} with reference dose
d∗B = 80 and target exposure value 1, 000. The ‘available dose-pairs’ refer to any
combination (one of drug A and one of drug B), of the available doses. The starting
dose-pair was taken to be the lowest available dose-pair (10mg of drug A and 20mg of
drug B in this case) and patients were treated in cohorts of size 3 for all simulations.
In the simulation study, toxicity and exposure data were generated from the mod-
els given in Equations 4.2.2, 4.2.5 and 4.2.6, with parameter values equal to their
corresponding prior means, with the exception of the interaction parameters values
which were varied depending upon the simulated scenario. A ‘true’ classification refers
to the toxicity or exposure classification (defined at the start of Section 4.3) that the
dose-pair of interest falls into. This is based upon the model specified and parameter
values which data were simulated from. The ‘true’ recommended dose-pair is the
dose-pair which optimises the escalation criteria under the specified models and pa-
rameter values. The models, with corresponding priors, were fitted to the data using
the Rstan package (Stan Development Team, 2013) in R (R Core Team, 2014).
Results are presented for the following five scenarios based on estimates from
1, 000 simulated trials under the given scenario and method. The corresponding true
probabilities of toxicity for each of the scenarios are given in Table 4.6.3 in Appendix
4.6.2:
1. No toxicity and no exposure interaction: This, perhaps unlikely, scenario is
included for comparison of the methods in a scenario where the ‘true’ recom-
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mended dose-pairs based on toxicity classification and that based on exposure
classification are similar;
2. No toxicity interaction but a 4-fold increase in exposure to drug B at the refer-
ence doses: This scenario differs from Scenario 1 only in the exposure interac-
tion. Although it appears to be an extreme scenario it is highly important as it
represents the case of an unexpected dose-exposure interaction. If the pharma-
cokinetic data are not accounted for in dose-escalation, a dose-pair with suitable
toxicity but high exposure could be identified as the recommended dose-pair.
When exposure data are considered as an indicator for long-term safety concerns
then this treatment at the recommended dose level could be found to be unsafe
in later trials. Escalation following Methods 1 and 2, which base decisions on
toxicity data alone, is not affected by this change of scenario;
3. A 3-fold increase in the odds of toxicity and a 2-fold increase in exposure of drug
B at the reference doses: This is a more realistic scenario where there is some
level of dose-toxicity and dose-exposure DDI. It is also included as a difficult
scenario in terms of ‘true’ classifications to demonstrate the safety criterion;
4. A 2-fold increase in odds of toxicity at the reference doses but no exposure
interaction: This scenario covers the case when the toxicity interaction is not
directly driven by an exposure interaction. It is similar to Scenario 2, but this
time the exposure escalation criteria of Method 3 will be pushing for escalation,
based on links to efficacy maybe, but based on short-term toxicity those dose-
pairs are not desirable;
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5. A 10-fold increase in the odds of toxicity and a 5-fold increase in exposure of drug
B at the reference doses with available dose range restricted to dA = {20, 25, 30}
and dB = {60, 80, 100}: This scenario is included to demonstrate the methods
in a setting where no available dose-pairs have desirable safety characteristics.
We want to ensure that the safety criteria are effective in such a case to reduce
the number of patients treated with a highly toxic treatment.
Tables of the operating characteristics of the methods under these scenarios are
given in Appendix 4.6.2. Initially we consider the results of Methods 1-3. Under these
methods, dose-escalation continued until a total of 60 patients had been treated in the
trial, unless (in Methods 2 and 3) the trial was stopped for safety before this point.
Consistency and accuracy of the recommended dose-pair
The proportion of times each available dose-pair was declared as the recommended
dose-pair is given in Table 4.6.4 (in Appendix 4.6.2) and ‘true’ recommended dose-pair
based on toxicity and exposure classification are marked. From this table we see that
the recommendations by Method 1 and 2 are fairly similar. More recommendations
by Method 1 are classified, based on the toxicity criteria, as being overdoses than
recommendations from Method 2. The lack of safety criteria in Method 1 also means
that escalation by this method is unethical.
From Table 4.6.4, we can see that the recommended dose-pairs from Method 3 were
more consistent than those of Method 2. That is, the number of dose-pairs at which
one or more simulated trials declared a recommended dose-pair was less, and more
condensed, in Method 3 than those by Method 2. This is most noticeable in Scenario 2
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where 97% of recommended dose-pairs were spread over only two dose-pairs, compared
to nine dose-pairs by Method 2. This can be seen clearly for all scenarios in Table
4.6.4 and is comforting given that in reality we only have one attempt to identify
the ‘best’ dose for patients. This improved consistency in recommended dose-pairs
when exposure data are used stems from exposure data being continuous. The result
is that escalation paths are more varied and escalation of both drugs, as opposed to
escalation of one drug at a time, is more likely than when these decisions are based
soley on toxicity data. This reduces the chance of escalation ‘sticking’ at a certain
dose of one or both drugs.
As well as improvements in consistency of the recommended dose-pair, other ben-
efits of Method 3 were observed. Under the setting of no DDIs (Scenario 1), the ‘true’
recommended dose-pair based on the toxicity classification and that based on expo-
sure classification are similar (as can be seen in Table 4.6.4). Despite the similarity
in location of the ‘true’ recommended dose-pairs, Method 3 led to a 6.4% decrease in
the proportion of recommended dose-pairs in the target toxicity interval compared to
Method 2. However, this compromise was for a 17.4% increase in the percentage of
recommended dose-pairs with desirable exposures.
A similar pattern is seen in Scenario 2 when there was a stronger dose-exposure
than dose-toxicity interaction. In this case, the ‘true’ recommended dose-pairs by
the toxicity and exposure classification differ, but are both still within the target
toxicity interval. Based on the toxicity classification, 6.7% more recommended dose-
pairs were classed as under-doses by Method 2 than by Method 3. However, there
was an 85.4% increase in the proportion of these dose-pairs proportion with desirable
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exposure values between these two methods.
In Scenario 3, there was both a toxicity and an exposure interaction. The result
was that the ‘true’ recommended dose-pair by the exposure classification edged into
the overdose category (with true probability of DLT of 0.37). Under this scenario,
Method 3 led to an increase in the proportion of recommended dose-pairs classified
as overdoses because escalation was effectively targeting the defined ideal exposure
values which occur at an overly toxic dose. In this case, the safety criterion was
not effective in stopping escalation to the dose with true probability of DLT of 0.37
in either Method 2 or Method 3. However, in Scenario 4 for example, the ‘true’
recommended dose-pair by the exposure classification has probability of DLT of 0.42.
In this case, the probability of DLT is great enough that in general the safety criterion
is effective. In this scenario, recommended dose-pairs with target toxicity classification
by Method 3 were actually slightly increased over those of Method 2 due to improved
exploration of available dose-pairs.
Overdosing and undesirable exposures
From Figure 4.4.1 we see that on average 16-24% of patients in a trial experienced a
DLT under Scenarios 1-4. Upon investigation, this value is reasonable because most
of the observed DLTs occured at the recommended dose-pair. It can also be seen that
the average proportion of toxicities per trial decreased from that in Method 1 as safety
constraints (Method 2) and pharmacokinetic data (Method 3) were incorporated into
the dose-escalation trial design. There was also a general decrease in the proportion
of undesirably high exposure values observed. This was most noticeable in Scenario
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2 when there was an exposure interaction but no toxicity interaction. Accounting for
pharmacokinetic data in escalation therefore has a notable effect on escalation, which
is reflected in the exposure values observed.
















Figure 4.4.1: Average proportion of patients experiencing DLTs (marked by a cross)
and undesirably high exposures (marked by a star) per trial under each dose-escalation
method and scenario.
Table 4.6.5 (in Appendix 4.6.2) and Figure 4.4.1 show the operating characteristics
of the trial simulations. Under Scenarios 1-4, Method 2, which employs the safety
criterion, was observed to have some benefit over Method 1 in terms of administered
doses and toxicity classification of the recommended dose-pair. This was most noti-
cable in Scenario 3 where the percentage of recommended dose-pairs classified as an
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overdose was reduced from 27.8% to 16.4% in Method 2 compared to Method 1. In
Scenario 5, when no dose-pairs were tolerated by safety criteria, the safety criterion
was effective in reducing the number of patients treated per trial. The number of trials
which identified a recommended dose-pair classified as an overdose was reduced from
100% under Method 1 to 1.9% under Method 2. Methods 2 and 3 were comparable
under this scenario because they employ the same safety criteria and corresponding
stopping rule.
Using the safety criterion in escalation is therefore beneficial for patient safety,
in the case of unexpectedly high exposure or a badly chosen dose range, without
considerable compromise in identification of the recommended dose-pair. However,
since Method 2 does not account for exposure data, there are high numbers of recom-
mended dose-pairs with undesirably high exposure values, especially in Scenarios 1
and 2. These undesirably high exposures, as well as being undesirable, may indicate
that an efficacious dose has already been reached. The additional risk to patients of
administering higher doses is therefore unnecessary and unethical. Alternatively, it
could indicate possible long-term safety concerns and in practice the exposure data
could well be used subjectively to over-ride model recommendations. The reduction
in undersirably high exposure levels experienced by patients was especially clear in
Scenario 2 where 87.7% of administered dose-pairs by Method 2 had a true exposure
classification of undesirably high.
The observed decrease in undesirably high exposures and average proportion of
DLTs patients experienced in a trial under Method 3 compared to Method 2 was
due to escalation being more cautious when exposure data were considered. This is
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due to the non-binary nature of exposure data leading to increased exploration of the
available dose-pairs.
One of the big assumptions made in the above evaluation was that the prior per-
fectly reflected the truth under which data were generated. A detailed sensitivity
analysis of Method 3 to prior specification (details of which are given in Appendix
4.6.3), however, showed that the method was found to be robust to priors deviating
from the true models. For example, the proportion of recommended dose-pairs classi-
fied as being in the target toxicity interval under Method 3 in Scenario 1 was reduced
from 77.1% to 67.1% based on a prior with only one tolerated start dose and half the
variance of that given at the start of this section.
Method 4: Allow for early stopping
The benefits observed from using pharmacokinetic data in escalation, such as the
improved consistency of the recommended dose-pair and general reduction in propor-
tion of patients experiencing DLTs and undesirably high exposures in a trial, are only
beneficial if the trial is practical to carry out. Method 4 considers the practicality of
the trial design in terms of the number of patients treated in the trial. Early stopping
of the trial (before the maximum of 60 patients have been treated) for accuracy of the
estimate, as well as for safety, was allowed in this method. The additional stopping
rules were based on a high probability of either toxicity or exposure being in the cor-
responding target interval, with no option to escalate to a higher dose-pair. Under the
stopping rules specified in Section 4.3, only small losses in operating characteristics
were observed from those observed in Method 3. This suggests that the stopping rules
CHAPTER 4. Dual-agent Dose-escalation Incorporating Pharmacokinetic Data 144
used were reasonable.
Figure 4.4.2 shows the proportion of times each stopping rule was met under each
scenario using Method 4. In Scenario 5, most trials stopped for safety due to the lack
of available tolerated dose-pair. In Scenarios 1, 3 and 4, practical use of the early
stopping rules is more clear. The toxicity and exposure stopping criteria are met a
reasonable number of times, in between 41% and 75% of trials in Scenarios 1-4. These
values are reflected in the average number of patients treated per trial, presented in
Table 4.6.5. The average number of patients required per trial is down to about 34




















Figure 4.4.2: Reasons trial stopped under dose-escalation Method 4 for the given
scenarios.
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In Scenario 2, the ‘true’ recommended dose-pair based on the toxicity classification
is higher than that targeted by exposure classification (this can be seen from Table
4.6.3 in Appendix 4.6.2). The toxicity stopping criterion is therefore highly unlikely
to be met. Therefore, stopping rules such as those employed in Method 4 which are
based around the precision of estimates, effectively make the trial size practical when
the interaction scenario and available dose levels allow this.
4.5 Discussion
We proposed a method of dose-escalation (presented as Method 3) for a dual-agent
treatment which, through the escalation rules specified, enables formal integration
of exposure information into dose-escalation decisions. The specific escalation rules
used in this chapter illustrate the design but these could be adjusted to cater for a
specific trial. Exposure data is typically available during dose-escalation trials but is
only used in a subjective manner. When prior knowledge links exposure data to long-
term toxicity and/or effiacy then pharamcokinetic data should be considered for the
safety and benefit of trial and future patients. The novel method is relatively simple to
implement and simulation results show good operating characteristics. Early stopping
of the trial (presented as Method 4), for safety concerns or accuracy of the estimate,
was also investigated and results show that the method is practical to employ.
In this work, we have used a two-parameter model for the dose-toxicity relation-
ship. This was chosen over a one-parameter model because of its flexibility to change
the target toxicity level corresponding to the recommended dose-pair. Although the
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target toxicity level is fixed throughout the trial, other considerations or new data can
lead to the target toxicity level being changed from that originally specified after the
trial has been conducted. For example, the target toxicity interval could be changed
from [0.16, 0.35) to a lower interval such as [0.10, 0.30). This is a request that we have
experienced on multiple occasions in practice. Additionally, more than one dose can
be taken to further trials from a dose-escalation trial (be this further phase I trials
such as dose expansion, or initial efficacy trials). In such a case, it is beneficial to be
able to obtain reasonable estimates of the probability of toxicity for a range of doses
below the recommended dose. This is to reduce the chance that any of the doses
taken for further testing has too low toxicity (and hence low efficacy).
Simulation results showed that formal incorporation of exposure data into dose-
escalation decisions can lead to a decrease in the proportion of patients who experience
toxicities, and generally also undesirably high exposures, within the trial. In addi-
tion, the continuous nature of exposure data makes escalation along the diagonal of
available dose-pairs more likely and means that escalation is unlikely to stick on a
dose level of one or both drugs, as can occur when toxicity data alone is considered.
This dose-sticking was apparent when dose-escalation patterns in individual trials
were investigated. This property can be especially beneficial when no/few DLTs are
observed early on in the dose-escalation trial, as is often the case. The result is that
dose-recommendations are more compacted around suitable dose-pairs when pharma-
cokinetic data is utilised, along with toxicity data, in escalation decisions.
The proposed method is flexible and practical since it can be used throughout esca-
lation, even in cases where pharamcokinetic data is delayed, for example. In practice
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it is also still possible for the clinical team to over-ride the model decision based on any
available data. The proposed method was presented for the case where ‘ideal’ values of
the exposure parameters had been identified and were in effect targeted, within dose-
pairs classified as safe by the safety criterion. The resulting recommended dose-pair
is therefore hoped to have an improved benefit-risk ratio over the dose-pair selected
as having highest toxicity within doses which satisfy the safety criterion. Equally, a
pharmacodynamic response could be used in place of the exposure parameter. An-
other simple alternative, which in some cases may better model the dose-exposure
relationship, is to model the exposure interaction in terms of exposure, rather than
dose, of the second drug. That is, in place of Equations 4.2.5 and 4.2.6, for reference
exposure values PK∗A and PK
∗
B using the models.
log(PKA) ∼ N
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and log(PKB) ∼ N
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A hierarchical model with probability of toxicity defined as a function of exposure,
in turn defined as a function of dose, may better model the effect of dose on toxicity.
Use of this model in dose-escalation enables decision rules to be based on toxicity cri-
teria alone, while formally including pharmacokinetic data in the model itself. This
could be advantageous if people were adverse to making escalation decisions on ex-
posure data, as required in our proposed method. However, the hierarchical model
requires direct modelling of the correlation between toxicity and exposure. Our pro-
posed method of incorporating pharmacokinetic data using independent dose-toxicity
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and dose-exposure models does not require such a strong assumption, and is there-
fore less prone to model mis-specification. On top of this it is computationally much
simpler than a hierarchical model.
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4.6 Appendix
4.6.1 Using Single-agent Data for Prior Derivation
The historical single-agent trial data used in Section 4.3 to illustrate the proposed
dual-agent dose-escalation trial design came from Bristol-Myers Squibb (2007-2011)
and Merck Sharp & Dohme Corp. (2009-2012) for drugs A and B respectively. The
relevant historical data from these publications which was used to derive priors on
the single-agent parameters of the dual-agent trial are presented in Tables 4.6.1 and
4.6.2. Where we were not able to obtain the required data for these tables directly,
the derivation is given here. The exposure values of both treatments were provided
as the summary statistics shown in the tables with no additional information on their
method of calculation.
Historical single-agent trial data
In the single-agent trial of drug A, drug A was administered once daily on days 1-5 of
a 21 day cycle. Escalation followed a 3 + 3 design with identification of the MTD at
25mg. An additional dose-expansion cohort was then treated at this dose, resulting
in a total of 44 patients being treated in the trial. The AUC over the 24 hour period
on day 5 of cycle 1 was available for all 44 patients and was the pharmacokinetic
parameter of drug A chosen for use in the dual-agent trial.
DLT data provided for drug A is given in Merck Sharp & Dohme Corp. (2009-2012)
in terms of the total number of DLTs experienced at each dose level. For example,
a cohort of three patients from which two patients did not experience a DLT, while
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the other experienced two DLTs, is recorded as two DLTs in three patients. For our
evaluations we were instead interested in the number of patients who experienced a
DLT at each dose-level. So, for the example, we record one out of three patients having
experienced a DLT. In Table 4.6.1, the derived values for the number of patients who
experienced a DLT at each dose level is given. These were calculated based upon a
3 + 3 design. At dose levels where it was unclear how many patients experienced a
DLT, the highest option was used.
Dose drug A 5 10 15 20 25 30
Number of patients 3 6 3 3 23 6
Number of DLT’s 0 1 0 0 2 4
AUC(0−24) on day 5 21.83 143.85 179.82 222.73 348.07 545.42
mean (sd) (28.59) (134.15) (126.95) (136.49) (370.95) (441.93)
Table 4.6.1: Data used to obtain priors for drug A (obtained/derived from Bristol-
Myers Squibb, 2007-2011).
In the single-agent trial of drug B, drug B was administered once daily on days
1, 3, 8, 10, 15 and 17 of a 28 day cycle. We assumed that escalation followed a 3 + 3
design resulting in declaration of the MTD at 80mg. This was based upon the fol-
lowing logic: before the multiple dosing trial, a single-dosing investigation, in which
patients were treated at 20, 40, 80 and 120mg, was carried out. We expect that the
multiple dosing trial had the same planned doses as the single-dosing trial. We ex-
pected that escalation proceeded as planned to 120mg, at which dose an undesirable
number of toxicities was observed. Instead of de-escalating to 80mg, we suspected
that an additional dose level was introduced at 100mg. This is the only dose level for
which cohorts do not appear to be of size three. We expected that observation of two
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DLTs in two patients treated at 100mg led to a decision not to recruit any further
patients at this dose level. The MTD was therefore declared at 80mg.
For drug B, the AUC over the 24 hour period on day 1 of each cycle was available
for all 17 patients enrolled in the trial. The summary statistics were for all day 1
AUC values and so these are effectively based upon a total of 51 observations. This
measure may not be overly helpful for understanding the pharmacokinetics of the
drug but can be used for simulations by assuming that the dual-agent trial records
the same data. We also assumed that both drugs have a 21 day cycle and observations
of DLTs for drug B over the reduced time period would be the same as those recorded
in the historical trial.
Dose drug B 20 40 80 100 120
Number of patients 3 3 6 2 3
Number of DLT’s 0 0 0 2 2
AUC(0−24) on day 1 of each week 122 302 936 2530 2320
mean (sd) (85.3) (47.7) (364.0) (81.2) (673.0)
Table 4.6.2: Data used to obtain priors for drug B (obtained/derived from Merck
Sharp & Dohme Corp., 2009-2012).
Obtaining prior distributions
The historical, single-agent data was fitted, in a frequentist manner, to the dose-
response models given in Equations 4.2.1 and 4.2.4. We have no additional beliefs to
incorporate and so we felt the additional complication and subjectivity of a Bayesian
model fit to be unnecessary in this case. For the dose-toxicity model, a logistic regres-
sion model was fitted to the historical toxicity data to obtain regression coefficient
estimates and corresponding standard deviations. For the exposure data of both
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drugs, only summary values of the exposure parameters were available. To overcome
this, data were simulated to obtain estimates for the mean and standard deviations of
the dose-exposure model parameters. To obtain mean estimates of the dose-exposure
model parameters, 1, 000 data points were simulated at each dose and a linear regres-
sion of log(PK) against log(dose) fitted. To obtain a reasonable estimate of the prior
standard deviations of the dose-exposure parameters, data were again simulated at
each dose, but this time only for the number of patients observed at each dose.
The regression coefficient estimates for the parameters of the single-agent dose-
toxicity and dose-exposure models were used directly as the mean prior parameter
values. The estimated variances, however, were increased to account for heterogeneity
between trials. This was achieved using a power prior (Ibrahim and Chen, 2000). In
a power prior, the likelihood of the historical data is raised to some power, a ∈ [0, 1],
effectively down-weighting the historical data in relation to the trial data. In the
case of a normal likelihood with known variance, this is equivalent to increasing the
variance by a factor of 1/a. In Section 2.2.2 under Step 4, the reasons for accounting
form heterogeneity and the choice of weight of the historical data were discussed. Since
we expect the single-agent data to be highly relevant to the action of the treatments
in combination, and given that the dose-toxicity model is specified as a combination of
two single-agent models, we assumed relatively low between-trial heterogeneity. We so
chose to make the prior data worth about 2/3 of the dual-agent data. So, assuming we
have normally distributed data with known variance, we increased the variances of the
historical posterior parameter estimates by a heterogeneity factor of 3/2. The prior
standard deviations were used as those obtained from the regression fits, multiplied
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by the heterogeneity factor. In addition, the prior correlation between parameters of
the models was set to 0. We chose to do this in order to further reduce the prior
information (since we are assuming relatively low between-trial heterogeneity). Of
course, covariance estimates obtained from the model fitted to historical data could
be used here instead.
The dose-exposure model also requires a prior distribution to be specified on the
parameter for inter-patient variability. The residual standard error (from the regres-
sion fit of the dose-exposure model which was used to estimate variance of the relevant
parameters) was set as the mean of this distribution. The variance of the prior distri-
bution was adjusted until the 95th percentile of the distribution was equal to residual
standard error multiplied by 3/2 (the heterogeneity factor). The result in our case
was a coefficient of variation of 25% around the exposure data mean. Target exposure
values were identified as the expected exposures based on this linear regression fit at
the single-agent maximum tolerated doses (300 for drug A and 1, 000 for drug B).
The plots in Figure 4.6.1 show the resulting prior distributions. The correspond-
ing prior distributions are given in Section 4.4, along with those on the interaction
parameters. No information was available on the interaction parameters and so we
specified normal priors on them centred at 0. The variance was chosen so that the
99th percentile of the distribution corresponded to a 3-fold DDI at the reference doses
(25mg for drug A and 80mg for drug B).
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Figure 4.6.1: Median and 90% credible interval for priors on the single-agent models
for a) dose-toxicity relationship of drug A, b) dose-toxicity relationship of drug B, c)
dose-exposure relationship of drug A, d) dose-exposure relationship of drug B. Dotted
lines indicate the recommended dose based on single-agent data.
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4.6.3 Sensitivity Analysis
In the main simulation study presented in Section 4.4, a series of scenarios with
differing DDIs are presented. These scenarios were all run using the same prior.
That is, priors on the single-agent parameters were derived from historical single-
agent data and priors on the interaction parameters were centered on the case of no
DDI. The dose-response models update well for the different scenarios (i.e. observed
interactions), which is reflected in the recommended dose-pairs.
In the main simulation study, simulated data were based on prior means for the
single-agent parameters. Here we consider the sensitivity of the dose-response models
to the prior on the single-agent parameters. That is, we investigate the cases when
simulated data is not generated from distributions with means equal to the prior
means, as in practice.
The largest effect of the prior on escalation occurs when an informative, but in-
correct, prior is specifed. That is, when the prior parameter values are different to
those observed in practice and the prior variance of the parameter estimates is small.
The following four prior settings which cover the extremes of the prior specification
on single-agent model parameters (i.e. log(αA), log(βA), log(αB), log(βB), φ1A, φ2A,
φ1B and φ2B) are considered;
1. Prior specified such that only the lowest dose-pair is tolerated based on
toxicity criteria and the lowest dose-pair also has target exposure values based
on the prior.
(a) With parameter variances set to be the same as those used in main
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simulation study.
(b) With parameter variances set to be half those used in main simulation
study.
2. Prior specified such that all dose-pairs are tolerated based on toxicity criteria
and the highest dose-pair also has target exposure values based on the prior.
(a) With parameter variances set to be the same as those used in main
simulation study.
(b) With parameter variances set to be half those used in main simulation
study.
The prior probability of toxicity for each dose combination based on the two set-
tings for the prior mean are given in Table 4.6.6. Simulations were carried out for the
proposed method (Method 3) with the four prior settings for Scenario 1 (the case of
no interaction) and Scenario 3 (a 3-fold increase in the odds of toxicity and a 2-fold
increase in the exposure of drug B). The results are presented in Figure 4.6.2 and
Tables 4.6.7 and 4.6.8.
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20 40 60 80 100 20 40 60 80 100 20 40 60 80 100
10 0.16 0.35 0.73 0.93 0.98 294 294 294 294 294 933 2787 2028 15660 31748
15 0.45 0.58 0.83 0.95 0.99 573 573 573 573 573 933 2787 2028 15660 31748
20 0.77 0.82 0.93 0.98 1.00 1032 1032 1032 1032 1032 933 2787 2028 15660 31748
25 0.92 0.94 0.98 0.99 1.00 1747 1747 1747 1747 1747 933 2787 2028 15660 31748
30 0.97 0.98 0.99 1.00 1.00 2814 2814 2814 2814 2814 933 2787 2028 15660 31748
10 0.01 0.01 0.01 0.02 0.14 40 40 40 40 40 61 153 330 643 1158
15 0.03 0.03 0.03 0.04 0.15 77 77 77 77 77 61 153 330 643 1158
20 0.07 0.07 0.07 0.08 0.19 140 140 140 140 140 61 153 330 643 1158
25 0.13 0.13 0.13 0.14 0.24 236 236 236 236 236 61 153 330 643 1158













Probability of toxicity PK of drug A PK of drug B
Dose of drug B Dose of drug B Dose of drug B
Table 4.6.6: Tables of the prior probability of toxicity. Dark grey cells highlight dose-
pairs with toxicity/exposure category overdose, light grey cells the target interval and
white cells underdoses. The ‘X’ and ‘*’ mark the ‘true’ recommended dose-pair for
each scenario based solely on toxicity and exposure data respectively.
















Figure 4.6.2: Average proportion of patients experiencing DLTs (marked by a cross)
and undesirably high exposures (marked by a star) per trial under dose-escalation
Method 3 with a range of prior settings for Scenarios 1 and 3.
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From Figure 4.6.2, we can see that the average proportion of DLTs and undesirable
exposures occuring in the trial is consistent, if not lower, than those observed in the
main simulation study with the original prior. From Table 4.6.7, we see that the
spread of recommended dose-pairs is different to that observed in the main simulation
study but recommendations are still condensed around values with target toxicity and
desirable exposure classifications. In Table 4.6.8, we see that in general there is a
slight increase in the proportion of recommended dose-pairs classified as underdoses
(by toxicity and exposure classifications) and a decrease in overdoses. Prior setting
1a under Scenario 3 is the only scenario where this is noticably not the case.
In Scenario 3, the true recommended dose-pair based on the exposure classification
is only just an overdose by the toxicity classification (with true probability of causing
a DLT in a patient equal to 0.37). In the main simulation results, the safety criterion
was not suitable to completely avoid escalation to this border-line classification dose-
pair, leading to 20% of recommended dose-pairs being classidied as overdoses by the
toxicity criterion under Method 3. The priors investigated in the sensitivity analysis
cause different patterns of escalation to become more likely. Observation of DLTs or
high exposures at low dose-pairs will be more difficult to overcome under prior 1a
(which reflects belief that there is only one safe dose) than under the original prior.
This is reflected in an increase in recommended dose-pairs in the top left corner of the
available dose grid. On the other hand, if few DLTs or high exposures are observed
early on in the trial, prior setting 1a is easily overcome and escalation occurs rapidly,
hence the increase in recommended dose-pairs classified as overdoses by the toxicity
classification for scenarios in this setting.
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Prior setting 1b was also investigated under Method 4 (because prior setting 2
is unlikely to arise in practice and prior setting 1a is easier to overcome with data
than prior setting 1b). From Figure 4.6.3 and Tables 4.6.9 and 4.6.10, we see that the
effect of the stopping rules on the operating characteristics of the dose-escalation trial
is minimal. From Figure 4.6.4 we see that even under the more cautious prior setting
1b compared to the original prior setting used in the main chapter, the toxicity and
exposure stopping rules are still effective, bringing the average trial size down to 44
and 40 patients in Scenarios 1 and 3, respectively.
















Figure 4.6.3: Average proportion of patients experiencing DLTs (marked by a cross)
and undesirably high exposures (marked by a star) per trial under dose-escalation
Method 4 with prior setting 1b for Scenarios 1 and 3.
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20 40 60 80 100
10 0.001 0.010 0.026 0.004 0
15 0 0.002 0.083 0.185 0
20 0 0 0.052 0.387 0
25 0 0 0 0.246* 0.002
30 0 0 0
X 0 0
10 0.011 0.004 0.049 0 0
15 0.001 0.078 0.216 0 0
20 0 0.014 0.485 0.002 0
25 0 0.001X 0.138* 0 0












Dose of drug B
Table 4.6.9: Proportion of times each available dose-pair declared as the recommended
dose-pair, out of those trials which identified a recommended dose-pair, under dose-
escalation Method 4 with prior setting 1b for Scenarios 1 and 3. Dark grey cells
highlight dose-pairs with toxicity category overdose, light grey cells the target interval
and white cells underdoses. The ‘X’ and ‘*’ mark the ‘true’ recommended dose-pair
for each scenario based solely on toxicity and exposure data respectively.
Figure 4.6.4: Reasons trial stopped under dose-escalation Method 4 with prior setting
1b for Scenarios 1 and 3.
































































































































































































































































































































































Sample Size Calculation in Phase
II Clinical Trials
5.1 Phase II Clinical Trials
Attention now switches from phase I dose-escalation trials to phase II clinical trials.
Phase II is a broad term encompassing a range of trial types. In general, phase II
clinical trials are hypothesis driven and non-confirmatory. They aim to confirm the
safety of the recommended dose of the treatment that was identified in phase I, and
to look for initial signs of the treatment’s efficacy. If the safety and efficacy profile
of the treatment appears to be promising after phase II trials, then the experimental
treatment is taken forward to large-scale phase III trials which focus on the treatment’s
efficacy, while collecting information on its long-term toxicity (Pocock, 2004).
If the results of the phase III trial are positive, then the treatment can be made
accessible to patients outside of clinical trials. For this reason, it is important that the
167
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chance of an incorrect conclusion being drawn from the phase III trial is minimised.
In light of this, phase III trials are usually large-scale randomised trials comparing the
experimental treatment with a control treatment. The primary endpoint considered
in the phase III trial is usually the outcome which is felt to provide the most relevant
measurement of the treatment’s efficacy for the patient population of interest. This is
often a time-to-event endpoint, often death in oncology, although this can be slow to
observe. The definitive nature of phase III trials mean that strict error controls are
placed on the hypotheses concerning the primary endpoint of interest. It also means
that frequentist methodology is generally used in order to avoid the subjective nature
of Bayesian designs.
As in phase III, the primary objective of phase II clinical trials is generally efficacy
related. However, phase II trials are considered to be non-confirmatory trials which
are carried out in order to justify progression of the experimental treatment to phase
III. For this reason, phase II trials tend to be much smaller and shorter in duration
than phase III trials. Despite the restrictions on the design of phase II trials, the
inferences drawn from the trial must be relatively accurate in order to minimise the
chance of a treatment with an undesirable benefit-risk ratio being taken to phase
III. The most common reason for failure in phase III trials is lack a efficacy of the
experimental treatment (Arrowsmith and Millar, 2013). So, as well as being costly in
terms of resources, failure at phase III can mean that large amounts of (potentially
severely ill) patients have been administered an inefficacious treatment. An alternative
outcome, which is also not favourable, is that in which patients in phase III trials are
administered an efficacious but unacceptably/unnecessarily toxic treatment.
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Collecting as much relevant information as possible in early phase trials could
improve the reliability concerning the decision over whether an experimental treat-
ment should progress to phase III clinical trials. Design restrictions on phase II trials
are common; largely these (implicitly or explicitly) concern the cost implications of
the trial. The more patients involved in a trial, the longer the duration (for a fixed
recruitment rate), more patients put at risk and higher the cost of the trial. In an
attempt to reduce the size of phase II trials there are certain design factors which are
commonly used. Some of these are (Seymour et al., 2010):
Short-term endpoint: The actual endpoint of interest for a disease can sometimes
take months, or even years, to observe. The trial duration is heavily depen-
dent on this observation time (as well as recruitment rate into the trial). As an
alternative, a short-term (often binary) endpoint which can be collected much
sooner, and is thought to be highly correlated with the actual endpoint of inter-
est, can be used. For example, in oncology trials, a binary indicator of tumour
growth or a continuous time-to-progression endpoint can often be used as an
alternative to the actual endpoint of interest, death (FDA et al., 2007).
• In some diseases there is no short-term endpoint which reliably predicts the
occurance of the actual endpoint of interest. The use of a poorly predictive
short-term endpoint in phase II would lead to an unreliable decision over
whether to progress the treatment to phase III. In other cases, the actual
endpoint of interest can be observed in a relatively short period, removing
the need for an endpoint to be used.
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Single-arm trial: In a single-arm trial, data are only collected on the experimental
treatment. The trial data on the experimental treatment is then compared to
historical control data. The number of patients required in the trial is therefore
less than that for a randomised trial which tests hypotheses with the same error
constraints. When the historical control data are suitably similar to that which
could be obtained in the trial if it were randomised, then reliable conclusions
can be drawn from the single-arm trial.
• Since the data used in analysing the results of a single-arm trial are not
concurrent, issues concerning comparability can arise. The gold-standard
is a randomised trial in which data are obtained concurrently on the ex-
perimental and a control treatment (Ratain and Sargent, 2009). The com-
parisons drawn from randomised trials are more reliable than those from
a single-arm trial (with same error constraints on the hypotheses) but the
number of patients required in the trial is increased.
Relaxed error constraints: The sample size of a trial is chosen such that the prob-
ability of making an incorrect decision concerning the trial hypotheses is con-
trolled to be less than the specified error constraints. The sample size for the
trial can be decreased if these error constraints are relaxed.
• Relaxing the error constraints on the hypotheses decreases the certainty
with which correct trial conclusions are made; increasing the chance of
wrongly abandoning a promising treatment or progressing with an unde-
sirable treatment.
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Early stopping allowed: If, at an interim analysis, the experimental treatment is
looking very promising (or not) compared to the control treatment, then the
trial can be stopped early, reducing the size and resource burden of the trial.
Early stopping for efficacy and/or futility such as this is often used in phase III
trials and is becoming more common in phase II.
• The use of interim analyses, to decide whether there is suitable evidence
(or lack) of efficacy to stop the trial early, increases the complexity of trial
designs (Whitehead, 1997). When a frequentist design is used, multiplicity
issues arise from having multiple analysis points. Trial planning (in terms of
funding) can also be more difficult when using an interim analysis because
a single sample size cannot be obtained for the trials - instead they are
calculated in terms of maximum or expected sample sizes.
Bayesian methodology: When designing phase II trials there is little physical data
available concerning the efficacy of the experimental treatment. There is how-
ever, a range of less formal data (for example, knowledge of the treatment in
a different application or efficacy observations in patients involved in phase I
trials) which can be incorporated into the trial design and/or analysis using
Bayesian methodology. When the available data are incorporated in a sensible
manner (with thorough consideration of the effect of historical data on the out-
come of the trial), and a confirmatory trial will follow, then Bayesian designs
are often justified and can reduce the trial size.
• Bayesian methods account for uncertainty in both the outcome of the trial
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and the model parameters and so the Bayesian sample size calculated for
a trial will not always be lower than a frequentist alternative. The subjec-
tive nature of Bayesian designs, and strict regulatory control, mean that
Bayesian methods are rarely used in confirmatory, phase III trials. They
are however endorsed for use in small clinical trials within the pharmaceu-
tical industry (CHMP et al., 2006).
Ideally, none of the above design factors would be used in phase II trials. However,
within cost restrictions on phase II trials, one or more of these design factors are likely
to be employed. In Section 5.2, a frequentist method of sample size calculation which
is commonly used in single-arm, phase II trials with a binary endpoint is given. This
example clarifies the standard set-up of phase II clinical trials and the use of error
constraints in sample size calculation. In Section 5.3, the discussion is extended to
time-to-event data. Methods of modelling the time-to-event data are described, as well
as a frequentist method of sample size calculation. A literature review of Bayesian and
frequentist alternatives for sample size calculation based on a time-to-event endpoint
is given in Section 6.1.
In Section 6.2, Bayesian methods of sample size calculation for phase II clinical
trials with a time-to-event endpoint are considered. Sample size calculations are pre-
sented for both single-arm and randomised trials and in each case the error constraints
on the hypotheses can be specified as desired. Calculations are given for a single anal-
ysis at the end of the trial but could be extended to account for interim analyses. The
methods are illustrated in Section 6.4 using uveal melanoma data but the method is
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also applicable outside of oncology when a time-to-event endpoints is of interest.
The calculations involved in the work in Chapter 6 rely on historical data on
the control treatment, together with a proportional hazards assumption (which is
discussed in detail in Section 5.3), to find the number of events which need to be
observed in order to test the trial hypothesis with given error constraints. Recruiting
only the number of patients equal to the number of events required and waiting for
them all to experience an event can be a lengthy process. An alternative, which can
reduce trial duration, is to recruit more patients than the number of events required.
For a given trial duration, the expected sample size can then be calculated. This
additional calculation requires some information on the time to the event of interest
for patients. In addition, for the case of a randomised design, selection of a suitable
allocation ratio of patients between experimental and control treatments is considered.
The methodology used for the proposed sample size calculations in Chapter 6
is Bayesian; there are several advantages of using Bayesian methods in early phase
clinical trials. At the design stage of the phase II trial, there will be some information
available on the experimental treatment. For example, data could be available from
the phase I trial of the treatment, use of the treatment in another application and
informal use of the treatment. More complete and relevant data is likely to be available
on the control treatment. The use of Bayesian methods for the phase II trial enables
this information to be incorporated along with the observed trial data to obtain
updated inferences on the experimental treatment. As well as being intuitive that
available data should be utilised, this can reduce the sample size required for the
current trial. Hence, reducing the cost and duration of the current trial.
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5.2 Sample Size Calculation Based on a Binary
Endpoint
At the design stage of a phase II clinical trial it is important to know what resources
are likely to be needed for the planned trial and, based on this, whether the trial
is indeed feasible. A sample size calculation can aid this decision. Analysis of the
trials we are concerned with involve testing pre-defined hypotheses concerning efficacy
response rates on the experimental (and control) treatment(s). Now, the more events
observed in the trial, the more likely that the correct decision will be made concerning
the trial hypotheses (in terms of type II error since type I error will be fixed in the
design). In the sample size calculation, an estimate of the number of events required
in order to control the probability of making an incorrect decision at a fixed error
level, is calculated.
Initially, consider a single-arm trial based on a binary endpoint. A frequentist
method of sample size calculation for such a trial is described in the following two
paragraphs as an introduction to sample size calculation. A more detailed account of
this approach can be found in Stallard (2008).
Take the endpoint of interest to be a positive binary response (observation that a
patient’s tumour has shrunk by some fixed amount, for example) at A years. Now,
historical data can be used to define p0, the expected response rate within A years
on the control treatment. We consider the experimental treatment to be sufficiently
promising to progress to phase III trials if the observed response rate at A years is at
least p1, for p1 > p0. Here, p1 can be considered as the clinically worthwhile response
CHAPTER 5. Sample Size Calculation in Phase II Clinical Trials 175
rate and it should be selected by assessing the needs of the treatment area and the
potential benefits of the experimental treatment.
Now consider the trial design: In the trial, n patients will be administered with the
experimental treatment. Say that m of these patients respond positively to treatment
within A years. The experimental treatment is considered promising if p1 > p0,
equivalently ifm ≥ κ for some κ. The values of n and κ are chosen to control the risk of
wrongly progressing the treatment to phase III (the one-sided type I error α, typically
0.05 or 0.10) and the risk of wrongly abandoning the treatment (the type II error β,
typically 0.2 or 0.1). Letting p be the true probability that a patient administered
the experimental treatment will respond within A years, a search procedure can be
used to identify pairs (n, κ), which satisfy:
P(m ≥ κ|p = p0) ≤ α and P(m ≥ κ|p = p1) ≥ 1− β.
The pair with the smallest n value is that which minimises the sample size and is
therefore the pair of interest. Note that, when analysing the trial data the value of
κ corresponding to the actual sample size used in the trial should be used, and not
that of the planned sample size.
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5.3 Utilising Time-to-event Data in Sample Size
Calculation for Phase II Clinical Trials
The sample size calculation presented in Section 5.2 is often suitable for traditional
phase II cancer trials. In these trials, a binary response (such as tumour shrinkage) is
often used as a short-term alternative for the more relevant endpoints of time to disease
progression or mortality. When considering a cytotoxic treatment for solid tumours,
where the aim is to reduce tumour size, an intermediate marker such as tumour
shrinkage may be suitable. However, many new cancer treatments are intended to be
cytostatic rather than cytotoxic; that is they will control the growth of the tumour
rather than destroying it (Millar and Lynch, 2003). In such cases, destruction or
shrinkage of the tumour is not anticipated and “tumour response” is no longer a
sensible endpoint. In the case of Ipilimumab, an immunotherapy approved by the
FDA in March 2011 for the treatment of uveal melanoma, no reliable alternative
endpoint for time to mortality could be identified. This led to the endpoint in uveal
melanoma trials of this treatment being changed from response to overall survival
(Hodi et al., 2010; Robert et al., 2011).
Another example is that of diseases such as pancreatic cancer, for which the use
of a short-term, binary endpoint appears to be unnecessary. In this disease, median
survival is of the order of six months (Amikura et al., 1995; Kayahara et al., 1993).
As a result, there is no substantial advantage in terms of trial duration in seeking
earlier endpoints such as tumour response or progression-free survival; sadly the most
objective endpoint, time to death, is likely to be quickly available. This can also
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be the case in other therapeutic areas for rapidly lethal conditions such as alcoholic
hepatitis (Ramond et al., 1992). Similarly in infectious diseases where time to fever
clearance or viral clearance is often taken as the endpoint of interest (Fox et al., 2011).
Arrowsmith and Millar (2013) agree that there is a need in oncology to design phase
II trials which “can deliver data that are sufficient to support good decision-making,
and to have suitably discriminatory proof-of-concept criteria agreed prospectively”.
That is, using an endpoint in phase II which is directly relevant to the efficacy end-
point of interest even though this may require longer, larger trials than has become
usual. The use of randomised, as opposed to single-arm, trials could also lead to more
informed decision making from phase II trials.
It is widely agreed that randomised trials are preferable to single-arm designs
(Ratain and Sargent, 2009). However, within the resources available for a phase II
clinical trial, a randomised trial might not be feasible. Such a design could be made
more feasible by relaxing the error constraints but this compromises certainty in the
trial conclusion. Alternatively, a Bayesian design can be used. Bayesian designs
enable incorporation of prior data on the experimental and/or control treatment. In
this way, the required sample sizes can be reduced (Whitehead et al., 2008).
In frequentist sample size calculations, a 1:1 allocation ratio between the experi-
mental and control treatments minimises the sample size. This is also be the case in a
Bayesian design where equal amounts of prior data are available on both treatments.
In reality, there will be more prior knowledge surrounding the control than experimen-
tal treatment; this imbalance in information can be incorporated into the Bayesian
design. The result is that a non-equal allocation ratio may minimise the sample size
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of the trial. In the case where a large amount of relevant data are available on the
control treatment, this could lead to a decision not to allocate any patients to the
control treatment (Whitehead et al., 2008).
An overview of methods of modelling time-to-event data is given in Section 5.3.1
in the context of a single-arm trial. The discussion is extended to the case which
arises from a randomised trial in Section 5.3.2. The information in these two sections
comes from Collett (2014), unless otherwise stated. This book contains additional
details on the topics discussed here, as well as their extensions in survival analysis.
More information on survival analysis can be found in Cox and Oakes (1996).
5.3.1 Modelling Time-to-event Data from a Single-arm Clin-
ical Trial
The time between a patient’s recruitment into the trial (also taken as the time they
were administered with treatment) and their (treatment-related) death is considered
as the survival time of the patient. As discussed, endpoints other than death, such
as time to disease progression, are commonly used as efficacy endpoints which are
available much sooner. The data arising from such endpoints is time-to-event data, as
opposed to being true survival data. Since mortality can be considered as the event
of interest, survival can also be considered as a time-to-event endpoint. The methods
of modelling and analysing time-to-event data are the same as those for survival data.
Consider time to the event of interest to be a continuous variable which is greater
than 0, i.e. the event of interest has not occured at the time that a patient is recruited
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into the trial.
In a clinical trial, patients are usually recruited over a period of months, or even
years. The recruitment time of each patient is therefore likely to be different, as is
their time of event. These key time-points are often both recorded in study time,
the time from commencement of the trial. It is often more useful to consider patient
time, the time from recruitment to event for each individual patient. Within the
practicalities of a clinical trial, it is unlikely that the trial will continue until all
patients have experienced an event. Instead the trial will end at a given time-point,
by which some patients will have experienced an event (and their actual time-to-event
can be calculated), while others have not. Those who have not experienced an event
by the end of the study are considered to have censored time-to-event observations.
Censored time-to-event observations, such as those considered here, are right-
censored. That is, the patient’s time-to-event is greater than the time they were
observed for in the trial. So, right-censoring can occur during the trial if a patient
chooses to leave the trial before experiencing an event, is lost to follow-up, or outlives
the final analysis point in the trial. Left and interval censored data can also arise
but are not considered here, for more information on these see Chapter 1 of Collett
(2014). The occurrance of censoring in time-to-event data is one of the main reasons,
along with the bad fitting normal assumption to the data, for the special handling
of this time-to-event data. In handling censored data, it is assumed that censoring
occurs at random, between patients and with time.
Table 5.3.1 presents an example data set, in terms of study and patient time, for a
clinical trial in which patients are recruited over 3 years and followed up for a further
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2 years. The total duration of the trial is therefore 5 years. In Figure 5.3.1 these
data are presented visally to clarify the concepts of patient time and censoring in
the context of a clinical trial. We see that patients 1, 2, 5, 7 and 8 experienced an
event within the trial and so their time-to-event is recorded (in Table 5.3.1 and by a
cross in Figure 5.3.1) as not censored. The time-to-event of the other patients were
censored, with patients 3 and 6 either leaving the trial or being lost to follow-up before
experiencing the event of interest. Patient 4 on the other hand did not experience an
event within the trial, leading to a censored time-to-event being recorded for them
too.
Patient Recruitment Event Time-to-event Censoring
number time time (patient time) indicator
1 0 3.5 3.5 1
2 0.6 2.8 2.2 1
3 1.0 2.2 1.2 0
4 1.3 5 3.7 0
5 2.1 2.6 0.5 1
6 2.2 4.5 2.3 0
7 2.5 4.8 2.3 1
8 3 3.4 0.4 1
Table 5.3.1: Example time-to-event data for 8 patients. Recruitment and event time
are given in terms of study time while time-to-event uses patient time. The censoring
indicator is equal to 0 if censored and 1 otherwise. These data are represented visually
in Figure 5.3.1.
From the time-to-event data observed in a trial, it may be desirable to make
inferences such as the probability that a patient experiences an event before a given
time-point of interest. Let the time from recruitment of a patient to the time they
experience the event of interest be t > 0 and let T be the random variable of which t
is a realisation. The distribution function F (t) = P(T < t) gives the probability that
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a patient experiences an event before time t. In the analysis of time-to-event data,
the quantity 1 − F (t) = P(T ≥ t) is often of interest. This is known as the survivor
function, S(t).
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Figure 5.3.1: Visual representation of the time-to-event data given in Table 5.3.1. The
patient time is shown with recruitment represented by a circle, an event by a cross
and censoring by a square.
Now, say that the probability of experiencing an event at time t is of interest.
Technically this probability is equal to 0. So, what we actually calculate is the prob-
ability of an event occurring between time t and t + δt; and consider the limit as
δt tends to 0. Logically, this probability is conditioned on the patient not having
experienced the event of interest by time t. The resulting probability is the hazard

















These probabilities can be estimated from a given data set. When the data closely
follow a parametric model, a probability distribution function can be used to accu-
rately estimate S(t), and hence h(t), for a given t. The Weibull distribution has been
used in medical statistics (such as in the analysis of pancreatic cancer survival data Ko
et al., 2008; Lima et al., 2004) and in engineering applications (where the distribution
was initially derived).
In the remainder of this section, time-to-event data are discussed in two settings:
when the data can be modelled by a Weibull distribution and when a parametric as-
sumption is not required/suitable. The Weibull distribution is also used in Chapter 6
when a parameteric distribution is considered for the time-to-event data. At the end
of this section, methods of checking whether a Weibull assumption is sufficient are de-
scribed. Although the parametric methods discussed are described and demonstrated
under a Weibull assumption, alternative parametric distributions could be used with
calculations and derivations following a similar logic.
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Weibull distributed data
The Weibull distribution is an extension of the exponential distribution, which it holds
as a special case. In the exponential special case, the hazard rate is constant with
time such that h(t) = λ for λ > 0. For a clinical trial with a time-to-event endpoint
which is assumed to be exponentially distributed, the implication is that a patient
has the same probability of experiencing an event at their time of recruitment into
the trial as they have at 3 years into the trial, say. This assumption may be suitable
to model the occurance of an adverse event, for which the patient’s risk is unaffected
by the duration of their treatment. However, it is clearly unrealistic for modelling the
endpoint of mortality, for example.
In addition to the scale parameter λ, which comprises the hazard function of
the exponential distribution, the Weibull distribution has a rate parameter, γ (with
γ > 0). The hazard and survivor functions under a Weibull model can be derived
from its probability distribution function as:
h(t) = λγtγ−1 and S(t) = e−λt
γ
.
So, when γ = 1, the Weibull distribution reduces to the exponential special case
in which the hazard rate is assumed to be constant with time. For γ > 1, the hazard
rate increases monotonically with time and for 0 < γ < 1, the hazard rate decreases
monotonically with time. This additional flexibility provided by the rate parameter
makes the Weibull distribution much better suited than the exponential distribution
for modelling time-to-event data. The distributional assumption is discussed here but
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this may still be too restrictive in practice. Non-parametric alternatives which may
be better suited if the Weibull distribution cannot be assumed are discussed later in
this section.
If the observed time-to-event data are assumed to follow a Weibull distribution,
then maximum likelihood estimates λˆ and γˆ can be obtained. The maximum like-
lihood estimates are the parameter values which maximise the likelihood function.
They correspond to the parameters of the best-fitting Weibull curve to the data.
Here, the likelihood function for complete and censored Weibull distributed data is
derived. A basic understanding of maximum likelihood methods is assumed and more
information on these methods can be found in Pawitan (2001). As well as being used
to obtain maximum likelihood estimates of the model parameters, which can be used
to estimate the survivor and hazard functions at a given time, the likelihood function
is used in deriving the posterior distribution of the model parameters. This topic was
discussed in Section 2.2.1 on Bayesian methods.
Take a trial in which n patients were treated with the experimental treatment
and their survival times observed. If m = n of these patients died during the trial,










−λtγj assuming Weibull distributed survival times.
When censoring is present in the data, we have n > m with the actual survival
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times of n−m patients not available. We still have some information about the survival
times of these patients; their survival times are greater than their last observation
time. For censoring indicator dj, equal to 0 if observation j is censored and 1 otherwise,























assuming Weibull distributed survival times.
No parametric assumption
The choice of parametric models may be too restrictive to sufficiently model the
observed data in some cases. An alternative approach, which does not require a dis-
tributional assumption, is to use non-parametric methods. Some parametric methods
for time-to-event data, which are used in the sample size calculation in Section 6.2
are described in this section.
If the time-to-event data set does not contain any censored observations, then
the survivor function can be estimated using an intuitive estimate; the proportion of






where Itj>t is an indicator equal to 1 if the survival time of patient i is greater than
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t and 0 otherwise. Assuming that all patients are alive at the start of the trial, Sˆ(t)
will be equal to 1 at commencement of the trial. The estimate will decrease at event
times until all patients in the trial have experienced an event, at which time Sˆ(t) = 0.
Between the observed event times, the empirical survivor function is constant. The
resulting curve is therefore a step function, of a similar form to that in Figure 5.3.2.






























Figure 5.3.2: Plot of the Kaplan-Meier estimate of the survivor function for the data
given in Table 5.3.1 with calculation of the estimate given in Table 5.3.2. Censored
observations are marked by a vertical dash.
Event time nj − rj Dj (nj − rj −Dj)/(nj − rj) Sˆ(t)
0 8 0 1 1.000
0.4 8 1 7/8 0.875
0.5 7 1 6/7 0.750
2.2 5 1 4/5 0.600
2.3 4 1 3/4 0.450
3.5 2 1 1/2 0.225
Table 5.3.2: Calculation of the Kaplan-Meier estimate of the survivor function, which
is shown in Figure 5.3.2, for the time-to-event data given in Table 5.3.1.
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It is unlikely that all of the trial data will be uncensored and so this empirical
estimate must be extended to account for censoring: Define the start time of the trial
as t0 and let times t(1), ...t(m) be the ascending, non-censored event times. The inter-
vals between consecutive event times may contain censored event times and at each
time point there may be more than one event (this is most likely due to recording
inaccuracies rather than truly spontaneous events). If n− rj patients have not expe-
rienced an event just before time t(j) and Dj events are observed at time t(j), then the
probability of experiencing an event at time t(j) is (n− rj −Dj)/(nj − rj). It can be
shown that this probability is in fact an estimate of the probability of experiencing an
event between times t(j) and t(j+1) is (n− rj −Dj)/(n− rj). A censored observation
which occurs at an event time is included in n but not in Dj at that event time. The






The calculation of the Kaplan-Meier estimate of the survivor function is demon-
strated in Table 5.3.2 for the data given in Table 5.3.1. The estimate is plotted as
in Figure 5.3.2. The Kaplan-Meier estimate is a step function from Sˆ(t) = 1 at time
t = 0. In the example data set in Table 5.3.1, the final event time was censored. So,
instead of the Kaplan-Meier estimate of the survivor curve decreasing to Sˆ(t) = 0 at
the final event time, the function is undefined after the final uncensored event time (at
4.8 years). Observed event times are marked on the plot by decreses in the function,
the size of the step determines the number of events which occurred at that time
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point. Censoring is also be marked on the curve by a vertical dash at censored event
times.
An alternative method of estimating the survivor function uses the Nelson-Aalen




h(u)du, which is in turn used to estimate the survivor function,
Sˆ(t) = e−Hˆ(t). In small samples, the properties of the Kaplan-Meier and Nelson-Aalen
estimates differ, with the Nelson-Aalen estimate often performing better (Colosimo
et al., 2002). However, asymptotically the estimates are the same and the Kaplan-
Meier estimate derives naturally from the empirical survivor function, making its
derivation and use more natural.
Using a Weibull assumption or non-parametric methods
The step-function approximation to the true survior function which results from non-
parametric methods does not always produce reliable estimates; this can be especially
problematic with sparse data sets. However, the use of parametric methods with an
invalid distributional assumption can also lead to unreliable estimates. The amount
and distribution of the data should be considered in order to select the most appro-
priate method of estimating the survivor function. If a parametric model is to be
assumed, it is important to check the validity of the distributional assumption.
An idea of the validity of a parametric assumption can be obtained visually by
plotting the non-parametric estimate of the survivor function alongside the best fitting
curve based on the selected parametric model. Similarity between the two curves
indicates a reasonably well fitting distributional model. When a Weibull model is
CHAPTER 5. Sample Size Calculation in Phase II Clinical Trials 189
assumed, the properties of the distribution mean that this judgement call can be made
clearer: Since the survivor function of the Weibull distribution is S(t) = e−λt
γ
, it can
be seen that log[− log{S(t)}] = log(λ) + γ log(t). Now plot log[− log{Sˆ(t)}] against
log(t) for Kaplan-Meier estimates Sˆ(t) of the survivor function. If the resulting curve
roughly follows a straight line with intercept and gradient similar to the maximum
likelihood estimates obtained for the logarithm of the scale parameter and the shape
parameter of the Weibull distribution respectively, then the Weibull distribution is
considered to fit the data reasonably well.
Numerical estimates for the goodness-of-fit of a parametric model to a data set can
also be assessed (Collett, 2014). For example, obtaining narrow confidence intervals
around the maximum likelihood parameter estimates can be indicative of a well-fitting
distributional assumption. Similarly, small Akaike information criterion or Bayesian
information criterion values indicate the model is a good fit to the data.
Unfortunatley, these numerical methods are only useful in selecting between a
series of candidate models. They do not indicate whether any model is a particularly
good fit. So, both numerical and visual methods suffer from vagueness over assessing
the validity of a model assumption.
5.3.2 Modelling Time-to-event Data from a Randomised Clin-
ical Trial
It is unlikely that there will be large amounts of relevant data available regarding the
time to the event of interest for the experimental treatment. However, such data is
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likely to be available for patients on the current standard or control treatment. The
historical control data can be used in the trial design and sample size calculation
together with any existing information on the experimental treatment.
A basic assumption in the analysis of time-to-event data from two treatments is
that of the proportional hazards model (Cox, 1972). Under the proportional hazards
model, the ratio of the hazard rate on the experimental treatment to that on the con-
trol treatment is considered to be constant with time. That is, for hazard rates hE(t)
and hC(t) on the experimental and control treatments, respectively, hE(t)/hC(t) = c
for constant c and t > 0. By the definition of the hazard function, c must be greater
than 0 and so set c = eg.
If hE(t) and hC(t) are proportional, then a baseline hazard rate h0(t) can be defined
to which they are also both proportional. Now, for constant gi relating the baseline
hazard function to the hazard rate on treatment i,
hi(t) = e
gih0(t) for i = E, C.
This can be re-written as hE(t) = e
ghC(t) for g = gE − gC,
equivalently, SE(t) = SC(t)
eg .
The proportional hazards assumption underlies the log-rank test which is a com-
monly used method of analysis for time-to-event data from two treatments. The
log-rank test is a hypothesis test of whether the time-to-event data from patients
treated with the experimental and control treatments originated from the same pop-
ulation. Equivalently, it tests the null hypothesis of no difference in time to the event
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of interest between the two treatment groups. The number of events observed in the
trial in each group (Oi for i = E, C) is straight-forward to calculate from the time-to-
event data. In addition, find the number of events which we would expect to observe
in each group (Ei) if there was in fact no difference between the treatment groups.
We have that Ei = niD/n where n = nE + nC and D is the total number of events








In Section 6.2, historical time-to-event data on the control and experimental treat-
ments are used to derive Bayesian sample sizes for single-arm and randomised trials
with time-to-event endpoints. Sample sizes based on the log-rank test are used later
in Chapter 6 as a frequentist sample size for comparison with those obtained from the
proposed Bayesian calculations.
Chapter 6
Bayesian Methods for Setting
Sample Sizes and Choosing
Allocation Ratios in Phase II
Clinical Trials with Time-to-event
Endpoints
Abstract
Conventional phase II trials using binary endpoints as early indicators of a time-to-
event outcome are not always feasible. Uveal melanoma has no reliable intermediate
marker of efficacy. In pancreatic cancer and viral clearance, the time to the event
of interest is short, making an early indicator unnecessary. In the latter application,
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Weibull models have been used to analyse corresponding time-to-event data.
Bayesian sample size calculations are presented for single-arm and randomised
phase II trials assuming proportional hazards models for time-to-event endpoints.
Special consideration is given to the case where survival times follow the Weibull
distribution. The proposed methods are demonstrated through an illustrative trial
based on uveal melanoma patient data. A procedure for prior specification based on
knowledge or predictions of survival patterns is described. This enables investigation
into the choice of allocation ratio in the randomised setting to assess whether a control
arm is indeed required.
The Bayesian framework enables sample sizes consistent with those used in practice
to be obtained. When a confirmatory phase III trial will follow if suitable evidence
of efficacy is identified, Bayesian approaches are less controversial than for definitive
trials. In the randomised setting, a compromise for obtaining feasible sample sizes
is a loss in certainty in the specified hypotheses: the Bayesian counterpart of power.
However, this approach may still be preferable to running a single-arm trial where no
data is collected on the control treatment. This dilemma is present in most phase II
trials, where resources are not sufficient to conduct a definitive trial.
Keywords: Phase II trial; proportional hazards model; sample size calculation; time-to-event
endpoint; Bayesian framework.
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6.1 Introduction
This chapter concerns phase II trials in which a single novel treatment is to be assessed
in terms of time-to-event data. The objective of such a trial is to establish whether
the experimental treatment shows sufficient promise to justify large-scale, definitive
investigation in phase III. Much has been written about the conduct of phase II trials
in oncology, but the development of treatments for infectious diseases and potentially
lethal conditions such as alcoholic hepatitis can involve similar investigations.
In conventional phase II clinical trials in oncology, all trial patients are allocated
to the experimental treatment (Stallard, 2008). Data are then collected on ‘tumour
response’, defined as a binary indicator of whether a patient’s tumour disappears or
shrinks by a pre-defined amount within a given follow-up period. Investigators will
proceed to further development of the treatment if the number of responses exceeds
some critical value, chosen together with the sample size to achieve specified risks of
type I and type II error. The subsequent phase III trial will then be a randomised
comparison of the experimental treatment with a placebo or standard control, in
which time until progression or death is the primary endpoint.
Here we focus on cases where it is either not feasible or not necessary to use a
short-term binary endpoint in place of the desired survival endpoint. In advanced
pancreatic cancer, for example, typical survival times are 6 months or less, removing
the necessity of using tumour response as an earlier indicator of survival. In primary
uveal melanoma, there is no observable counterpart to the shrinkage of tumours and
investigators have to rely on survival patterns. Similarly, new cytostatic cancer drugs
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are designed to limit the growth of tumours rather than to kill them, so that tumour
shrinkage is not a necessary condition for efficacy (Millar and Lynch, 2003). Outside
the field of oncology, infectious diseases can be assessed in terms of the time to fever
clearance or viral clearance: a desirable event occurring within a matter of days. Fox
et al. (2011) describe an analysis of the latter. Another example is alcoholic hepatitis
that can be rapidly lethal (Ramond et al., 1992) without an intermediate marker
through which efficacy is signalled.
Frequentist approaches to the design of phase II trials yielding survival endpoints
have been described by various authors. For single-arm studies, proposed designs in-
clude a two-stage procedure based on the Nelson-Aalen estimate (Case and Morgan,
2003) and one-stage procedures based on a one-sample log-rank test (Sun et al., 2011).
Owzar and Jung (2008) consider various parametric and non-parametric approaches,
while Whitehead (2014) constructs a method from survival rates past a limited num-
ber of landmark time points. Randomised studies can be based on more familiar
frequentist survival approaches, devised to operate with small samples (Evans and
Ildstad, 2001, for example).
The Bayesian method of sample size calculation described in this chapter is based
on an idea briefly mentioned by Simon (2000) and developed for binary and normally
distributed endpoints by Whitehead et al. (2008). We extend this work to the case of
time-to-event endpoints when a proportional hazards assumption can be made. For
trials where sample sizes are to be set in the absence of detailed knowledge of the
likely survival pattern, the Weibull model is suggested for use at the design stage.
The method has similarities to that of Thall et al. (2005), which adopts an expo-
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nential model to construct a sequential version without explicit calculation of the
required sample size. Gittins and Pezeshk (2000) consider sample size determination
for survival data through consideration of the cost-benefit of a randomised clinical
trial. Various other alternative methods for Bayesian sample size calculations have
been described (Dong et al., 2012; O’Hagan and Stevens, 2002; Spiegelhalter et al.,
2004; Zaslavsky, 2012; Zaslavsky and Whitehead, 2012; Zhao et al., 2012) but these
use different Bayesian principles than those underlying the sample size calculations
we present in this chapter.
The Bayesian approach has several advantages over frequentist methods in early
phase trials. Incorporation of informative prior opinion about treatment properties
allows a reduction in sample size. This strategy has to be used cautiously as it will
reduce the amount of real phase II data available for planning later trials. However,
particularly in rare diseases, it can enable otherwise infeasible studies to be conducted,
and conclusions drawn will be confirmed in subsequent large-scale and probably fre-
quentist phase III trials. Furthermore, in randomised trials the Bayesian approach
offers a basis for choosing the ratio of patients allocated to experimental and control
treatments. Time-to-event data is such that non-parametric approaches such as pro-
portional hazards regression are difficult to implement without recourse to Markov
chain Monte Carlo methods (such as those of Gelfand and Mallick, 1995), and these
do not lend themselves for use at the design stage.
In this chapter we adopt a proportional hazards model for the time-to-event data
to be collected. In Section 6.2, formulae are developed for the number of events
required in a Bayesian trial with time-to-event endpoints in which all patients receive
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the experimental therapy and for randomised trials with an R:1 allocation ratio. To
transform the number of events required to a target sample size, further assumptions
are required concerning the nature of the survival distribution. A detailed example for
the special cases, where an exponential or Weibull model is assumed for the purpose of
trial design, is presented for illustration in Section 6.3. The choice of R (including the
single-arm option, R =∞) is explored in the context of differential prior knowledge of
the two treatments. Clinical data show good agreement between exponential models
and survival experience following diagnosis of pancreatic cancer (Ko et al., 2008;
Lima et al., 2004). In infectious diseases, Weibull models have been used to analyse
viral clearance times in dengue fever (Fox et al., 2011). Alternatively, if an estimated
survival function based on existing data is available, then a sample size calculation can
be based on this in a similar manner to Whitehead (2001). This option is compared
to the Weibull case through an illustration, based on data from uveal cancer patients,
and is presented in Section 6.4. A discussion of the method and its applications is
presented in Section 6.5.
6.2 Bayesian Approach to Sample Size Setting
6.2.1 A Model for the Data and Criteria for Sample Size
Consider testing the null hypothesis of no treatment difference between experimental
(E) and control (C) treatments against the alternative of a clinically relevant advan-
tage of E. Survival from time of entry to the trial to occurrence of a certain event is
recorded. In this chapter, an event is taken as being undesirable, such as death or dis-
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ease progression. Obvious modifications are required if the event is positive, such as
viral clearance. Survival times tij and censoring indicators dij (= 0 if censored and 1
otherwise) are collected for the jth trial patient receiving treatment i, for j = 1, ..., ni;
i = E, C, and they are assumed to be independent. The total number of patients
treated in the trial is then n = nE + nC.
Let the survival function for a patient on treatment i be given by Si(t) for t > 0, i =
E, C. In designing the study, a third survival function, S0(t), will also be considered.
This represents the survival experience of patients with whom the investigators are
already familiar. There might be historical data from such patients, or there might be
a consensus concerning values of S0(t) for one or more values of t. It will be assumed
that Si(t) = S0(t)
λi for i = E,C leading to SE(t) = SC(t)
e−θ (which is derived from the
more familiar proportional hazards model hE(t) = hC(t)e
−θ, where hi(t) denotes the
hazard function for patients on treatment i for i = E,C) where the negative log-hazard
ratio θ = − log(λE/λC) represents the advantage of treatment E over treatment C.
Let θ1 > 0 be the negative log-hazard ratio corresponding to a clinically worthwhile
treatment effect. It may be convenient, especially when designing a single-arm trial,
to assume that S0(t) = SC(t) for all t: that is λC = 1.
Denote all data collected as x = (t,d) for t = {tE1, ..., tEnE , tC1, ..., tCnC} and d =
{dE1, ..., dEnE , dC1, ..., dCnC}. Then denote data from the ni patients on treatment i as
xi = (ti,di) for i = E, C. Letting wij = − log{S0(tij)} implies that the corresponding
random variable Wij follows the exponential distribution with parameter λi for i =
E, C and all j. The likelihood of λi based on wij, which at this stage cannot be
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where Di denotes the total number of events observed on treatment i and Si =
wi1 + ...+wini , the sum of the transformed survival times of patients on treatment i.
In Sections 6.2.2 and 6.2.3 in the succeeding paragraphs, the numbers of events
required for a single-arm trial (nC = 0) and for a randomised trial will be derived. To
deduce the required sample size expected to yield this number of events in a given
time-frame, some knowledge of the function S0(t) is required. If sufficient historic
data exist, then a Kaplan-Meier estimate, S¯0(t) of S0(t), might be used. Failing that,
it might be possible to fix values for S0(t1) and S0(t2) for two time points t1 and
t2 from clinical experience. This would allow S0(t) to be modelled as the Weibull
distribution function with rate parameter φ0 and shape parameter γ that takes the
specified values at times t1 and t2. As we are also assuming that Si(t) = S0(t)
λi for
i = E, C, the Weibull assumption implies that survival times on treatment i follow
the Weibull distribution function with rate parameter φ0λi and shape parameter γ,
i = E, C. If the value for S0(t) can be reliably fixed for only one value of t, then
an exponential model can be imposed. Of course, in some settings, the parametric
approach might be the method of choice. As discussed at the end of Section 6.1, a
Weibull model might be preferred for trials in infectious diseases or an exponential
model for trials in pancreatic cancer.
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A Bayesian should decide to proceed to further testing in phase III if the posterior
belief that the treatment effect is positive is sufficiently strong. Thus, the value of
P(Θ > 0|x), where Θ denotes the random parameter of which θ is a realisation, should
be computed. Before the trial is conducted, a critical value η should be specified
(usually as a value close to 1) such that the null hypothesis will be rejected and the
experimental treatment taken forward to further testing in phase III provided that
P(Θ > 0|x) ≥ η. More formally, a rejection region R can be specified such that if
x ∈ R, the null hypothesis will be rejected and the experimental treatment taken
forward to further testing in phase III. If x /∈ R, the experimental treatment will be
abandoned. The posterior probability satisfies,
P(Θ > 0|x) ≥ η for all x ∈ R. (6.2.1)
Taking forward the experimental treatment will always be associated with a strong
belief that it is more effective than the control treatment, which can be seen to be
similar to the frequentist criterion of continuing to further trials if the p-value is
sufficiently small.
In determining the number of events required in the trial, a second criterion is
defined. This is effectively the Bayesian counterpart of a frequentist power calculation.
We specify that the sample size and critical region will be chosen so that the posterior
probability satisfies Equation 6.2.1 and
P(Θ < θ1|x) ≥ ζ for all x /∈ R, (6.2.2)
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where ζ is a value close to 1. In this case, abandoning the experimental treat-
ment will correspond to being convinced that it does not achieve the pre-specified
worthwhile treatment effect, θ1.
In the Bayesian sample size calculations presented in this chapter, a search proce-
dure is used to identify pairs (m, k) that satisfy Equations 6.2.1 and 6.2.2, where m
is the number of events that need to be observed in the trial and k is a critical value
defining the rejection region. Clearly m patients could be recruited and followed until
they all experience an event. However, it may be more practical to recruit n > m
patients and follow them all up until m events are observed.
Once the data have been collected in the trial, any form of analysis, frequentist or
Bayesian, could be used. It would be consistent with the sample size determination
described in this chapter to use a Bayesian analysis based on the prior for λE adopted
during the design stage and on the proportional hazards model and adopted prior
for λC in the case of a randomised trial. The underlying survival function can be
estimated using a Weibull or exponential model if such an assumption was made
during the design of the trial. Alternatively, as a substantial amount of data should
be available at this stage, parametric modelling might not be necessary or appropriate
for the analysis.
A simple Bayesian analysis of the trial, conducted to determine whether to proceed
to phase III, requires only calculation of the probability given in Equation 6.2.1. A
more thorough analysis should also consider the probability given in Equation 6.2.2
and the full posterior distribution of λE (and, where appropriate, of λC). When only
one of Equation 6.2.1 or 6.2.2 is satisfied, the conclusion of the trial is clear. If both are
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satisfied, then the data show with relative certainty that the experimental treatment
is better than control but does not reach the worthwhile treatment effect. In this
case, the posterior distribution of λE and the needs of the treatment area should be
used to decide whether to proceed to phase III trials.
The frequentist counterpart to the Bayesian method presented here involves cal-
culating the number of events required in order to control the risk of one-sided type
I error α and the power 1 − β. The required number of events is derived from the
amount of information required, V . In the single-arm case, the number of events re-
quired is equal to V , while for a 1:1 randomised trial, 4V events are required. With z
denoting the 100 percentage point of the standard normal distribution, the required
information is calculated as V = [(z1−α + z1−β)/θ1]
2 (Whitehead, 1997).
6.2.2 A Bayesian Single-arm Trial
In a single-arm trial, all patients are allocated the experimental treatment so that
n = nE and nC = 0. Suppose that the experimental treatment should proceed to
further trials if the value of the parameter λE (introduced in Section 6.2.1) is lower than
some pre-specified value λ0. Denote the random variable representing this parameter
by ΛE, and the value representing a clinically worthwhile treatment effect by λ1 (λ1 <
λ0). Thus, θ1 = − log(λ1/λ0), is the clinically relevant negative log-hazard ratio. A
prior gamma distribution will be taken for ΛE, with parameters aE and bE so that
f0(λE) ∝ λaE−1E e−bEλE . Given the likelihood, L(λE) ∝ λDEE e−SEλE , it follows that
the resulting posterior density is h(λE|xE) ∝ λaE+DE−1E e−(bE+SE)λE so that λE|xE ∼
Gamma(aE +DE, bE + SE).
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Since P(ΛE < λ0) is monotone increasing in SE for given aE, bE and DE, the
rejection region R corresponds to the region where SE ≥ k for a suitable value of k.
To identify a suitable number of events and corresponding critical value, note that
Equations 6.2.1 and 6.2.2 will be true if borderline data for which SE = k leads to;
P(ΛE < λ0|SE = k) ≥ η (6.2.3)
and P(ΛE > λ1|SE = k) ≥ ζ. (6.2.4)
A search procedure is used to identify pairs (mE, k) which satisfy Equations 6.2.3
and 6.2.4, where mE is the number of events which need to be observed on the ex-
perimental treatment. Notice that to calculate the number of events required in the
trial only proportional hazards are required.
From the value of mE, a suitable sample size can be found as follows: assume that
entry into the trial is uniform with P patients recruited per year for Y years. After
Y years, recruitment ceases, and all patients are followed up for a further A years.
The probability piE(λE, S0) of an event during the trial for patient j, given λE, S0 and
entry to the trial at time u can be expressed as follows:




S0(Y + A− u)λEdu.
Letting v = (Y + A− u), this becomes
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Integrating over all possible values of λE, weighted by the prior density of λE,
leads to an expression for the prior predictive probability p¯iE(S0) that a patient will
experience an event during the trial:
















[bE − log{S0(v)}]−aE dv. (6.2.6)
Given sufficient historical data to obtain a Kaplan-Meier estimate S¯0 of S0 with a
suitable degree of accuracy. The Kaplan-Meier estimate can be used to approximate
the integrals that appear in Equations 6.2.5 and 6.2.6. Suppose that S¯0 takes the
form
S¯0(t) = s¯h for t ∈ (th−1, th), h = 1, 2, ..., H,
where t0 = 0. The grid of points {t1, t2, ..., tH} comprises all of the uncensored
event times and also A and (Y + A). Suppose that it is the (a + 1)th such point, ta,
that is equal to A, and the (b+ 1)th such point, tb, that is equal to Y +A. (Note that,
unless deaths are recorded at the times A or Y + A, then s¯a = s¯a+1 and s¯b = s¯b+1.)
Equation 6.2.5 can be approximated from




(th − th−1)s¯λEh ,
and Equation 6.2.6 from






(th − th−1)[bE − log{s¯h}]−aE .
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When a Weibull model for S0(t) is preferred or when it has to be used in the absence
of sufficient historical data, Equations 6.2.5 and 6.2.6 can be simplified. Taking the
parameters of the Weibull model to be φ0 and γ, we have S0(t) = exp(−φ0tγ), t > 0,
so that



















γ (bE + w)
−aE dw for aE > 1, bE > 0.
In the exponential case (when γ = 1), these equations have closed forms, but in
the general Weibull case they could be calculated using Simpson’s rule with a suitably
fine grid.
The number of events, DE observed in nE patients treated with the experimental
treatment is binomially distributed with parameters nE, and piE(λE, S0) when λE is
assumed known and p¯i(S0) otherwise. We propose the following three methods for
deducing the sample size:
Method 1: Sample until mE events have been observed. This method will always
satisfy the required Bayesian criteria and requires only proportional hazards
(and, in the Weibull case, it does not depend on the value of γ). However, even
when this method is used, estimates of patient numbers and trial duration are
likely to be of interest for planning. Either of Methods 2 or 3 that follow could
be used to do this, and an expression for S0(t) is required for their operation.
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Method 2: Identify a combination (P, Y,A), and corresponding sample size nE such
that the expected number of events, nEpiE(λ1, S0) is equal to mE, using Equation
6.2.5 to evaluate piE(λ1, S0). This method matches the frequentist approach and
is straightforward to use. However, it does not guarantee conditions in Equations
6.2.3 and 6.2.4 with any degree of certainty.
Method 3: Identify a combination (P, Y,A), and corresponding sample size nE,
such that Equations 6.2.3 and 6.2.4 are satisfied with high probability; ensuring
that P(DE ≥ mE) = 1−FDE(mE− 1) ≥ ξ for large ξ, where FDE is the cumula-
tive distribution function of DE that is binomially distributed with parameters
nE and p¯iE(S0). The sample size calculated under this method accounts for
uncertainty in λE.
Both Methods 2 and 3 require knowledge of the underlying survival function to
enable calculation of the integrals in Equations 6.2.5 and 6.2.6. In the Weibull case
for both of these methods, decreasing the value of γ leads to an increased sample
size. This fact can be used to calculate a conservative sample size, perhaps based on
a percentile of the prior distribution of γ in this case.
The value of mE found in the search procedure described at the start of Section
6.2.2 is dependent upon the amount of prior information. The choice of the prior
parameters aE and bE can be made by expressing bE as aE/λ
∗, so that the prior mean
of ΛE is λ
∗, and its standard deviation is λ∗/
√
aE. A weighted average of λ0 and λ1,
such as (λ0 + λ1)/2, might be chosen for λ
∗, where λ1 = λ0e−θ1 . Then aE is chosen to
determine the strength of the prior, informed after consideration of properties such
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as the prior 95% credibility interval for the median survival time on the experimental
treatment. Prior determination will be discussed in more detail in the context of an
example in Section 6.3.
6.2.3 A Bayesian Randomised Trial
Now consider a trial in which patients are randomised either to treatment E or treat-
ment C. We have nE, nC ≥ 0 and λE, λC unknown. Independent prior gamma dis-
tributions with parameters (aE, bE) and (aC, bC) will be assumed for the random rate
parameters ΛE and ΛC. The corresponding posterior distributions will be independent
and gamma with parameters (aE +DE, bE + SE) and (aC +DC, bC + SC) respectively.
Let Θ = − log(ΛE/ΛC). Upon collecting data, (bi + Si)Λi ∼ Gamma(ai +Di, 1).
It follows that
(bC + SC)ΛC
(bC + SC)ΛC + (bE + SE)ΛE
∼ Beta(aC +DC, aE +DE),
which can be re-written as Θ = log{(bE + SE)Z}/{(bC + SC)(1 − Z)}, where
Z ∼ Beta(aC + DC, aE + DE) (see, for example, Chapter V, Example 25 in Mood
et al., 1974). Putting T = (bE + SE)/(bC + SC), it follows that









∣∣∣∣x} = P(Z > 11 + T
∣∣∣∣x) ,
which is monotone increasing in T . Hence, we will reject the null hypothesis if
T ≥ k for a suitable critical value k. Equations 6.2.1 and 6.2.2 will be true if borderline
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data for which T = k leads to
P(Z > 1/(1 + T )|T = k) ≥ η (6.2.7)
and P(Z < 1/{1 + e−θ1T}|T = k) ≥ ζ, (6.2.8)
where P(Θ < θ1) = P{Z < (1 + e−θ1k)−1}. As with the single-arm trial, these
equations can be used to identify pairs (m, k) which satisfy trial requirements, where
m = (mE,mC) is the number of events observed in the trial on experimental and
control treatments respectively.
Three methods of sample size calculation that are parallel to those presented for
the single-arm trial are available for the randomised case. For Method 1, a conservative
sample size choice that minimises the number of events observed in the trial can be
obtained by specifying that mE = mC are both equal to some common value m.
In that case Z ∼ Beta(aC + m, aE + m), and the value of m can be deduced from
Equations 6.2.7 and 6.2.8. Under the same constraint, it is relatively straightforward
to extend Methods 2 and 3 presented for the single-arm case to the randomised setting.
However, because survival times are expected to be greater, and so the rate of events
lower, on the experimental than control treatment, setting mE = mC will not generally
yield the smallest sample size for a given combination (P, Y,A).
It may be preferable to minimise the sample size. Suppose that Y and A are fixed,
and that the allocation of patients between the experimental and control treatments is
to be in an R:1 ratio. In the case of Method 2, Equation 6.2.5 can be used to determine
piE(λ1, S0) and piC(λ0, S0) and the expected numbers of events on each treatment can
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be deduced for any patient entry rate P . The value of P can be adjusted so that
when these values are used for DE and DC respectively in the beta distribution of Z,
Equations 6.2.7 and 6.2.8 are valid. Finally, the process can be repeated for a variety
of feasible allocation ratios R and a value chosen that gives rise to the smallest total
sample size.
For Method 3, Equation 6.2.6 can be used to find p¯iE(S0) and p¯iC(S0) and thus
determine the corresponding independent binomial distributions for the numbers of
events on each treatment for any value of P . Thus, for any pair (mE,mC) of numbers
of events in the two treatment groups, we have the probability of their joint occurrence
and, from Equations 6.2.7 and 6.2.8, an indicator of whether they lead to a distribution
for Z in which the Bayesian criteria will be satisfied. The minimum value of P is then
sought for which, summing these probabilities over the cases in which the criteria
are achieved leads to a total that is greater than ξ. Once more, the process can be
repeated for a variety of values of R.
For a randomised trial, priors must be specified on both ΛE and ΛC. It seems
logical for the prior on ΛE to be specified as in the single-arm trial because the
available information concerning this parameter is unchanged. In a similar way, take
bC = aC/λ0 so that the prior mean of ΛC is λ0 and its standard deviation is λ0/
√
aC.
The prior mean is therefore equal to that observed in historical, conventionally treated
patients, and aC is chosen to determine the strength of the prior.
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6.3 Illustrative Sample Size Comparisons Based on
a Weibull Assumption
Various Weibull settings (including the special case exponential distribution) are in-
vestigated in detail, for the single-arm and randomised trial cases. They are illustrated
in this section under the assumption that the anticipated probability of survival past
3 years for conventionally treated patients is 0.530. Suppose that increasing this
probability to 0.683 is considered to be of clinical importance. Such an improve-
ment represents a hazard ratio relative to the conventional treatment of 0.6. We take
λC = λ0 = 1 so that λ1 = 0.6 and θ1 = − log[0.6] = 0.511.
In order to be confident in the conclusions drawn from the trial, we choose η =
0.95 and ζ = 0.90 in Equations 6.2.1 and 6.2.2. Although the interpretations of
these parameters differ greatly from their frequentist counterparts (1 − α and 1 − β
respectively), in practice their numerical values are likely to be chosen to coincide,
partly because of lack of experience in choosing the Bayesian values. When Method
3 is used, we choose ξ = 0.95 to ensure a high probability of observing enough events
within the duration of the trial. In all methods considered, we assume constant
recruitment of P patients per year for 4 years and conduct an analysis at 6 years.
The total sample size is, thus, n = 4P . Comparisons are made in terms of the total
sample size required to meet the sample size criterion, and searches are taken to the
nearest integer value.
Under the frequentist methodology, V = {(1.645 + 1.282)/0.511}2 = 32.81, so at
least 33 events need to be observed in the single-arm trial in order to satisfy the power
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requirements. In the frequentist case, λ is not treated as a random variable and we
use λ = λ1 to find the probability of an event using Equation 6.2.5 for a given γ. For a
single-arm trial, the sample size is then the smallest value of n such that the expected
number of events in the trial npiE(λ1, S0) ≥ 33. Setting λ = λ1 in this calculation is
an arbitrary choice, which could be varied. A frequentist approach to a randomised
trial assuming exponential survival times gives a sample size to obtain a required
number of events equivalent to that obtained from calculation based on the logrank
test. A detailed account of this approach can be found in Whitehead (1997). As in
the single-arm approach, the information required is V = 32.81. For a 1:1 allocation
ratio, this necessitates observing m = 132 events.
6.3.1 A Bayesian Single-arm Trial
We take the prior for ΛE to be gamma with parameters aE and bE, where bE =
2aE/(λ0 + λ1). Assume that survival times of conventionally treated patients are
Weibull distributed with parameters φ0 and γ. Under the transformation of survival
times to the exponential distribution, ΦE, the random variable corresponding to the
parameter φE, is equal to φ0ΛE with Φ0 ∼ Gamma(aE, bE/φ0). As S0(3) is assumed
to be equal to 0.530, φ0 = − log(0.530)/3γ. For a clinically relevant treatment effect,
φ1 = 0.6φ0. With γ = 1, we have φ0 = 0.212, the prior mean of ΦE is φ0(λ0 +λ1)/2 =





of aE therefore correspond to increasing levels of certainty in the prior estimate of ΛE.
Table 6.3.1 gives the number of events required for Method 1 and the corresponding
sample sizes calculated under Methods 2 and 3 for a range of priors and values of γ
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consistent with S0(3) = 0.530. Considerations of the interpretation of the prior on λ
in terms of median survival is discussed in Section 6.3.2 in relation to the prior on λC.
First consider the exponential case when γ = 1. Weak prior belief, aE = 2, requires
observation of 31 events and gives sample sizes of 80 and 89 under Methods 2 and 3
respectively. These are close to the frequentist alternative that requires 85 patients to
observe 33 events. With an informative prior, the sample size calculated by Method 2
is always less than the frequentist counterpart because fewer events are required. This
is down to the use of the prior. It is also less than that by Method 3 because in the
latter approach, uncertainty in the estimate of λ is accounted for. As the precision of
prior information increases, the number of events required and corresponding sample
sizes from Methods 2 and 3 decrease.























Figure 6.3.1: For varying strength of prior opinion aE, the number of events mE
(dashed line), required to satisfy trial requirements along with the corresponding
single-arm sample size n, calculated using Method 2 (solid line) and Method 3 (dotted
line), assuming exponentially distributed survival times.
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Figure 6.3.1 plots the number of events required to satisfy the error controls
and corresponding sample sizes under Methods 2 and 3, assuming exponentially dis-
tributed survival times. It can be seen that aE can be interpreted as being equivalent
to a number of imaginary events observed on the experimental treatment prior to the
trial. This can also be deduced directly from the gamma posterior with parameters
aE + DE and bE + SE. Hence, with prior evidence of aE ≥ 33, we obtain nE = 0: no
phase II trial is needed. Under this prior setting, for aE ≥ 33 both error constraints
are satisfied. When this is the case, prior data alone provides convincing evidence
that the experimental treatment is better than no treatment and also that it is not
better than the control treatment. This leads to a decision about conducting a phase
III trial based on the needs of the treatment area, for which available information
should be sufficient.
Table 6.3.1 presents numbers of events and sample sizes for a range of values of
γ with their corresponding values of φ0 and φ1 for priors constructed as described in
the first paragraph of this section. It can be seen that, as the value of γ increases, the
required sample size decreases until some point. This is because the rate of events
increases with time and so fewer patients are required to observe a fixed number of
events. As expected, the greater the value of aE, the more information is contained
in the prior and the greater the reduction in the required sample size.
For the situations portrayed in Figure 6.3.1, the difference in sample sizes between
Methods 2 and 3 is relatively small (about three patients). Reducing ξ to 0.9 makes
the sample sizes from the two methods almost indistinguishable, while a value of
ξ < 0.9 leads to smaller sample sizes from Method 3 than from Method 2. This is
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due to the value of λ being fixed at λ1 for Method 2 in the example, corresponding
to a desirable, low rate of events. In comparison, Method 3 involves integrating over
all possible values of λ, including those with high rates of events.
Suppose that previous data led to an estimate and corresponding 95% confidence
interval for γ of 1.30 and (1.14, 1.46). Under Method 3, with a moderate prior of
aE = 5, an optimistic sample size calculation for a single-arm trial using the estimate
of γ requires 71 patients. Alternatively, a conservative calculation using the lower
limit of the 95% confidence interval for γ gives a sample size of 74. Both of these
are lower than the corresponding frequentist alternatives of 79 and 82, respectively,
because they utilise prior information.
Frequentist properties corresponding to the Bayesian sample sizes can be calcu-
lated. The frequentist power calculation from observing the number of events required
by the Bayesian methods for a given prior to achieve one-sided significance at level
0.05, is given in the penultimate column of Table 6.3.1. As expected, with weak prior
belief that aE = 2, the power is high at 0.885. With strengthening prior belief, the
frequentist power of the Bayesian design decreases. For comparison, Bayesian prop-
erties of the frequentist designs can be found. The final column of Table 6.3.1 shows
values of ζ, computed using the Bayesian prior specified but based on the frequentist
sample size. With observation of 33 events, as required by the frequentist design, the
value of ζ is inflated to 0.954 for moderate prior belief in the novel treatment with
aE = 10. A frequentist would be concerned that the Bayesian designs achieved too
little power, whereas a Bayesian would feel that the frequentist designs were adding
an unnecessary amount of information to the prior opinion already held.
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Frequentist Bayesian Frequentist power arising Bayesian ζ arising
aE γ φ0 nE mE nE (Method 2) nE (Method 3) from Bayesian mE from frequentist mE
0.1 0.57 103 31 96 104
0.3 0.46 98 31 93 101
0.5 0.37 94 31 89 97
0.7 0.29 90 31 85 94
2 1.0 0.21 85 31 80 89 0.885 0.917
1.3 0.15 79 31 75 84
1.5 0.12 76 31 72 81
1.7 0.10 73 31 69 78
1.9 0.08 70 31 66 76
0.1 0.57 103 28 87 90
0.3 0.46 98 28 84 87
0.5 0.37 94 28 80 83
0.7 0.29 90 28 77 80
5 1.0 0.21 85 28 72 76 0.855 0.933
1.3 0.15 79 28 67 71
1.5 0.12 76 28 65 69
1.7 0.10 73 28 62 66
1.9 0.08 70 28 60 64
0.1 0.57 103 23 72 74
0.3 0.46 98 23 69 71
0.5 0.37 94 23 66 68
0.7 0.29 90 23 63 66
10 1.0 0.21 85 23 59 62 0.790 0.954
1.3 0.15 79 23 55 58
1.5 0.12 76 23 53 56
1.7 0.10 73 23 51 54
1.9 0.08 70 23 49 52
0.1 0.57 103 13 41 45
0.3 0.46 98 13 39 43
0.5 0.37 94 13 37 41
0.7 0.29 90 13 36 40
20 1.0 0.21 85 13 34 37 0.578 0.979
1.3 0.15 79 13 32 35
1.5 0.12 76 13 30 34
1.7 0.10 73 13 29 32
1.9 0.08 70 13 28 31
Table 6.3.1: Sample sizes for single-arm frequentist and Bayesian designs for a range
of prior settings and values of γ. The final two columns give some operating character-
istics of the design: The frequentist power calculation for the corresponding Bayesian
number of events to achieve one-sided significance at level 0.05 and the Bayesian ζ of
the frequentist required number of events.
6.3.2 A Bayesian Randomised Trial
As mentioned in Section 6.2.1, we assume that γ is known and equal for the control and
experimental treatments. The properties of Bayesian randomised trial designs depend
on the priors taken for ΛE and ΛC and on the ratio of allocations to the two treatments.
We take these to be gamma with parameters aC and bC = aC/λ0, and aE and bE =
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2aE/(λ0 + λ1), respectively. Assuming Weibull distributed survival times, Table 6.3.2
gives sample sizes for a range of allocation ratios and γ values under Method 3 with
ξ set at 0.95. Method 3 is chosen here because it explicitly quantifies the uncertainty
about the sample size calculation (aside from the uncertainty associated with the
value of γ). The values of φ0 and φ1 corresponding to each value of γ are the same as
for the single-arm setting presented in Table 6.3.1.
Recall that we are assuming that, for conventionally treated patients, the proba-
bility of survival past 3 years is 0.530; hence, setting γ = 1 implies that φ0 = 0.212.
When aC = 100, then bC = 472.5. Thus, ΦC has a 95% prior credibility interval of
(0.172, 0.255), corresponding to a 95% prior credibility interval of (2.7, 4.0) for median
survival time (in years) on C. Such prior certainty is not unreasonable for a standard
therapy that has been widely used. By contrast, taking aC = 2 gives bC = 9.5. This
leads to respective 95% prior credibility intervals of (0.026, 0.590) and (1.2, 27.1) for
ΦC and for the median survival time on C. This really does virtually represent no
knowledge of the control treatment.
The lack of prior knowledge is reflected in prior scenarios 1, 10 and 19 for which
aC = 2. For a 1:1 treatment allocation ratio under Method 3, the sample size is greater
than the corresponding frequentist sample sizes that are 296, 280 and 264 for γ = 0.7,
1 and 1.3, respectively. As in the single-arm case, the Bayesian estimate is greater due
to the additional uncertainty in the estimate of λE and λC. For a randomised study
with aC = 2, unequal allocation ratios lead to an increase in the estimated sample
size, as they would for frequentist calculations. The priors are essentially providing
little useful information. The priors in scenarios 6, 15 and 24 (for which aC = 5),
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contain more information than in scenarios 1, 10 and 19, but again, assume equal
amounts of prior information on the two treatments. This is reflected in the smaller
sample sizes, just less than the frequentist counterparts.
Prior Prior Estimated total sample size, n,
scenario γ parameters for R:1 allocation ratio on E:C
aE aC R = 1 R = 2 R = 3 R = 4 R =∞
1 0.7 2 2 328 366 436 510 ∞
2 0.7 2 5 312 336 392 455 ∞
3 0.7 2 20 286 279 304 335 ∞
4 0.7 2 50 258 222 216 215 ∞
5 0.7 2 100 234 186 172 165 141
6 0.7 5 5 292 324 384 450 ∞
7 0.7 5 20 264 264 292 325 ∞
8 0.7 5 50 232 201 196 200 ∞
9 0.7 5 100 206 165 152 145 125
10 1.0 2 2 310 348 412 485 ∞
11 1.0 2 5 296 318 372 435 ∞
12 1.0 2 20 272 264 288 320 ∞
13 1.0 2 50 244 210 204 205 ∞
14 1.0 2 100 220 177 160 155 134
15 1.0 5 5 278 309 364 425 ∞
16 1.0 5 20 250 249 276 305 ∞
17 1.0 5 50 220 192 188 185 ∞
18 1.0 5 100 194 156 144 135 118
19 1.3 2 2 296 330 396 465 ∞
20 1.3 2 5 282 303 356 415 ∞
21 1.3 2 20 258 252 272 300 ∞
22 1.3 2 50 232 201 192 195 ∞
23 1.3 2 100 210 168 152 145 127
24 1.3 5 5 264 294 348 405 ∞
25 1.3 5 20 236 237 260 290 ∞
26 1.3 5 50 208 180 176 180 ∞
27 1.3 5 100 184 147 136 130 112
Table 6.3.2: Sample sizes for randomised Bayesian designs under Method 3 for various
prior and allocation ratio settings. The blocks of results correspond to sample sizes
for γ = 0.7, 1 and 1.3 respectively. Results for R = ∞ are chosen as those observed
with an allocation ratio of RE = 30.
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Looking at the exponential case when γ = 1, when aC is larger than aE (as in
prior scenarios 11-14 and 16-18), indicating that more is known about the control than
about the experimental treatment, there can be advantage in taking more observations
on the experimental than the control treatment. For prior scenario 12, a 2:1 allocation
ratio is worthwhile, while for prior scenarios 14 and 18, it is better not to take any
observations on the control. Even when no observations are taken on control, this
analysis differs from the single-arm case of Section 6.3.1 as uncertainty about the
effect of control is being allowed for. In scenarios 10-13 and 15-17 when no patients are
allocated to control, no recruitment rate is satisfactory: the prior information about
the control is insufficient to allow a suitable design to be found. Similar patterns are
seen when γ 6= 1. It can also be seen, as in the single-arm case, that decreasing the
value of γ leads to an increase in sample size.
For a randomised trial with prior mean estimate γˆ = 1.30, it can be seen that the
sample sizes are not really feasible for a standard phase II trial. An option is to relax
the Bayesian criteria in Equations 6.2.3 and 6.2.4 and/or the value of ξ. Table 6.3.3
presents the sample sizes for η = 0.85, ζ = 0.75 and ξ = 0.90. The resulting sample
sizes are much more consistent with practice in phase II, where a confirmatory phase
III trial will follow if suitable evidence of efficacy is apparent in phase II.
CHAPTER 6. Bayesian Sample Sizes in Trials with a Time-to-event Endpoint 219
Prior Estimated sample size, n,
Prior parameters for R:1 allocation ratio on E:C
scenario γ aE aC R = 1 R = 2 R = 3 R = 4 R =∞
1 1.3 2 2 184 201 240 280 ∞
2 1.3 2 5 174 183 208 240 ∞
3 1.3 2 20 154 141 144 150 ∞
4 1.3 2 50 136 111 104 100 89
5 1.3 2 100 124 96 88 85 69
6 1.3 5 5 160 174 204 235 ∞
7 1.3 5 20 136 129 132 140 ∞
8 1.3 5 50 116 96 88 85 77
9 1.3 5 100 104 78 72 70 56
Table 6.3.3: Sample sizes for randomised Bayesian designs under Method 3 for γ = 1.3
with relaxed Bayesian criteria such that η = 0.85, ζ = 0.75 and ξ = 0.90.
6.4 Evaluation of Therapy for Uveal Melanoma
In this section, the methods described in this chapter are illustrated for the design of
a potential trial in high-risk, early ocular melanoma - a rare and serious condition for
which there are few treatment options. Throughout this section, we take λC = λ0 = 1
so that for a hazard ratio of the novel treatment relative to control treatment of 0.6,
we have λ1 = 0.6 and θ1 = − log(0.6) = 0.511. Choosing η = 0.95 and ζ = 0.90 in
Equations 6.2.1 and 6.2.2, this information can be used to calculate that 28 events
are required to be observed in a single-arm trial. Assume a constant recruitment of
P patients per year for 4 years and conduct an analysis at 6 years. Method 3 is the
preferred method of sample size calculation and will be used for calculations with ξ
equal to 0.95. Take a vague prior on the experimental treatment with aE = 5 and
bE = 2aE/(λ0 + λ1).
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If the only reliable information on the survival of conventionally treated patients
available at the time of trial design was that the survival probability past 1.5 years is
equal to 0.85, then sample size calculation can be based upon an exponential assump-
tion for survival times. Suppose that increasing this probability to 0.907 is considered
to be of clinical importance. Such an improvement represents a hazard ratio relative
to the conventional treatment of 0.6. We calculate from the exponential survival func-
tion that φ0 = − log(0.85)/1.5 = 0.11, giving an estimate of p¯iE(S0) = 0.281. Hence,
a total of 128 patients would be required to observe the required 28 events under the
given trial specification by Method 3.
Next, suppose that clinicians doubt the suitability of an exponential model but
suggest that the probability of survival past 6 years for conventionally treated patients
is 0.3. Assuming survival times of conventially treated patients follow a Weibull(φ0, γ)
distribution, we have S0(tp) = exp(−φ0tγp) for time-points tp = 1.5, 6. Solving simul-




and φ0 = − log{S0(t1.5)}
tγ1.5
.
These values can be used to calculate a sample size of 90 for a single-arm trial using
Method 3. This is derived from an estimated probability of event of p¯iE(S0) = 0.393.
Note that, as discussed in the previous section, it may be desirable to relax the
error constraints - a relatively small change can have an appreciable effect on the
sample size calculation. For example, decreasing ξ to 0.9 leads to a sample size of 85.
Alternatively, η or ζ could be relaxed depending on the requirements of the trial.
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Finally, suppose that sufficient survival data on conventionally treated patients is
available to remove the need for a distributional assumption. This is the case for the
uveal melanoma data presented in Figure 6.4.1 that shows the survival pattern for 264
high-risk patients with uveal melanoma and is based on records from the database of
the Liverpool Ocular Oncology Service. Patients were selected if resident in mainland
Britain and diagnosed clinically or histologically with uveal melanoma with a tumour
involving the choroid and a metasizing uveal melanoma exceeding 15mm in diameter.
They were excluded if they had bilateral uveal melanoma, the genetic tumour type
was not identified or the basal tumour diameter was not recorded. These patients
have also been used to illustrate a different approach in Whitehead et al. (2012).
Instead of using a distributional assumption in this case, the Kaplan-Meier curve
can be used to estimate p¯iE(S0) = 0.447 following the method described in Section
6.2.2. This leads to a sample size of 78 patients for a single-arm trial according to
Method 3. In this example, the sample size calculated using a Weibull approximation
is seen to be conservative. This comes from the fact that, in the area of interest
(between A = 2 and Y + A = 6 years), the Kaplan-Meier curve lies below the best-
fitting Weibull curve, as can be seen in Figure 6.4.1.
These calculations can be extended to the randomised setting. Suppose that there
is moderate prior information corresponding to aC = 20 available on the control treat-
ment. We take bC = aE/λ0, a 2:1 allocation ratio and the remaining parameters as
described for the single-arm setting. The total sample sizes calculated under exponen-
tial and Weibull assumptions are 414 and 294, respectively, and based on the Kaplan-
Meier estimate of the survival curve, the total sample size is 258. Re-calculating these
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sample sizes based on relaxed error constraints with η = 0.85, ζ = 0.75 and ξ = 0.9
leads to sample sizes of 96, 69 and 60 respectively. This demonstrates the large effect
that altering the error constraints can have and why their choice should be carefully
considered. As in the single-agent case, the Weibull estimate is conservative.
Figure 6.4.1: For varying strength of prior opinion aE, the number of events mE
(dashed line), required to satisfy trial requirements along with the corresponding
single-arm sample size n, calculated using Method 2 (solid line) and Method 3 (dotted
line), assuming exponentially distributed survival times.
6.5 Discussion and Conclusions
In this chapter, we have presented novel Bayesian methods of sample size estimation
based on a proportional hazards model for time-to-event outcomes. The method
allows the number of events required in a trial to be calculated without knowledge
of the survival function. With no knowledge of the survival function, under only the
assumption of proportional hazards, Method 1 could be used and the trial run until the
required m events had been observed. To predict whether this number of events will be
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observed within a specified time requires knowledge concerning the survival function;
be this a distributional assumption or suitable information to reliably estimate the
survival function. The fact that, under a Weibull assumption, lower values of γ lead
to increased sample sizes can be used to obtain conservative sample size calculations.
In addition, when the survival curve lies above the fitted Weibull model, sample
size estimates using the Weibull assumption will be greater than those based on the
survival function itself. An alternative and more reliable approach involves conducting
an interim analysis leading to sample-size re-assessment.
For the final analysis of the trial data, the quantities in Equations 6.2.1 and 6.2.2
can be estimated using the posterior estimate of γ or by a Bayesian analysis which
allows for a prior on γ. By Methods 2 and 3, achievement of one of the criteria
is then very likely but no longer guaranteed. The critical value corresponding to
the actual number of events observed in the trial and observed γ should be used in
analysis. Within the Bayesian framework, Equations 6.2.1 and 6.2.2 can be applied at
interim analyses without penalty - enabling early stopping as soon as the experimental
treatment shows sufficient promise, or lack of it.
The Bayesian methods of sample size calculation presented involve calculation of
the number of events required in the trial. This is recorded as Method 1 and results
in fewer events being required in the trial than its frequentist counterpart with type
I error rate and power equated to 1 − η and ζ, respectively. Similarly, the nature
of Method 2 leads to a sample size smaller than that from a frequentist calcula-
tion. Method 3 does not always produce sample sizes smaller than the frequentist
approach because it is a more thorough calculation as uncertainty in λE (and λC in
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the randomised setting) is accounted for rather than anticipated values being treated
as known. Once a suitable number of events have been observed in the trial, the trial
can be stopped regardless of whether the calculated sample size has been reached. By
accounting for uncertainty in the parameter estimates, the Bayesian designs should
provide more accurate sample size calculations than a frequentist counterpart for valid
assumptions concerning the survival distribution.
In the methodology and examples presented in this chapter for the single-arm case,
λ0 was taken to equal λC, which in turn was set at the value 1. This need not be the
case. Actually λ0 is a value that we wish to show that the experimental treatment
improves upon (is lower than) by some margin. It may therefore be the case that,
instead of being derived from historical control data, λ0 is a standard or agreed value.
Frequentist sample sizes, and those from Method 2, could be made more conservative
by choosing less arbitrary values than λ1 and λ0 in place of λ in calculating Equation
6.2.5 for the experimental and, when relevant, control treatments. Similarly one could
increase the value of ξ in Method 3. The calculation presented for Methods 2 and
3 can be extended to cater for non-constant recruitment rates. For example, the
recruitment period could be split into three time blocks; [0, Y1), [Y1, Y2) and [Y2, Y ]
with corresponding recruitment rates P1, P2 and P3. The expected number of events
by analysis time A can be found for each time block and the sum of these is used to
identify the required sample size (Whitehead, 2001).
A Bayesian analysis must incorporate the prior according to Bayes theorem: any
other approach departs from the Bayesian principle. If the results of the trial are
contrary to prior optimism, which was used to create a well-formulated prior favour-
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ing the novel treatment, then there might be some concern in the interpretation.
Nevertheless, if the prior expressed confidence in the new treatment (but not enough
to warrant direct progress to phase III), then unfavourable trial results will lead to
weakened posterior confidence in the new treatment. Investigators will therefore be
less ready to proceed to phase III than they were before the phase II trial begun.
In the examples of Sections 6.3 and 6.4, the prior mean on the experimental
treatment was selected as a value that was a compromise between the survival rate
on control treatment and the hypothesised clinically relevant rate. The effect on
the sample size of altering the standard deviation was then investigated by altering
aE. Alternative values of the prior mean and indeed prior formulation, in terms of the
relationship between the prior parameters, are possible. In a real implementation, one
should determine expert clinicians’ views on the performance of the novel treatment
to elicit a more appropriate prior. This could be achieved through a formal elicitation
meeting (Hampson et al., 2014) in which details of the sample size calculation could
then be re-worked according to a variety of priors. However, this process cannot be
illustrated in an abstract example such as that presented in this chapter.
By formally expressing what is known about survival patterns on the trial treat-
ments as priors, it is possible to address directly questions of whether more patients
should be allocated to the experimental treatment, whether there should be a control
arm and whether a trial should be conducted at all. The prior information substi-
tutes for observed data, and so it has to be based on reliable considerations. Provided
the study is a true phase II investigation, that is one that, if successful, will be con-
firmed by a conventional, comparative, frequentist phase III study with strict control
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of type I and type II error; then it would appear to be reasonable to make use of prior
knowledge.
Ratain and Sargent (2009), among others, argue in favour of randomising between
control and experimental treatments. However, it seems natural that there will be
situations where, given the limited number of patients available for phase II and the
experience already available about use of the control treatment, the optimal strategy
is to allocate all patients to the experimental treatment. If a small control group
is recruited, and their outcomes prove to be at odds with previous experience, it is
unlikely that they would be taken at face value anyway. The Bayesian approach also
allows a middle way between a single-arm and a randomised study. That is, a study in
which uncertainty about responses to the control treatment is expressed as a Bayesian
prior, but no new control patients are studied in the trial. While the experimental
prior is updated from new data, the control prior is not: nevertheless, allowance is
made for uncertainty in the predictions for the control. For this reason, in the Weibull
setting Bayesian randomised sample sizes with R =∞ are greater than those from a
single-arm trial for the same value of γ.
The sample sizes calculated for a Bayesian single-arm trial assuming Weibull dis-
tributed survival times given in Table 6.3.1 are reasonable for a phase II trial. Those
for a randomised phase II trial given in Table 6.3.2 may not be. However, an alter-
native that involves relaxing the Bayesian criteria gave more reasonable sample sizes
(Table 6.3.3). The compromise for obtaining these feasible, randomised sample sizes
is a loss in the eventual certainty concerning the specified hypotheses. Depending
upon the situation, this may still be preferable to a single-arm trial where the treat-
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ment comparison is based purely on historical control data which may not be strictly
comparable to the data collected in the trial. This dilemma is present in most phase
II trials where resources are not sufficient to conduct a definitive trial.
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Chapter 7
Summary and Further Work
7.1 Summary
Three manuscripts concerning novel methods for early phase clinical trials are con-
tained in this thesis. These span two important stages in early phase clinical trial
design. First, dose-escalation trials were considered; in the single-agent setting in
Chapter 3 and in the dual-agent setting in Chapter 4. The focus changed in Chapter
6 to non-confirmatory phase II trials with time-to-event endpoints. Bayesian methods
were used in all approaches and each approach was illustrated using real trial data.
The dose-escalation trial designs presented in Chapters 3 and 4 were based on
standard model-based dose-escalation procedures for oncology trials. The set-up and
running of the proposed designs is therefore similar to that of methods currently used
in practice. The proposed designs are practical in that they utilise data which is
feasibly available within the constraints of a dose-escalation trial. The stopping rules
employed in each case show that the designs are also practical in terms of sample size.
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In addition, the flexibility of standard model-based dose-escalation trial designs (for
example, their ability to use varied cohort sizes, account for delayed availablility of
pharmacokinetic data and for a clinical team to over-ride model decisions if required)
is maintained.
Instead of the Whitehead and Williamson (1998) method being used as the under-
lying dose-escalation trial design in Chapter 3, that of Neuenschwander et al. (2008)
(demonstrated with regard to the inclusion of pharmacokinetic exposure data in dose-
escalation in Chapter 4) could be used, with escalation and stopping rules updated
accordingly. The reverse case is also possible. The proposed dose-escalation trial de-
signs are transferable to therapeutic areas aside from oncology but adaptions may be
required to meet the specific needs of patients involved in the trial. The escalation
and stopping rules can also be altered based on knowledge of the planned trial in
order to make them better suited.
A limitation of all model-based dose-escalation trial designs is the assumption on
the form of the underlying dose-toxicity relationship. Alternative monotonic dose-
toxicity models (the power model used by O’Quigley et al., 1990, in the CRM or the
copula regression model used by Thall et al., 2003 for dual-agent dose-escalation, for
example) could be substituted in the dose-escalation methods presented in Chapters
3 and 4. Assuming a non-monotonic dose-toxicity relationship may require additional
alterations to the design but in such a case, methods which account for efficacy as
well as toxicity are likely to be more suitable than those considered in this thesis.
In Chapter 3, pre-existing knowledge concerning a biomarker is utilised. The
selected biomarker is indicative of patient membership of one of two subgroups within
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the population, between which the reaction to treatment is expected to differ. Dose-
escalation methods which accounted for a potential subgroup effect were considered
with the aim of recommending a different dose in each subgroup, for use in future
trials, when this was necessary. Through a simulation study, the use of a hypothesis
test for identifying whether a subgroup effect had been observed was compared to a
design using spike and slab priors. The hypothesis test was found to be low powered
in the sample sizes feasible for a dose-escalation trial but the method using spike and
slab priors performed better. The potential benefits of correctly identifying different
recommended doses in each subgroup greatly outweighs the risks of a missed, or
masked, treatment effect; which is more likely when the trial population is treated as
being homogeneous.
The small sample sizes considered in dose-escalation trials mean that conclusive
evidence on the presence of a subgroup effect cannot be obtained. That is why it
is required for the biomarker of interest to be identified before the trial commences.
Unfortunately, this means that a subgroup effect can only potentially be identified if
the biomarker considered in the trial identifies the relevant subgroups. In addition,
only the case of two potential subgroups was considered but there may be more than
two relevant, distinct subgroups in a population. This could arise in a paediatric trial
for example, with subgroup membership defined by age.
Dual-agent dose-escalation was the subject of Chapter 4. In this setting, single-
agent trials of the experimental treatments will have been completed. This single-
agent data was used to develop decision rules for escalation, and stopping, which were
based on both toxicity and pharmacokinetic exposure data. Simulations showed that
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the use of pharmacokinetic data leads to more informed escalation decisions, increas-
ing the safety of the trial, and more importantly, the consistency of the recommended
dose-pair. Formal incorporation of pharmacokinetic data removes the inconsistent and
subjective use of this data in current practice. Stopping rules can be based upon tox-
icity and/or pharmacokinetic data, enabling early stopping of dose-escalation having
identified the recommended dose-pair with suitable accuracy.
To observe the greatest benefits from utilising exposure data in dose-escalation,
the data sould be available in a short time span. Although modern technology makes
this possible, higher priority needs to be placed on this data than is currently standard
to achieve this in practice. This design could also encounter problems in uptake by
medical teams stemming from a reluctance to formally base escalation decisions on
pharmacokinetic data. Methodological limitations of the dual-agent dose-escalation
design presented surround the assumed dose-response models. Since pre-clinical data
on drug-drug interactions does not transfer reliably to the clinical setting, specification
of a suitable model for a combination treatment is especially difficult.
The setting of Chapter 6 is that of a phase II clinical trial with a time-to-event
endpoint. Bayesian sample size calculations for a single-arm and a randomised trial
were presented. The calculation of the number of events required in order to achieve
specified Bayesian error constraints was calculated based soley on an assumption of
proportional hazards. To obtain the more useful estimate of the number of patients
required to achieve this number of events in a given time-frame, further information on
the expected time to the event of interest of patients was required. Depending on the
amount of relevant historical time-to-event data available, this additional information
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could take the form of a parametric assumption. Alternatively, the historical time-to-
event data could be used directly. The flexibility of this method makes it applicable in
a range of situations. In the randomised setting, the method also enables identification
of an optimum allocation ratio which minimises the total sample size of the trial.
Consequently, this method can be used to make a decision over whether a control
group is indeed required in the trial. That is, when the optimum allocation ratio
of patients on experimental and control treatments is ∞:1 suggesting that suitable
information is already available on control treatment.
Bayesian methods of sample size calculation require a reduced number of events to
be observed than their frequentist counterparts to achieve comparable error controls
over trial conclusions. When a confirmatory frequentist trial will follow the Bayesian
phase II trial, this is often acceptable. Reducing the size of the trial by using historical
data can enable trials to commence which, due to funding restrictions, otherwise could
not. Similar arguments arise over the use of single-arm, as opposed to randomised,
trials. The subjectivity of Bayesian methods, and the lack of a concurrent control in
single-arm trials, when using a time-to-event endpoint can also be considered a rea-
sonable compromise over a potential alternative; using a short-term binary endpoint
which is not a good predictor of the long-term time-to-event endpoint of interest.
The proposed sample size calculations are applicable in a range of therapeutic areas
when a relevant time-to-event endpoint, which is likely to be observed in a relatively
short time-frame, can be identified. Another situation where such a calculation may be
relevant is that when there is no short-term binary endpoint which reliably predicts
the long-term response of interest. When this is the case, a phase II trial design
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using a time-to-event endpoint could be beneficial in reducing the chance of wrongly
progressing to phase III trials. However, if the time to observation of the time-to-event
endpoint of interest is too great, then it may be difficult to obtain funding for such
a trial, even though it could have resource savings in the long-term. In the setting
where there is a short-term binary endpoint, which is known to be a reliable predictor
of the long-term endpoint of interest, then our design is unlikely to be applied. In such
a situation, it is likely that a phase II trial with a binary endpoint could be carried
out significantly quicker (potentially leading to earlier progression of the treatment
to confirmatory phase III trials) than one based on a time-to-event endpoint. The
conclusive nature of phase III trials means that the proposed Bayesian sample size
calculation is unlikely to have application in the phase III setting.
The main limitation of the proposed Bayesian sample size calculation is the as-
sumption of proportional hazards, between the experimental treatment and a control
treatment, which is used to calculate the number of events required in the trial. The
calculation also assumes that observations are independent, as is any potential censor-
ing which occurs in the trial, and there is no missing data in the trial. In addition, it
is assumed that the control data upon which calculations are based is similar to that
which could be obtained in the trial. The validity of the trial assumptions should
be checked to ensure that the calculation is valid and as accurate as possible. An
interim analysis which checks these assumptions and updates calculations based upon
the updated assumptions could be beneficial.
In calculating the number of patients needed to observe the required number of
events in a given time-frame, further assumptions concerning the survival time of
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patients on the control treatment are required. When Kaplan-Meier estimates are
used for sample size calculation, then high levels of censoring and/or small samples
can lead to increased variance in estimates of the survivor function. In these situations,
the assumtion that survival is constant between observed events also potentially fails,
decreasing the accuracy of Kaplan-Meier estimates. If a parametric assumption (such
as Weibull distributed survival times) is utilised, then a conservative sample size
estimate can be obtained based on properties of the calculation. This is not ideal and
if the parametric assumption is not justified, then the sample size calculation could be
inaccurate. However, in either of these cases, if the proportional hazards assumption
holds and the trial continues until the calculated number of events are obtained, then
the error constraints on trial conclusions will be maintained.
7.2 Further Work
It would be interesting to develop frequentist (based on maximum likelihood esti-
mates) and curve-free alternatives to the Bayesian model-based dose-escalation trial
designs proposed in Chapters 3 and 4. This has been done in the single-agent set-
ting for the CRM, as published in O’Quigley and Shen (1996) and O’Quigley (2002),
respectively. Another extension of the dose-escalation designs could be to healthy
volunteer studies. In this situation, the same patient may receive multiple doses of
the treatment over the course of the trial. The dose-response models therefore need
to account for inter- as well as intra-patient variability. Whitehead et al. (2001)
demonstrate this for a single-agent trial which incorporates pharmacokinetic data.
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The dose-escalation trial design presented in Chapter 3, which accounts for a
potential subgroup effect, could be made more flexible by extending the design to
allow for more than two subgroups within the patient population. Ordinal responses
could also be considered. This could be achieved in a similar manner to that in
which Tighioutart et al. (2012) extend the EWOC design to allow for ordinal toxicity
grading. The possibility that every patient cannot be definitively classified into a
subgroup based on their biomarker status could be considered. This would require
consideration of how best to dose the patient with unknown subgroup membership
and how to utilise the resulting data for the benefit of future patients.
Development of a phase I/II design which continues the investigation of a potential
subgroup effect beyond dose-escalation would be beneficial to obtain more confirma-
tory evidence of a subgroup effect. In this setting, the chance of detecting variability
between subgroups (which materialises in different reactions to the treatment via toxi-
city and/or efficacy outcomes) would be increased. If the sample size of such a design
were great enough, it may become possible to consider multiple biomarkers which
divide the patient population in different ways.
Now consider the dual-agent dose-escalation trial design in Chapter 4 which utilised
pharmacokinetic data in the trial decision rules. The issue of a reluctance of uptake
of a dose-escalation design which formally incorporates pharmacokinetic data could
potentially be reduced by using a hierarchical model for dose-exposure-toxicity rela-
tionship. In using this model, escalation decisions could be based on toxicity alone,
whilst still being heavily influenced by the observed exposures. However, such a design
is expected to be prone to model mis-specification and so an in-depth investigation
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would be required into the sensitivity of the hierarchical model to mis-specification.
Looking into alternative formulations for the case of no interaction in the dose-
response models used in this design would increase its flexiblity, enabling the most
suitable model to be used for the particular drug combination of interest. In addition,
this design could be extended to allow for a three (or more) agent combination. Again,
the main difficulty in this arises in defining models for the dose-toxicity and dose-
exposure relationships which have enough flexibity to be able to model the wide
range of drug-drug interaction which could arise.
The main down-fall of the sample size calculation presented in Chapter 6 arises if
the proportional hazards assumption is not valid. Royston and Parmar (2011) have
proposed a method of analysis for a randomised trial with a time-to-event endpoint
which does not require a proportional hazards assumption. It may be possible to
develop a Bayesian method of sample size calculation based upon such a method. A
potentially more straight-forward extension of the calculation is to ordinal data, based
on the binary calculation presented by Whitehead et al. (2008).
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